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ABSTRACT 
PCB-ASSOCIATED STEATOHEPATITIS AND THE ROLE OF NUCLEAR RECEPTORS 
Heather B. Clair 
May 17, 2017 
Metabolic diseases, including fatty liver disease, hyperglycemia, and obesity, result when 
body systems responsible for managing allostasis (dynamic homeostasis across systems) are 
pressured beyond their collective compensatory reserve.  Nutritional excess contributes to this 
state, the capacity of which is limited by genetic variation, and failure of one system will gradually 
lead to pathological overload in the others.  Agents which act directly on the communication 
machinery linking these connected systems can also change the point at which allostatic load 
becomes allostatic overload.  Environmental exposure to polychlorinated biphenyls (PCBs), a 
class of persistent organic pollutant, is associated with a specific form of toxicant-associated 
steatohepatitis, fatty liver disease with inflammatory infiltration.   PCBs are known to be ligands 
for the xenobiotic receptors, which, when activated, modulate the transcription of both xenobiotic 
and intermediary metabolic targets.  We investigated the prevalence and characteristics of liver 
disease in a human population with high environmental PCB exposure, transcriptional changes in 
the liver in a mouse model of PCB/high-fat diet coexposure, and transcriptional changes 
attributable to xenobiotic receptors in a primary hepatocyte model.
vi 
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BACKGROUND 
Toxicant-associated steatohepatitis (TASH) is a term applied to a unique subset of 
nonalcoholic fatty liver disease (NAFLD) related to chemical exposures.  Though the liver is 
known to be a primary target in many industrial chemical exposures, environmental chemical 
exposures represent a much more widespread and insidious threat to liver health. Persistent 
organic pollutants (POPs) are lipophilic, and while some compounds are metabolized, relatively 
unmetabolizable chemicals distribute to fat depots of exposed biota.  Consumption of these 
POPs-bearing biota represents the major route of environmental toxicant exposure for humans 
and other apex consumers. Consequently, even though the same classes of chemicals may be 
involved in industrial and environmental exposures, an environmental toxicant exposome is 
acquired slowly throughout the life cycle and is enriched in less metabolizable chemicals, while 
an industrially-acquired exposome more likely involves higher levels of more readily metabolized 
chemicals acquired acutely by adults.  This is an important consideration, because the same 
endpoints are used to evaluate toxicity in either case, but the differences in acquisition timeframe 
and composition may render the effects of chronic exposures subclinical and change toxicity 
mechanisms.  These differences can affect the biomarkers used for screening assays, hindering 
diagnosis and treatment of TAFLD and TASH at earlier, more reversible stages and thereby 
masking the extent of liver injury. 
The class of POPs collectively referred to as polychlorinated biphenyls (PCBs) typify the 
most challenging aspects of research in environmentally-acquired toxicant exposures.  1) 
Because of their chemical stability, PCBs continue to persist in the environment and in the tissues 
of humans decades after discontinuation of production. 2) PCBs are a class of chemicals 
invariably encountered as mixtures both in industrial and environmental exposures, and the 
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structures present within those mixtures are diverse enough that they are likely to have multiple 
and potentially overlapping or competing mechanisms of toxicity. 3) Although compositions of 
these mixtures have been exhaustively documented in production, the environment, and in the 
tissues of biota including humans, for historical and political reasons, both the mixtures 
themselves and their effects are still often summarized by a single component which assumes 
one mechanism: in this case the subset of congeners bearing structural similarity to dioxins and 
expected to act as arylhydrocarbon receptor (AhR) agonists.  4) The direct effects of chronic, low-
level PCB exposures differ from the more thoroughly evaluated effects of high-level, industrial 
exposures – likely because different distributions of congeners drive different engagement of 
xenobiotic receptors.  5) The ultimate effects of chronic PCB exposure-related TASH have great 
potential to be modulated or exacerbated by long-term nutritional coexposures, and race/ethnicity 
and gender differences, and these differences are understudied. 6) PCBs, like other toxicants 
associated with TASH, appear to cause a form of liver disease which is mechanistically and 
diagnostically distinct from other forms of fatty liver disease, making its detection by typical 
laboratory screening techniques difficult. These points may explain some characteristics which 
frustrate the recognition of environmentally-acquired PCB impact on human health and hinder its 
resolution. 
PCBs remain a focus of environmental and human health research, occupying (in various 
groupings) 3 out of the top 20 positions in the 2015 Substance Priority List published by the 
Agency for Toxic Substances Disease Registry (ATSDR)1.  We hypothesized that, in humans, 
chronic environmental PCB exposure would be associated with increased liver injury biomarkers 
indicating TASH.  We furthermore hypothesized that PCB exposure in mice and primary mouse 
hepatocytes would induce differential transcription of targets related to liver disease and that in 
primary mouse hepatocytes, that differential transcription would overlap with the response to 
prototypical ligands for specific xenobiotic receptors. 
2
Manufacture and chemical characteristics of PCBs 
Every human health effect of PCBs must be evaluated in light of one critical 
consideration: from the moment of manufacture to the moment of exposure, PCBs never exist as 
a single chemical, but as a fluctuating mixture of related chemicals each with unique biological 
and chemical properties.  The basic structure of a PCB, shown in Figure 1, is that of a biphenyl 
ring with as few as 1 or as many as 10 chlorine substitutions in various positions about the 
molecule, leading to 209 potential congener configurations.  PCBs were produced throughout the 
world via ferric chloride-catalyzed chlorination of biphenyl. Three cities in the U.S. were sites for 
commercial manufacture of PCBs: Anniston, AL from 1929-1930 (Swann Research, Inc.) and 
1930-1971 (Monsanto, Inc.), Saguet, IL until 1977 (Monsanto, Inc.) and Houston, TX from 1972-
1974 (Geneva Industries)2.  PCBs were produced mainly for use as dielectric fluids in electrical 
equipment, but were also used as lubricants, plasticizers, sealants and carriers in many products.  
The desired material properties of chemical stability and low flammability offered by PCB mixtures 
are related to the component structures and correspond roughly to the degree of chlorination.  
PCBs produced by Monsanto, Inc. were marketed as mixtures called Aroclors, with a number 
corresponding to the nominal average percent chlorine (e.g. Aroclor 1260 is approximately 60% 
chlorine by weight)3.  
This production and marketing methodology gives rise to one scheme for grouping PCBs:  
PCB homologs are defined as sets of congeners with a common number of chlorine substitutions. 
In addition to providing a way to estimate levels of total production, use and disposal of PCBs and 
to equate these amounts with contamination levels, grouping by homologs allows the 
appreciation of certain general characteristics and trends. More heavily substituted homologs 
have higher average melting and boiling points, higher vapor pressure and are more miscible in 
lipids (quantified as higher octanol-water partition coefficients) 3.  Aroclor mixtures including 
Aroclor 1260, 1254 and 1248 were composed mainly of higher-molecular weight homologs 
(tetrachlorobiphenyl and above).  Within each homolog group, PCB congeners with different 
substitution patterns are referred to as isomers. The composition of commercial Aroclor mixtures 
by PCB homolog group is shown in Table 1. 
3
Figure 1. Basic structure of a polychlorinated biphenyl. 
The basic structure of a PCB is a biphenyl ring with 1-10 chlorine substitutions at carbons 2 (2’) 
and 6 (6’).  Substitutions in the ortho positions favor rotation of the rings relative to one another, 
with the functional consequence of reduced coplanarity with each additional ortho substitution.  
PCB congeners with less (tri, di, mono-ortho) or no ortho substitutions (non-ortho) assume an 
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Unsurprisingly, the environmental persistence of individual congeners within the mixture 
is also related to structure.  Weathering is a term applied to PCB mixtures undergoing profile 
changes due to physical or chemical processes such as water washing, photodegradation, 
volatilization, and evaporation.  It can also refer to aerobic degradation due to microbial action.  
Weathering disproportionately affects lighter molecular weight congeners, particularly mono-, di-, 
and tri- substituted congeners, resulting in mixtures with proportionately more tetra- and penta- 
substituted congeners4.  Congeners bioaccumulating within the fatty tissue of exposed biota also 
tend to be those with more chlorine substitutions, and are dependent on two properties related to 
structure and influenced by degree of chlorination: resistance to non-metabolic clearance 
(increased lipophilicity) and structural inaccessibility to metabolic machinery (substitution 
pattern)5.   
In summary, PCBs were manufactured to meet a demand for industrial fluids that were 
highly stable, thermoresistant, and miscible in lipids, the same characteristics underlying the 
persistence of PCBs in the environment.  It is important to note, however, that PCB congeners 
are not equally affected by processes of physical and chemical degradation, leading to changes 
in the profile of PCB mixtures from manufacture to environmental substrates to eventual 
bioaccumulation in humans.  This is particularly critical to the design of models which reflect the 
current PCB exposure conditions: uptake of weathered and pre-metabolized PCBs through 
ingestion of contaminated biota.  
Bioactivity of PCBs in mixtures with widespread relevance to human health 
Over 80 years have elapsed since the initial reports of human toxicity from PCB 
exposure3, 6, and in that time, substantial research efforts have been put toward understanding 
the chemical composition and health effects of manufactured PCB mixtures and occupational 
exposures7-12.  While this work has been critical to characterizing human disease resulting from 
industrial exposures, it has become somewhat obsolete for several reasons.  First, except from a 
standpoint of longitudinal health and mortality assessment, research modeled on occupational 
PCB exposures is less relevant today because PCB production has been banned for 40 years, 
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therefore, new occupational exposures no longer occur in the process of PCB manufacture.  
Second, the most common route of exposure in humans is low-level, environmental acquisition 
through ingestion of contaminated foodstuffs, and as congeners bioaccumulate at different rates, 
PCBs which make up the current exposome are more likely to be higher-substituted, highly-
bioaccumulated and less metabolizable, generalizations which are reflected in assessments of 
serum PCB levels in exposed populations.  Third, emerging data on the impact of nutritional 
coexposures suggests that the current obesity epidemic may significantly modulate the effects of 
PCBs on human health.  Thus, different PCBs may be exerting their effects in a different internal 
environment currently than was explored in the original toxicity studies. 
Early evaluation of the toxicity of PCBs focused on high-level exposures and acute 
toxicity which modeled the human health effects seen in occupational exposures7-9, accidental 
contamination from PCB-containing electrical equipment12, 13, and poisoning incidents such as the 
Yusho and Yucheng9, 14, 15 events in which thousands of people in Japan and Taiwan 
(respectively) were exposed to PCBs, dioxins and dibenzofurans through ingestion of rice oil 
contaminated with a commercial PCB mixture. These incidents differ from the PCB exposure 
experienced by most U.S. citizens in both scale and composition.  Health consequences such as 
chloracne (a noninflammatory skin condition characterized by cyst and closed comedone 
development with sebaceous gland atrophy), immunosuppression, reproductive and 
developmental effects, acute liver damage, and cancer were observed in some individuals within 
these cohorts. Importantly, elevated liver enzyme activity and other biomarkers of these effects 
were typically observed at very high exposures.  This observation as well as a superficial 
resemblance of this pattern of human health effects to the constellation of pathologies induced by 
dioxins in laboratory animals16 led researchers to focus on a small subset of congeners within the 
exposure mixture with a specific structural characteristic: absence of chlorine substitutions in the 
four available ortho positions.  This characteristic is related to but independent of the overall 
degree of chlorination in the molecule.  Chlorine substitutions at these ortho positions affect the 
orientation of the rings relative to one another such that congeners with no substitutions in these 
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positions are relatively coplanar, while increasing numbers of chlorine substitutions in these 
positions increases the likelihood of a molecule with rings that are non-coplanar (perpendicular).   
Coplanar PCBs share structural similarity to the molecule 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), which is an extensively studied, potent agonist for the AhR.  Structural 
characteristics of PCBs compared to TCDD and other dioxin-like chemicals are shown in Figure 
2. Coplanar PCBs, which can induce transactivation of targets under the control of a dioxin
response element (DRE), are considered dioxin-like (DL) PCBs, while increasing ortho 
substitutions render a congener increasingly non-dioxin-like (NDL).  The number of relatively 
potent (non-ortho) dioxin-like congeners is constrained by the requirement for unsubstituted ortho 
carbons (2, 2’, 4, and 4’) and becomes increasingly unlikely as the number of substitutions 
increases, such that only 1 non-ortho congener (PCB 169) exists among hexachlorobiphenyls 
and none exist among the higher molecular weight congeners.  
Most research has focused on these dioxin-like congeners, which are present in only 
trace amounts within most commercial PCB mixtures and found at extraordinarily low levels in the 
tissues of exposed biota including humans. In rodent models, exposure to TCDD has been linked 
to many of the disease endpoints listed above, including immunotoxicity, reproductive effects, and 
cancer16, although the connection between TCDD and other dioxins and these effects in humans 
is less clear17.  Even chloracne, which is the only consistently-reported human health marker of 
dioxin intoxication18, is not a clear outcome of AhR induction and does not follow AhR induction 
by all ligands.  Nevertheless, coplanar PCBs are also ligands for AhR, although they are much 
less effective than prototypical ligand TCDD at inducing transcription of Cyp1a1, the prototypical 
target of AhR, in vivo16.  
NDL congeners are characterized by chlorine substitutions in the ortho positions, which 
induce non-coplanarity. These congeners tend to be more resistant to degradation and 
bioaccumulate to much higher levels.  Historically, these congeners were dismissed as less toxic 
to humans and of a lower priority in remediation and human health research16, however more 
recently, the recognition that these congeners are ligand activators of other xenobiotic receptors 
has led to a resurgence of interest. NDL congeners are direct ligands for the pregnane and 
8
Figure 2. Structural characteristics of PCBs compared to TCDD and other dioxin-like chemicals. 
(Adapted from Int. J. Mol. Sci. 2014, 15(8), 14044‐14057.) 
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xenobiotic receptor (PXR) and the human constitutive androstane receptor isoforms 2 and 3  
(hCAR2/3) but not human CAR isoform 1 (hCAR1), which is homologous to murine CAR 
(mCAR)19.  However, our laboratory recently reported that the both NDL and DL PCB congeners, 
as well as the mixture Aroclor 1260, inhibit activation of the human and murine epidermal growth 
factor receptor (EGFR), which provides an indirect mechanism for mCAR activation20, 21.  
Importantly, though AhR, CAR, and PXR are considered xenobiotic receptors and most 
research has focused on describing their role in the drug- or toxicant-dependent induction of 
xenobiotic metabolic machinery, they are also involved in transcriptional control of intermediary 
metabolism and inflammatory response. These functions may ultimately explain both the link 
between PCB exposure and metabolic disruption and some complexities of diet/PCB 
coexposures in metabolic disease.  Our laboratory reported that, in mice, exposure to Aroclor 
1260 alone was insufficient to induce a phenotype of steatohepatitis, and that a coexposure to 
high fat diet was required to observe the phenotypes of fatty liver and diabetes22, 23. 
Beyond the DL/NDL stratification, other groupings of PCB congeners reflect the ability of 
individual congeners to alter the function of receptors such as the ryanodine receptor24-26, 
estrogen receptor27, 28, and androgen receptor29, 30, shown in Table 2.  
In summary, humans encounter PCBs not as individual chemicals, but as complex 
mixtures of congeners, each of which has unique structural characteristics that influence stability 
and bioaccumulation patterns as well as the mechanisms of biological effect.  The composition of 
PCB mixtures represented in historic occupational and accidental PCB intoxication events differs 
significantly from the mixture accumulated slowly through chronic environmental exposure, and 
this is likely to alter both the mechanism of effect and the phenotype. Therefore, experimental 
designs which involve single congeners and risk-assessment algorithms which assume only one 
mechanism are unlikely to realistically model the effect of environmental exposure. 
Historic context for reliance on AhR induction estimates to define PCB toxicity 
As stated above, although PCBs are encountered as complex mixtures with complex 
effects, historically, the toxicity of PCBs was attributed entirely to AhR-mediated effects of dioxin-
10
Table 2 
Structural/functional groupings of PCB congeners measured in ACHS-II 
Structural groupings 
All (ƩPCB) 
28, 44, 49, 52, 66, 74, 87, 99, 101, 105, 110, 
118, 128, 138–158, 146, 149, 151, 153, 156, 
157, 167, 170, 172, 177, 178, 180, 183, 187, 
189, 194, 195, 196–203, 199, 206, 209 
Ortho-Substituted (ƩPCB-O) 
28, 44, 49, 52, 66, 74, 87, 99, 101, 105, 110, 
118, 128, 138, 146, 149, 151, 153, 156, 157, 
167,170, 172, 177, 178, 180, 183, 187, 189, 
194, 195, 196, 199, 206, 209 
Tri- and Tetra-ortho (ƩPCB-TO) 
149, 151, 177, 178, 183, 187, 195, 196-203, 
199, 206, 209 
Di-Ortho (ƩPCB-DO) 
44,49, 52, 87, 99, 101, 110, 128, 138-158, 146, 
153, 170, 172, 180, 194 
Mono-Ortho (ƩPCB-MO) 28, 66, 74, 105, 118, 156, 157, 167, 189 
Non-Ortho (ƩPCB-NO) 81, 126, 169 
Functional groupings 
Dioxin-Like (ƩDL) 81, 105, 118, 156, 157, 167, 189, 126, 169 
Non-Dioxin-Like (ƩNDL) 
28, 44, 49, 52, 66, 74, 87, 99, 101, 110, 128, 
138, 146, 149, 151, 153, 170, 172, 177, 178, 
180, 183, 187, 194, 195, 196, 199, 206, 209 
Estrogen receptor (estrogenic) 18, 28, 30, 44, 49, 52, 99, 101, 103, 110, 128 
Estrogen receptor (anti-estrogenic) 118, 138, 163, 170, 180, 187, 194, 199, 203 
Androgen receptor (anti-androgenic) 28, 49, 66, 74, 105, 118 
Ryanodine receptor 
95, 136, 149, 176, 84, 96, 52, 151, 183, 187, 
170, 101, 132, 180, 18 
PCBs are grouped by structural and structural/functional characteristics to assess relationships 
between disease or biomarker parameters and the total serum levels of structures with common 
characteristics (structural) or mechanisms (structural/functional).  For dioxin-like/non-dioxin-like 
congeners, the designation is based on the presence of ortho-substitutions (0 or 1 for dioxin-
like, 2-4 for non-dioxin-like).  
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like congeners. Both political and practical considerations motivated this focus.  From a practical 
standpoint, acute occupational exposures and high-level accidental poisoning with relatively 
undegraded PCB mixtures were readily observable, and therefore exposure to mixtures 
containing lower molecular weight and dioxin-like congeners was the primary PCB-related human 
health concern at the time.  Aggressive exploration of environmental PCB contamination began in 
the 1970’s, following adoption of gas chromatography techniques which allowed identification of 
PCBs (as well as chlorinated pesticides) in the environment3.  In the same general time, political 
pressure revolving around the use of Agent Orange in the Vietnam War steered a great deal of 
research toward the health effects of dioxins and dioxin-like chemicals.  The result of this was the 
adoption of the TCDD-equivalent factor (TEF) protocol to determine the TCDD equivalency 
(TEQ), a value normalizing any dioxin-like compound to TCDD based on its ability to induce AhR-
mediated response in an in vivo or in vitro system 31.  Classes included in this protocol include 
PCDDs, PCDFs and PCBs, the structures of which are shown in Figure 2.  While this system 
allows for the quick estimation of AhR-mediated toxicity in complex mixtures and clinical or 
environmental samples by summing concentrations of individual compounds multiplied by their 
respective TEQs, there are problems inherent in the concept. 
First, the protocol presupposes that “Most, if not all, toxic and biological effects of 
[PCDDs, PCDFs and PCBs] are mediated through the aryl hydrocarbon receptor”31. This is 
certainly not true of mixtures such as PCBs in which all potential AhR ligands make up less than 
1.5% of even unweathered commercial mixtures like 126032.  Far from being inert, the remaining 
98.5% of this mixture contains congeners which are known to induce other receptors, including 
both classical xenobiotic nuclear receptors19, 33-35 and cell surface receptors20. Second, classic 
assays based on induction or activity of xenobiotic metabolic targets of AhR presume that 
exposure-dependent changes in AhR-mediated induction in this subset of targets can be 
extrapolated to the entire complement of AhR targets.  In fact, the transcriptional effects of AhR 
are selectively modified by the ligand, with more widely conserved effects across ligands on 
targets involved in xenobiotic metabolism or response to oxidative stress and more ligand-specific 
modulation of targets involved in lipid carbohydrate metabolism36.  Finally, the most powerful 
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application of the TEQ protocol is the ability to quickly summarize the AhR-mediated effects of 
various chemicals quantified by gas chromatography coupled to high-resolution mass 
spectrometry (GC/HRMS) by normalizing the contribution of each compound to TCDD using the 
TEF and then summing the resulting TEQs.  This allows a total TEQ to be derived from multiple 
dioxin-like classes of chemical, including PCDDs, PCDFs and PCBs (Figure 3).  Perhaps most 
pertinent to this particular study, although data from multiple human exposures to these 
compounds, including Yusho and Yucheng poisoning events14 and exposed individuals residing 
near the PCB manufacturing facility in Anniston, AL suggest that PCDDs and PCDFs contribute 
more to the overall TEQ.  However, our laboratory’s evaluation of the 2003-2004 NHANES data 
showed that, among these classes, after adjustment for multiple comparisons, only PCBs were 
positively associated with liver injury37 (shown in Table 3). 
In summary, a need to prioritize exposures for reasons of risk assessment and 
remediation led to methods, like the TEQ protocol, which weight the importance of one 
mechanism over others, and the selection of dioxins/AhR as the flagship toxicant was driven by 
both practical and political considerations. While this method may accurately represent the 
likelihood that PCBs will have effects mediated by AhR, neither AhR activation nor modulation of 
any other single mechanism can sufficiently describe the toxic/biological effects of complex 
environmental exposures.  This is particularly true in the case of PCBs, where both the overall 
exposure level and the distribution of congeners comprising the mixture are known to differ 
considerably between acute/occupational and chronic/environmental exposures. 
Environmental PCB exposures vs. industrial PCB exposures 
High-level exposures to industrial PCB mixtures are known to cause liver injury as well as 
pathologies in other tissues in humans and other animals, as previously described.  Although the 
effects of chronic, environmental PCB exposures on the liver are less well characterized, some 
conclusions can be drawn about the relationship between PCBs and liver injury based on the 
results of several studies: the NHANES study described above, a longitudinal examination of the 
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Equation 1. PCDD TEQ 
	 	 	 	  
Equation 2. PCDF TEQ 
	 	 	 	  
Equation 3. PCB TEQ 
	 	 	  
Equation 4. Total TEQ 










Equation 7: Total Lipids 
	 2.27	 	 	 62.3	 /  
Figure 3. Equations for calculated parameters in human epidemiological studies. 
These equations are used to summarize and interpret differential biomarkers in human serum.  
Equations 1-4 are used to calculate the effects of various PCB congener groupings on the 
arylhydrocarbon receptor.  Equations 5 & 6 are used the in homeostatic method of assessment 
(HOMA) model to discriminate between different etiologies in abnormal glycemic control.  
Equation 7 is used to estimate the total lipid content of serum from measured parameters of total 
cholesterol and triglycerides. “Total lipids” is then used as a variable to correct serum content of 
hydrophobic contaminants such as PCBs. 
14
Table 3 







Adjusted* Odds Ratios for 
Unexplained ALT Elevation 
by Exposure Quartile ptrend-
adj
†1st 2nd 3rd 4th 
Coplanar PCBs Ref 2.2 4.4 7.6 <0.001
Non-dioxin-like 
PCBs  
Ref 0.8 2.4 4.5 0.001 
Total PCBs Ref 0.8 2.2 4.3 0.010 
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historically exposed Yusho population12, PCB exposure in the Michigan fisheaters study38, and 
data from exposed wildlife16, 39.  
At higher molecular weights, the distribution of congeners heavily disfavors non-ortho, 
strong AhR ligands.  Bioaccumulation patterns favor higher molecular weight congeners, meaning 
that, for humans acquiring PCBs through the ingestion of contaminated biota, the initial exposure 
is to a higher average molecular weight, more ortho mixture (shown in Table 1), and the steady 
state distribution of congeners further reinforces this pattern, shown in Figure 4 and Table 1.  
Sex, genotype and diet interactions in PCB-exposed humans and animal models 
From a standpoint of complexity, there is no more daunting area of human health 
research than metabolic disease. The metabolic machinery of humans is both versatile and 
robust.  We can adapt to frequent physiological fluctuations in nutritional status, different food 
sources, and varying demands from multiple tissues to support daily function, development, and 
reproduction.  In many cases, tissues can weather temporary metabolic disruption due to illness 
or intoxication and eventually regain homeostasis. This process is described by the concept of 
allostasis, or maintaining stability through change, an energy-dependent process involving 
concerted actions between multiple tissues40.  On the other hand, in the multistep and 
multisystem process that converts nutrients into metabolites and energy, a mutation leading to 
loss of function in one critical enzyme can eventually lead to failure in connected systems. 
Complex disease etiologies occur where additive pressures across connected systems eventually 
overwhelm compensatory processes. Eventually, component systems fail as additive pressures 
overwhelm their capacity to adapt, meaning that pressure from different causes can converge on 
shared pathological outcomes. Because of the multitude of processes in play, disease 
progression may be slow and pleiotropic, and the direct effects of causal agents may be obscured 
as the allostatic load is shunted to other systems. 
In mammals, the liver is the primary biochemical interface between the environment and 
the organism, transducing signals and substrates in multiple directions to sense and respond to 
constantly-changing conditions.  In terms of allostatic processes, this places the liver as both a 
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Figure 4. Distribution of ortho/non-ortho structures within homolog groups. 
As molecular weight and number of chlorine substitutions increases, ortho substitutions become 
more likely.  The four non-ortho substituted congeners which bioaccumulate to appreciable levels 



























hub (because of its position in lipid and carbohydrate trafficking) and as a temporary terminus 
(because of its capacity for lipid and carbohydrate storage). The adaptive capacity of the liver is 
extraordinary, but not limitless. Lipid and carbohydrate uptake which chronically exceeds hepatic 
metabolic/export capacity can lead to steatosis.  This has been demonstrated experimentally, 
using diets enriched in various fats or sugars to induce steatosis, (as well as obesity, 
dyslipidemia, hyperglycemia and hyperinsulinemia) in laboratory animals41-44.  The process is also 
indicated in humans by epidemiological studies which show a strong relationship between BMI or 
visceral obesity (proxy measurements for hypercaloric/high-fat/high-sugar diets) and metabolic 
dysregulation. In addition to the higher PCB exposures found in Anniston and other exposed 
human populations vs. the NHANES 2003-2004 population, the contributions of 
overweight/obesity to steatohepatitis and other metabolic disease cannot be ignored.  These 
nutritional factors are additive stressors, increasing demand on tissues whose adaptive capacity 
is compromised by the effects of sensing or responding to xenobiotics. The boundaries of that 
capacity arise from genetic variation in the components of metabolic machinery and the 
combination of endobiotic and xenobiotic molecules interpreted as a need for functional change.  
Examples drawn from epidemiological studies include patatin-like phosphospholipase domain-
containing-protein 3 (PNPLA3), which has been shown to segregate with racial/ethnic variations 
in NAFLD prevalence45 and the prevalent Q84R (missense) mutation in the human tribbles 
pseudokinase 3 gene (TRIB3) which is associated with insulin resistance/T2DM46, 47, 
cardiovascular risk46, and polycystic ovary syndrome in various human populations.  Humans 
homozygous for dominant-negative PPARγ (adipose-prevalent isoform) have reduced body fat 
and greatly increased insulin resistance48.   Sex effects are also clear in epidemiological studies 
of PCB-associated disease. In exposed individuals from Anniston, AL, T2DM prevalence was 
increased only in females49, a finding which echoed reports from a 24-year follow-up of the 
historic Yucheng poisoning incident, which found a 2-fold increase in the prevalence of diabetes 
among female but not male subjects50.  Males in the Yucheng cohort had a higher prevalence of 
mortality from liver cirrhosis and liver cancer51. 
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In summary, additive pressures from chemical exposures and nutrition can combine with 
sex- and genotype- specific variation in adaptive capacity to change the prevalence or the 
manifestation of metabolic disease.  Because of its central position in both allostatic maintenance 
and metabolic and detoxification processes, the liver might be expected to show early and 
extensive effects from the multiple “hits” of xenobiotic and dietary exposures. 
PCBs and TASH 
The extraordinary range of molecular structures which can be recognized and 
successfully handled by one or more hepatic metabolic pathways is rivaled only by another 
unique quality:  the liver can really take a beating. The liver can successfully regenerate after 
surgical removal more than 70% of its total mass52, 53, or the necrosis of 1/3 of the hepatic lobule 
following exposure to toxicants such as acetaminophen or carbon tetrachloride54. 
Nonalcoholic fatty liver disease (NAFLD) is a widespread metabolic disease of the liver, 
affecting an estimated 25% of the population worldwide55.  NAFLD is defined histologically by 
steatosis (pathological accumulation of lipids) within 5% or more of hepatocytes in the absence of 
excess alcohol consumption. First considering the liver as an isolated system, four general 
mechanisms can initiate lipid accumulation: increased lipid transport into the hepatocyte, 
increased de novo synthesis of lipids, decreased β-oxidation, or decreased lipid export56.  As the 
hub of both intermediary metabolism and xenobiotic metabolism, the liver is essential to systemic 
homeostasis of both lipids and glucose as well as metabolism of endogenous and exogenous 
toxicants.  It therefore possesses highly concerted machinery for sensing xenobiotics and 
systemic signaling molecules, and incorporating this context into programs that regulate 
nutrient/energy balance and nutrient outflow.  From this perspective, it is not difficult to 
understand how a chemical could alter systemic lipid and glucose homeostasis through its direct 
effects on the liver; that is the concept underlying the use of metabolism-altering drugs with 
primary effects in the liver such as statins, fibrates, and metformin to affect systemic homeostasis 
of cholesterol, lipids, and glucose, respectively57-59.  Toxicants which exert effects in the liver 
could be expected to have similar effects, depending on what combination of mechanisms they 
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perturb.  In addition, both intrinsic and idiosyncratic reactions to drugs or toxicants can result in 
the development of steatosis60, highlighting the complexity of exposure-genotype or exposure-
genotype-nutrient interactions. 
NAFLD is recognized as the liver manifestation of metabolic syndrome (MS), a 
constellation of metabolic alterations in multiple organ systems, including obesity, insulin 
resistance, dyslipidemia and hypertension, that appear to be connected (appear together more 
often than would be expected by chance). In 2004, the National Heart, Lung and Blood Institute 
(NHLBI) and the American Heart Association (AHA) released recommendations for diagnosis of 
MS with a primary outcome of cardiovascular disease.  According to the Adult Treatment Panel-III 
(ATP-III), MS may be diagnosed by the presence of abnormalities in  three or more of the 
following five criteria, shown in Table 461. With similar tools but a focus on insulin-resistant 
diabetes as the pathological endpoint of interest, the International Diabetes Federation released 
similar guidelines which require obesity as well as abnormality in two of the other criteria62.   
Regardless of the exact cutoffs required for diagnosis, the criteria cluster around several 
interrelated components:  obesity, insulin resistance, dyslipidemia, and progressive 
cardiovascular disease. NAFLD is not currently part of the criteria for MS diagnosis, however, it is 
frequently found with other components of MS and the presence of NAFLD (by persistent 
elevations in liver enzymes ALT using the lower, gender-specific ranges defined by Prati et al., 
200263) had a significantly higher positive predictive value for development of insulin resistance 
than ATP-III in nonobese, nondiabetic subjects64. Multiple studies (reviewed in Anstee et al., 
2013) indicate that the presence of NAFLD/NASH can predict the development of cardiovascular 
disease and T2DM after adjustment for obesity65.  The significance of these findings is 
straightforward: the liver is an early site of dysfunction in MS, and liver injury can predict both MS 
and its component diseases early in the natural history of this complex syndrome.   
The liver, therefore, is a central hub in the progression of MS, however, because fatty 
liver disease may be a cause or effect of systemic metabolic dysfunction, there may be 
differences in specific direct and compensatory responses of hepatocytes depending on the 
initiating event(s).  These differences in engaged pathways may also affect the mechanisms 
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Table 4 






Test Parameter NHLBI/AHA: 
ATP-III Criteria, CHF/CVD 
primary outcome 
(3 of the 5 required) 
IDF: 
IR/T2DM primary outcome 
(Visceral obesity required + 2 of 
the 4 remaining) 
Obesity Visceral obesity 
(waist 
circumference) 
> 102 cm in men or 
> 88 cm in women 
For Europid, Sub-Saharan 
African and Eastern 
Mediterranean and Middle 
Eastern 
Men: ≥ 94cm 
Women: ≥ 80cm  
For South Asian, Chinese, 
Ethnic south and central 
American 
Men: ≥ 90 cm 
Women: ≥ 80 cm  
For Japanese 
Men ≥ 85 cm 
Women ≥ 90 cm 
Hypertension Elevated blood 
pressure 
> 130⁄ 85 mm Hg > 130⁄ 85 mm Hg 












> 1.7 mmol/L ≥ 1.7 mmol/l 
(or treatment history) 
Low HDL 
cholesterol 
 < 1.04 mmol/L < 1.03 mmol/l for men 
< 1.29 mmol/l for women 
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which drive changes in circulating biomarkers, including mechanistic biomarkers of hepatocyte 
death, transcription and release of microRNAs, and release of liver-specific functional enzymes 
which can be used for liver injury screening.  This is important, because while liver disease 
occurs early in MS and can be causal, it is also generally asymptomatic, making non-invasive, 
low-risk detection techniques imperative. 
Imaging techniques are non-invasive and low-risk and may eventually (in combination 
with serum biomarkers) provide sensitive and specific diagnosis and staging of fatty liver disease 
to subclinical populations.  At present, however, ultrasonography is both subjective and 
qualitative, and X-ray computed tomography (CT), proton magnetic resonance spectroscopy (1H-
MRS), and magnetic resonance imaging (MRI) are all resource-intensive and still cannot reliably 
distinguish simple steatosis from steatohepatitis65.  Elevated liver transaminases are widely used 
clinically for diagnosis of liver injury, but they are far more effective for indicating liver injury from 
endogenous causes (cholestatic, vascular, or autoimmune injury) acute, severe intoxication (i.e. 
occupational exposures to chemicals or alcohol-induced liver injury) overdose-related or 
idiosyncratic drug-induced liver injury (DILI), or infectious hepatitis (Hepatitis A, B, C).  TASH 
related to chronic organochlorine exposure may be particularly problematic, as previous research 
suggests that transaminase levels may remain subclinical even with severe injury66.  For the 
purposes of environmental health research, the use of transaminases as indicators of liver injury 
presents an additional problem: transaminase activity is lost relatively quickly in stored blood or 
serum, even under optimal storage conditions67, 68, reducing the ability of liver transaminase 
panels to reflect injury in archived samples. Emerging serum biomarkers such as microRNA 122, 
or the mechanistic biomarker cytokeratin 18 (CK18) may offer alternative methods to non-
invasively detect subacute or chronic liver injury and liver injury of different etiologies, including 
TASH.  CK18, because it is relatively storage-stable66 and can be detected in both whole and 
caspase-cleaved forms66, 69, 70, can discriminate hepatocyte death due to necrosis (the 
predominant mechanism in TASH) from hepatocellular apoptosis (the predominant mechanism in 
ASH, NASH, and viral hepatitis71-73), is a particularly appealing biomarker. 
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In summary, NAFLD is recognized as a component of MS, and the functional role of the 
liver in both intermediary and xenobiotic metabolism suggests that progressive hepatic 
dysfunction could cause, contribute to, or derive from systemic metabolic dysfunction.  TASH is a 
subcategory of NAFLD which is histologically indistinguishable from NASH and ASH but 
mechanistically and diagnostically unique.  This difference presents an opportunity to distinguish 
TASH from other forms of fatty liver disease using mechanistic biomarkers, but also hinders 
diagnosis of liver injury due to chronic toxicant exposure because it is undetectable using typical 
clinical laboratory screening techniques.  This is important to the field of environmental health 
science because exposures occurring incrementally through ingestion of contaminants are more 
likely to be low-level and chronic, resulting in slowly-progressive subclinical disease. 
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CHAPTER ONE: PCBS ARE ASSOCIATED WITH TOXICANT-ASSOCIATED 
STEATOHEPATITIS, INFLAMMATION, AND METABOLIC DYSREGULATION IN AN 
EXPOSED HUMAN POPULATION 
Anniston, Alabama was the location of a chemical manufacturing plant where an estimated 
400,000 metric tons of PCBs were produced between 1929 and the 197174.  At least 20.5 metric 
tons of PCBs were released into the atmosphere prior to plant closure in 1971, and nearly 19,000 
metric tons of PCBs or PCB distillation residue were buried in unlined landfills near the plant site 
before and after production was halted74.  The environment near the manufacturing plant is highly 
contaminated; assessment of tree bark in the area revealed PCB concentrations of 171.93 µg/g 
lipid near the plant and landfills, which dropped dramatically to 35 ng/g lipid within 17 kilometers75.  
In the late 1990s and early 2000s, several environmental assessments of contamination in Anniston 
were published, renewing concern over exposures in the residential population and the potential 
health effects.  At that time, there existed over 6 decades of data indicating the status of PCBs as 
human toxicants6, although the human health effects from environmental exposure were less well 
characterized than industrial exposures.  Nevertheless, concerns from residents, university 
collaborators and environmental groups initiated the Anniston Community Health Survey (ACHS) 
in 2003, funded by the Agency for Toxic Substances Disease Registry (ATSDR)76, 77.   
ACHS, and a follow-up study (ACHS-II, undertaken in 2014) are both large, cross-
sectional research projects which provided an opportunity to evaluate accumulation of 
environmental pollutants (POPs, heavy metals, etc.) in a residential population, and to assess 
health effects related to these exposures as well as the effects of coexposures/comorbid 
conditions49, 76, 78-80. Important findings from the ACHS include increased mean PCB levels 
compared to NHANES (2-3 fold), which are significantly different between non-Hispanic white and 
African-American/black participants78. Importantly, laboratories working with serum samples and 
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data from the ACHS project have independently reported elevated prevalence of diseases related 
to metabolic syndrome including obesity (54%)81, hypertension76, diabetes49, and dyslipidemia79. 
Blood pressure elevations (both in hypertensive and normotensive ranges), dyslipidemia, and 
diabetes (particularly in women over 55 years of age) were significantly associated with the total 
body burden of PCBs49, 76, 79, 82.   
As previously stated, NAFLD is the liver manifestation of metabolic syndrome, therefore, 
we undertook an investigation of liver disease in the Anniston cohorts.  We hypothesized that 
biomarker-indicated liver injury would be prevalent in the ACHS and ACHS-II populations, due to 
the high prevalence of other metabolic disease. Because of the BMI-independent relationship 
between liver injury and PCB load reported in our NHANES study37 and the specific hepatocyte 
death mechanism detected in other studies of TASH66, 69, we further hypothesized that PCB-
exposed individuals in Anniston would display a pattern of hepatocellular necrosis indicative of 
TASH. Because steatohepatitis has previously been associated with insulin resistance and 
systemic inflammation 83, 84, we anticipated that dysregulation in biomarkers of these conditions 
would be observed along with elevations in indicators of liver damage and death. 
Our primary biomarker of hepatocyte injury was cytokeratin 18, an intermediate filament 
enriched in epithelioid cells, especially hepatocytes (Figure 5).  Early in apoptosis, CK-18 is 
cleaved by caspases, producing a neoepitope, CK18-M30.  Both total CK18-M65 and the 
caspase-cleaved component CK18-M30 are released from dying cells and can be detected in 
the serum, therefore, the relative levels of these two forms can provide insight as to whether 
hepatocytes are undergoing predominantly apoptotic or predominantly necrotic cell death.  
CK18-M30 is a well-characterized biomarker of hepatocellular apoptosis. Many groups have 
demonstrated the utility of CK18-M30 as a diagnostic tool for steatohepatitis due to infection, 
alcohol, and NASH.  Our lab previously demonstrated that total CK18, but not caspase-cleaved 
CK18, was elevated in individuals with severe liver damage due to vinyl chloride inhalation.  We 
recognized that the effect of PCBs on liver injury could be direct or indirect (by promoting 
systemic metabolic dysfunction through some other mechanism or target).  We 
25
Figure 5. Origin and detection of cytokeratin 18 in serum samples 
(A) Cytokeratin 18 (CK18) is an intermediate filament enriched in hepatocytes and arranged in 
filaments from the nuclear surface to the plasma membrane. (B) In cells undergoing apoptosis, 
CK18 is cleaved by caspases and released from disintegrating apoptotic bodies. (C) In cells 
undergoing necrosis, disintegration of the plasma membrane releases whole CK18. (D) Both 
cleaved and uncleaved CK18 can be detected in the serum, using an antibody against an epitope 
on all CK18 proteins (M65 – red stars) or an antibody against a neoepitope exposed by cleavage 
(M30 – yellow stars).  The predominance of each form indicates the primary mechanism of 
hepatocyte death.  Serum from individuals with NASH related to metabolic disease have a 
primarily apoptotic CK18 profile, while serum from individuals exposed to vinyl chloride have a 
primarily necrotic CK18 profile. 
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hypothesized in the Anniston cohorts, a positive relationship would exist between serum 
concentrations of PCBs and serum levels of total CK18 due to their toxicant exposure. We 
hypothesized that a positive relationship between serum concentrations of PCBs and serum 
levels of caspase-cleaved CK18 would exist if PCBs influenced liver injury indirectly through 
effects on other organ systems, leading to NASH.  
In addition, we evaluated the relationships between serum PCB levels and various other 
biomarkers of liver pathology and systemic inflammation, as well as biomarkers and calculated 
values reflecting metabolic function.  The purpose of these evaluations was to determine the 
relationship (if any) between serum PCB concentration and components of the metabolic 
syndrome.   
Lastly, because PCBs exist as a mixture, different congeners and/or groups of congeners 
acting on shared mechanism(s) could have differential effects, depending on the mechanisms. In 
the NHANES study, a significant association was found between liver injury and several individual 
congeners (Table 5). We hypothesized that serum levels individual congeners and congener 
groups would have differential associations with biomarkers of hepatocyte apoptosis and 
necrosis, fibrosis, insulin resistance, pancreatic function, and systemic inflammation. 
 To investigate our hypotheses, we determined the prevalence of TASH in both populations 
using the mechanistic hepatocyte death biomarker cytokeratin 18 (CK18) and other liver injury 
biomarkers, as well as serologic biomarkers of systemic inflammation and metabolic function 
(glucose and lipid metabolism).
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Table 5 
PCB congeners associated with AOR for unexplained ALT elevations in NHANES 2003-2004. 
Quartile p-value 
1st 2nd 3rd 4th Ptrend Ptrend-adj 






















































































































































































In the 2003-2004 NHANES study, individual PCB congeners associated with a significantly 
increased odds ratio for unexplained ALT elevation.  The adjusted p-trend adjusts for age, sex, 
race/ethnicity, insulin resistance (HOMA-IR), income (PIR), and obesity (BMI).  Adapted from 
Cave, et al 2010x.  Used with permission.
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CHAPTER ONE: MATERIALS AND METHODS 
Study design and recruitment of the ACHS and ACHS-II Cohorts 
ACHS 
The ACHS cohort was assembled in 2003 and has been previously described49, 76.  The 
two-stage sampling procedure involved, first, the random selection of 3,320 households from a list 
of all residences within the Anniston city limits.  Residences in West Anniston, nearer to the PCB 
manufacturing facility, were oversampled.  ACHS staff visited each of the selected residences, 
contacting 1,823 of the targeted households.  One adult (>18 years of age) from each of 1,110 
households agreed to participate and completed an exhaustive questionnaire covering 
demographic, family history, health history, and specific exposure- and lifestyle-relevant questions. 
The selected individual also completed a clinic visit, in which biometric measurements (height, 
weight, blood pressure) were assessed and a fasting serum sample was submitted.  The overall 
completion rate was 61% (of targeted households). 
The 738 serum samples represented in our ACHS mechanistic liver damage assessment 
and cyto/adipokine evaluation are comprised of adults completing both the survey and a clinic visit, 
in which a fasting blood sample was successfully submitted for analysis.  
ACHS MicroRNA subcohort 
152 ACHS samples submitted to the laboratory of Dr. Brian Chorley (US EPA) were 
selected from a stratified subset of the original 738 in which the above parameters were assessed 
(stratifications based on CK18 determined TASH/no liver disease, sex and race).
29
ACHS-II 
ACHS-II was designed to remedy limitations in the original ACHS study design and to 
provide longitudinal data on exposures and health outcomes in this population.  ACHS-II is a subset 
of the original ACHS cohort, and was approached as an effort to recontact every surviving subject 
from ACHS. Individuals were recruited to the ACHS-II cohort by a multi-stage and multi-platform 
methodology described in detail by Birnbaum et al.80  Methods used by ACHS staff to initiate contact 
or determine ineligibility were: recruitment letters (to all original ACHS participants at baseline 
addresses) and a public meeting (advertised and covered by local media), further attempts via 
phone contact (to last known phone numbers of ACHS participants), Social Security Death Index 
searches.  To determine the status and location of participants not reachable at their last listed 
number, study staff searched the Social Security Death Index, and a second recruitment mailing to 
all original and updated addresses. Through a combination of these approaches, 359 eligible 
participants were enrolled in ACHS-II, and of these, the blood volumes of 345 subjects were of 
adequate quantity for biomarker determination. 
The University of Louisville Institutional Review Board approved the studies performed on 
archived, de-identified samples from these cohorts. 
Collection of samples and analysis of polychlorinated organic pollutant concentrations  
The de-identified serum samples examined in these studies were collected during the 
ACHS and ACHS-II studies and archived at -800C.   Identification and quantification of the levels 
of PCBs (35 ortho-substituted congeners in ACHS and 38 dioxin-like and non-dioxin-like congeners 
for ACHS-II) and other contaminants was determined by high-resolution gas 
chromatography/isotope dilution high-resolution mass spectrometry performed at the National 
Center for Environmental Health Laboratory of the Centers for Disease Control and Prevention 
(Atlanta, GA)49, 76, 78, 79.   
Serum concentrations of contaminants were compared to biomarkers and calculated 
disease parameters both individually and based on several summation schemes based on 
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previously reported risk assessment protocols and mechanistic studies. For ACHS, 35 ortho-
substituted congeners were analyzed. In ACHS-II, 35 ortho-substituted congeners, 3 non-ortho, 
and several other classes of chemical contaminants were analyzed, including the polychlorinated 
dibenzo dioxin (PCDD) and polychlorinated dibenzofuran (PCDF) classes.  Composition of these 
groupings by individual congener are described in Table 2. Structural/functional groupings of PCB 
congeners measured in ACHS-II.  
Measurement of steatohepatitis biomarkers   
CK18 is a structural protein enriched in hepatocytes which can be detected in both whole 
and caspase-cleaved forms, allowing for the differentiation of hepatocellular apoptosis (caspase-
cleaved CK18 or M30) from necrosis (CK18 M65). Because the hepatocellular death mechanism 
appears to vary by etiology of fatty liver disease 83, 84, the pattern of CK18 elevation has been used 
to differentiate TASH (predominantly necrotic, elevations in CK18 M65 alone) from other fatty liver 
diseases (predominantly apoptotic, elevated CK18 M30 and M65)69. Moreover, unlike 
transaminases, which the detectable property of enzyme activity is not retained during long-term 
storage67, CK18 levels are determined by immunoassay-based protein quantitation, detectable in 
samples archived for several decades66, 69.  This was an important consideration for biomarker 
selection, as the original ACHS samples had been archived for 7-9 years prior to our analysis. In 
both phases of the Anniston Community Health Survey, CK18 M65 and M30 (PEVIVA 10020 and 
10010, Diapharma, Cincinnati, OH) were measured by separate enzyme-linked immunosorbent 
assays each using a monoclonal antibody recognizing a different CK18 epitope.  
Quantifiable variations in several serum microRNA are associated with liver injury and 
other metabolic diseases.  A subset of serum samples from the ACHS cohort representing subjects 
randomly selected from groups stratified by sex, race and liver disease status (TASH vs. no liver 
disease as determined by CK-18) were evaluated for serum levels of 60 liver-associated 
microRNAs.  These analyses were performed by firefly analysis through our collaborator Brian 
Chorley of the EPA.  
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Liver function tests including alanine transaminase (ALT), asparagine transaminase (AST), 
alkaline phosphatase (ALP), bilirubin, and albumin are widely used non-invasive clinical screening 
tools for the assessment of liver injury (of diverse origins).  Importantly, however, toxicant-
associated steatohepatitis usually presents without transaminitis, in contrast to other forms of liver 
injury including NASH and ASH when commonly-used normal ranges are applied. A liver function 
panel including ALT, AST, ALP, total and direct bilirubin and albumin was carried out on ACHS-II 
samples at the University of Louisville Hospital Clinical Laboratory.  Due to limited sample volumes 
and long storage times, clinical liver function tests were not performed on serum from ACHS.   
Evaluation of other serum biomarkers 
Fasting insulin, adipokines, and pro-inflammatory cytokines were also measured in 
archived samples from both phases of the Anniston Community Health Survey.  Adipocytokines 
were measured using two separate multiplex bead arrays run on a Luminex IS100 system (EMD 
Millipore Corporation, Billerica, MA).  The first array (HADK2MAG-61K) measured interleukin 6 (IL-
6), interleukin 8 (IL-8), monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor α (TNFα), 
interleukin 1-β (IL-1β), insulin, and leptin.  For the second array (HADK1MAG-61K), samples were 
diluted 1:400 in the provided assay buffer, and adiponectin, resistin, and total plasminogen activator 
inhibitor-1 (PAI-1) were measured.  The homeostatic models of assessment (HOMA)85 were used 
to evaluate insulin resistance (HOMA-IR) and pancreatic beta cell function (HOMA-B).  
In ACHS-II, hyaluronic acid, an additional fibrosis biomarker was measured by ELISA 
(#029-001, Corgenix, Inc., Broomfield, CO).  Endotoxin was measured by limulus amoebocyte 
assay (#50-650U, Lonza Walkersville, Inc., Walkersville, MD) and total antioxidant activity was 
measured by chromogenic assay (#709001, Cayman Chemical Company, Ann Arbor, MI). Serum 
levels of a wide range of cytokines were provided by collaborators at ATSDR and SUNY, and were 
evaluated for associations with PCB exposures and TASH indicators. 
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Derivation of calculated values 
Substituted values for contaminant levels beyond the detectable range 
Levels of individual congeners reported by the ATSDR laboratory as “undetectable” were 
substituted with a value equal to the lower limit of detection for the specific congener divided by the 
square root of 286. When measured concentrations below the stated lower limit of detection were 
reported from the laboratory, those measurements (rather than substituted values) were used78. 
This method was previously employed to analyze and report associations between serum PCB 
level and diabetes49 and hypertension76 in the ACHS cohort.   
Substituted values for serum biomarker levels beyond the detectable range 
Biomarkers assessed in our laboratory which were below the level of detection (IL-1β < 1.3 
pg/ml; IL-6 < 0.96 pg/ml; insulin < 9.6 pg/ml; IL-8 < 0.64 pg/ml; MCP-1 < 1.3 pg/ml; TNFα < 0.64 
pg/ml) were set to half the lower limit of detection. Leptin levels greater than the upper limit of 
quantification (leptin > 600 ng/ml, 1 record) were set to 600 ng/ml. 
Total Lipids 
Values for total lipids were calculated by a standard87 which has been used previously to report 
findings in the ACHS cohort49, 76. The formula for total lipids is listed in Figure 3, Equation 7. 
Lipid-adjusted PCB 
PCBs are highly lipophilic and move between physiological compartments along with lipids.  
Therefore, adjustment for the total lipid content of serum is used to normalize total PCB 
concentrations in serum, and PCBs are expressed PCB wet weight per gram lipid.   
HOMA-IR and HOMA-B 
The homeostatic model of assessment uses weighted fasting serum glucose and insulin 
measurements to assess adequacy of compensation mechanisms: insulin secretion in response to 
glucose load and glucose disposal in response to insulin secretion.  Together, they are models 
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used to determine pancreatic dysfunction vs. insulin resistance as etiologies in hyperglycemia85, 88. 
The results are dimensionless and represent insulin resistance and percent pancreatic function.  
Formulae for calculating HOMA parameters are listed in Figure 3, Equations 5 and 6. 
PCB groupings and TEQ 
PCBs have been grouped in various ways by structure and function for purposes of risk 
assessment and association studies.  We incorporated several of these techniques into our 
analyses.  Because only 35 ortho PCBs were quantified in serum samples from the ACHS cohort, 
for purposes of evaluating significant associations with our measured parameters, we presented 
the data as lipid-adjusted serum levels of individual congeners and lipid-adjusted levels of the sum 
of all 35 congeners measured (ƩPCB-O). In ACHS-II, the panel of PCBs and other contaminants 
was expanded, increasing the number of dioxin-like compounds measured.  In this group, we were 
therefore able to present associations between measured parameters and the lipid-adjusted serum 
levels of individual congeners and various summations listed in Table 2. Structural/functional 
groupings of PCB congeners measured in ACHS-II. 
As discussed in the introduction, historic focus on toxicity mechanisms dependent on AhR 
led to the adoption of the toxic equivalency, which is a measure of potency with regards to AhR 
normalized to the effects of the AhR ligand TCDD.  Toxic equivalency factors (TEFs) have been 
established for some dioxin-like chemicals31. Besides PCBs, other chemical contributors to the total 
dioxin equivalency (Total Dioxin TEQ) that were measured in ACHS2 included polychlorinated 
dibenzo-p-dioxins (PCDDs, n=7), polychlorinated dibenzofurans (PCDFs, n=10) and 
polybrominated diphenyl ethers (PBDEs, n=12). Using the 2005 World Health Organization TEFs, 
we established toxic equivalency (TEQ) values for each dioxin-like congener, as well as TEQ by 
class (PCBs, PCDDs, PCDFs) and Total Dioxin TEQ for each sample within the ACHS-II cohort to 
explore the relationship between AhR activation and biomarker/disease status. TEQs for each 
congener were derived by multiplying the concentration in each sample by the TEF, and summation 
of TEQ by class and for all dioxins was carried out by the formulae listed in Figure 3, Equations 1-
3 and 4, respectively. 
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Statistical Analysis   
Stratification into liver disease categories 
For each cohort, subjects were stratified into three groups based solely on the combination 
of CK18 M65 and M30 levels: one group without evident liver disease (no liver disease, or NLD, 
M30<200 U/L and M65<300 U/L) and two groups with liver disease.  The two liver disease groups 
differ by hepatocyte death mechanism: primarily necrotic hepatocyte death characteristic of TASH 
(M30<200 U/L and M65>300 U/L), and primarily apoptotic hepatocyte death encompassing other 
forms of liver disease (other liver disease, or OLD, M30>200 U/L). These cutoff values were based 
on prior studies 69, 89.  
Associations between liver disease category and demographic groups or biomarkers 
Counts and percentages for the main predictors were determined in the entire ACHS 
population and for each stratification based on liver disease category. Differences in means and 
frequencies by liver disease category were tested with a one-way ANOVA or chi-square test, 
respectively. The TASH and OLD liver disease categories were always compared against NLD.  
For each biomarker, regression lines were plotted within each category of liver disease status to 
generate a β coefficient describing the relationship between biomarker and status. Biomarkers 
were analyzed with multivariable generalized linear models to assess the relationship between 
serum PCB levels and each outcome including with or without confounders. Unless specified 
elsewhere, PCB levels were adjusted for log-transformed lipid levels.   
Using SAS version 9.4 (SAS Institute, Cary, NC), and a statistical significance level of 0.05, 
Multinomial logistic regressions models were constructed to analyze the associations of PCB, BMI, 
and an interaction between PCB levels and BMI adjusted with and without additional confounders. 
Biomarkers, PCB levels, and total lipid levels were log-transformed. All models used wet-weight 
(ng/g serum) log-transformed individual PCB congeners with total lipids (also log-transformed) as 
a covariate.  Unless noted elsewhere, all analyses were adjusted for age (years; continuous), body 
mass index (BMI, kg/m2; continuous), gender (male vs. female), race (African-American vs. non-
Hispanic white), diabetes status (none, pre-diabetic, or diabetic), alcohol use and lipid levels.
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CHAPTER ONE: RESULTS 
Liver injury is prevalent and persistent in a human population highly exposed to 
environmentally-acquired PCBs  
Summaries of population demographics for the three cohorts described are provided in 
Tables 6-12. In ACHS, the 738-subject cohort was comprised of a high percentage of African-
Americans (46.8%), females (70.1%), subjects ≥50 years old (63.0%), non-drinkers (70.6%), and 
non-smokers (69.0%). Most subjects (80.3%) were either overweight (BMI≥25 kg/m2) or obese 
(BMI≥30 kg/m2).  Subjects were categorized by liver disease status based on elevated CK18 levels 
consistent with either hepatocellular necrosis (TASH) – elevated CK18-M65 without CK18-M30 
elevation, or apoptosis (OLD) with elevated CK18-M30.  The prevalence of liver disease was 60.2% 
including 48.6% with TASH and 11.5% with Other. Higher CK18 M65 levels were found in non-
Hispanic whites compared to African-Americans (p<0.001). A univariate sensitivity analysis 
excluding thirteen subjects with total wet-weight PCB levels beyond four standard deviations of the 
mean was performed (Table 13).  This analysis showed that CK18 M65 was higher in non-Hispanic 
whites (p<0.001) and in males (p=0.03); while CK18 M30 was higher in non-Hispanic whites 
(p<0.001) and decreased with age (p=0.01). 
In ACHS-II, the 345-subject cohort was comprised of a high percentage of African-
Americans (48.7%), females (73.0%), and subjects ≥50 years old (86.1%).  As in ACHS, most of 
the subjects were non-smokers (79.4%), however, more of the participants in ACHS-II consumed 
alcohol (60.0%), with 51.3% drinking within defined limits and 8.7% drinking more than defined 
limits.  Most subjects (80.0%) were either overweight (25.5%) or obese (51.3%) by the criteria listed 
above. Prevalence of liver disease in this cohort was 62.0%: 46% with TASH and 16% with OLD. 
Participants with liver disease were more likely to be younger (p=0.03) and white (p=0.01).
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Table 6 
Demographics in ACHS by Liver Disease Status – continuous variables 
Liver disease status 
Characteristic 
None TASH Other P-value Total 
(n = 294) (n = 359) (n = 85) (n = 738) 
Age (years) 54.1±15.7 56.0±16.3a 51.5±15.1 0.04 54.7±15.9 
BMI (kg/m2) 31.5±7.8 30.9±7.7 32.1±7.7 0.34 31.25±7.7 
∑PCBs (ortho, 
whole weight) 










233.6±42.6 430.6±122.1a,b 792.5±584.9c <0.001 393.8±276.0 
Cytokeratin 18 
M30 (U/dL) 
97.9±22.0 124.0±28.2a,b 407.6±324.6c <0.001 146.3±147.1 
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that 
cytokeratin 18 levels were used for categorization procedures. 
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease 
categories. 
a adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category. 
b adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category. 
c adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.  
d Limits are <= 30 drinks for females and <=60 drinks for males. 
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Table 7 
Demographics in ACHS by Liver Disease Status – biometric categorical variables 
Liver disease status 
Characteristic 
None TASH Other P-value Total 
(n = 294) (n = 359) (n = 85) (n = 738) 
Gender 0.03 
Male 72 (24.5) 123b (34.3)  26 (30.6) 221 (30.0) 
 Female 222 (75.5) 236 (65.7) 59 (69.4) 517 (70.1) 
Race/ethnicity <0.001 
Non-Hispanic White 117 (39.8) 223b (62.1) 53c (62.4) 393 (53.3) 
African/American 177 (60.2) 136 (37.9) 32 (37.7) 345 (46.8) 
Age (years) 0.13 
< 30 24 (8.2) 31 (8.7) 8 (9.4) 63 (8.5) 
30-40 41 (14.0) 25 (7.0) 12 (14.1) 78 (10.6) 
40-50 45 (15.3) 69 (19.2) 18 (21.2) 132 (17.9) 
50-60 66 (22.5) 75 (20.9) 20 (23.5) 161 (21.8) 
60-70 63 (21.4) 75 (20.9) 15 (17.7) 153 (20.7) 
≥70 55 (18.7) 84 (23.4) 12 (14.1) 151 (20.5) 
BMI (kg/m2) 0.40 
< 18.5 3 (1.0) 2 (0.6) 0 (0.0) 5 (0.7) 
18.5 - 24.9 61 (20.8) 67 (18.7) 14 (16.5) 142 (19.3) 
25 - 29.9 62 (21.1) 109 (30.4) 20 (23.5) 191 (26.0) 
30 - 34.9 77 (26.2) 90 (25.1) 22 (25.9) 189 (25.7) 
35 -39.9 48 (16.3) 48 (13.4) 15 (17.7) 111 (15.1) 
≥40 42 (14.3) 42 (11.7) 14 (16.5) 98 (13.3) 
Missing 1 (0.3) 1 (0.3) 0 (0.0) 
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that 
cytokeratin 18 levels were used for categorization procedures. 
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease 
categories. 
a adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category. 
b adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category. 
c adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.  
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Table 8 
Demographics in ACHS by Liver Disease Status – lifestyle categorical variables 
Liver disease status 
Characteristic 
None TASH Other P-value Total 
(n = 294) (n = 359) (n = 85) (n = 738) 
Number of drinks in last 30 days 0.70 
No drinks 205 (69.7) 254 (70.8) 62 (72.9) 521 (70.6) 
Within defined limitsd 63 (21.4) 73 (20.3) 14 (16.5) 150 (20.3) 
More than limit 16 (5.4) 23 (6.4) 8 (9.4) 47 (6.4) 
Missing 10 (3.4) 9 (2.5) 1 (1.2) 20 (2.7) 
Current Smoker 0.69 
No 208 (70.8) 243 (67.7) 58 (68.2) 509 (69.0) 
 Yes 86 (29.3) 116 (32.3) 27 (31.8) 229 (31.0) 
West Anniston resident 0.25 
No 43 (14.6) 62 (17.3) 12 (14.1) 117 (15.9) 
Yes 251 (85.4) 297 (82.7) 73 (85.9) 621 (84.2) 
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. Note that 
cytokeratin 18 levels were used for categorization procedures. 
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease 
categories. 
a adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category. 
b adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category. 
c adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.  
d Limits are <= 30 drinks for females and <=60 drinks for males. 
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Table 9 
Demographics in ACHS-II by Liver Disease Status – continuous variables 
Liver disease status 
Characteristic None TASH Other P-value Total 
(n = 131) (n = 158) (n = 56) (n = 345) 
Age (years) 63.8±12.7 63.4±13.3 59.1±12.9 0.06 62.9±13.1 
BMI (kg/m2) 32.0±9.5 31.2±7.2 32.2±7.2 0.59 31.7±8.1 
∑PCBs (ortho and 
non-ortho, whole 
weight), ppb 
6.0±6.4 5.4±7.2 5.6±9.8 0.20 5.7±7.4 
Cytokeratin 18 M65 
(U/dL) 
231.8±46.0 436.7±142.9 624.8±368.1 <.001 389.4±226.5 
Cytokeratin 18 M30 
(U/dL) 
84.1±26.5 111.6±36.3 380.1±269.8 <.001 144.7±153.1 
Total lipids (mg/dL) 611.1±143.7 632.5±162.1 622.1±154.8 0.47 622.7±154.0 
Gender 0.07 
Male 26 (19.9) 49 (31.0) 18 (32.1) 93 (27.0) 
Female 105 (80.2) 109 (69.0) 38 (67.9) 252 (73.0) 
Race/ethnicity 0.01 
Non-Hispanic 
White 50 (38.2) 90 (57.0) 28 (50.0) 168 (48.7) 
African/ 
American 81 (61.8) 68 (43.0) 28 (50.0) 177 (51.3) 
Data are n(%) or mean±SD. Not all percents add to 100% due to rounding. 
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease 
categories. 
Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease; 
ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis 
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Table 10 
Demographics in ACHS-II by Liver Disease Status – biometric categorical variables 
Liver disease status 
Characteristic None TASH Other P-value Total 
(n = 131) (n = 158) (n = 56) (n = 345) 
Gender 0.07 
Male 26 (19.9) 49 (31.0) 18 (32.1) 93 (27.0) 
 Female 105 (80.2) 109 (69.0) 38 (67.9) 252 (73.0) 
Race/ethnicity 0.01 
Non-Hispanic 
White 50 (38.2) 90 (57.0) 28 (50.0) 168 (48.7) 
African/American 81 (61.8) 68 (43.0) 28 (50.0) 177 (51.3) 
Age (years) 0.03 
< 30 0 3 (1.9) 0 3 (0.9) 
30-40 6 (4.6) 5 (3.2) 5 (8.9) 16 (4.6) 
40-50 13 (9.9) 11 (7.0) 5 (8.9) 29 (8.4) 
50-60 24 (18.3) 43 (27.2) 23 (41.1) 90 (26.1) 
60-70 42 (32.0) 41 (26.0) 10 (17.9) 93 (27.0) 
≥70 46 (35.1) 55 (34.8) 13 (23.2) 114 (33.0) 
BMI (kg/m2) 0.73 
< 18.5 1 (0.8) 0 0 1 (0.3) 
18.5 - 24.9 26 (20.0) 32 (20.8) 9 (16.1) 67 (19.5) 
25 - 29.9 39 (30) 44 (28.6) 15 (26.8) 99 (28.8) 
30 - 34.9 28 (21.5) 33 (21.4) 11 (19.6) 73 (21.2) 
35 -39.9 16 (12.3) 28 (18.2) 9 (16.1) 54 (15.7) 
≥40 20 (15.4) 17 (11.0) 12 (21.4) 50 (14.5) 
Missing 1 1 
Data are n(%) or mean±SD. Not all percents add to 100% due to 
rounding. 
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease 
categories. 
Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease; 
ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis 
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Table 11 
Demographics in ACHS-II by Liver Disease Status – health and lifestyle categorical variables 
Liver disease status 
Characteristic 
None TASH Other 
P-
value Total 
(n = 131) (n = 158) (n = 56) (n = 345) 
Diabetes Status 0.19 
Ever Diabetic 44 (33.6) 69 (43.7) 24 (42.9) 137 (39.7) 
Non-diabetic 87 (66.4) 89 (56.3) 32 (57.1) 208 (60.3) 
Typical Number of Drinks in Past 12 
Months 
0.43 
No drinks 56 (42.8) 57 (36.1) 25 (44.6) 138 (40.0) 
Within defined limitsd 66 (50.4) 87 (55.1) 24 (42.9) 177 (51.3) 
 More than limit 9 (6.9) 14 (8.9) 7 (12.5) 30 (8.7) 
Current Smoker 0.88 
No 105 (80.8) 124 (78.5) 44 (78.6) 273 (79.4) 
Yes 25 (19.2) 34 (21.5) 12 (21.4) 71 (20.6) 
Missing 1 1 
Data are n(%) or mean±SD. Not all percents add to 100% due to 
rounding. 
P-value is one-way ANOVA (means) or Pearson chi-square test, across liver disease 
categories. 
d Limits are <= 1 drink/day for females and <=2 drinks/day for males. 
Abbreviations: BMI, body mass index; None, no liver disease; Other, other liver disease; 
ΣPCB, sum of polychlorinated biphenyl congeners; TASH, toxicant associated steatohepatitis 
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Table 12 
Demographic characteristics and liver disease status of ACHS microRNA subcohort 
Liver disease status 
Characteristic 
None TASH P-Value 
(n = 76) (n = 76) 
Age (years) 56.5±13.8 55.3±14.5 0.62 
BMI (kg/m2) 30.2±6.0 32.6±8.1 0.045 
∑PCBs (whole weight) 6.8±8.6 11.3±26.6 0.16 
Total lipids (mg/dL) 605.8±139.0 658.6±173.5 0.04 
Gender 
Male 38 (50.0) 38 (50.0) 
Female 38 (50.0) 38 (50.0) 
Race/ethnicity 0.03 
Non-Hispanic 
White 31 (40.8) 44 (57.9) 
Nonwhite 45 (59.2) 32 (42.1) 
Age (years) 0.32 
< 30 2 (2.6) 4 (5.3) 
30-40 10 (13.2) 6 (7.9) 
40-50 11 (14.5) 16 (20.1) 
50-60 16 (20.1) 22 (29.0) 
60-70 22 (29.0) 13 (17.1) 
≥70 15 (19.7) 15 (19.7) 
BMI (kg/m2) 0.31 
18.5 - 24.9 17 (22.7) 9 (12.0) 
25 - 29.9 18 (24.0) 20 (26.7) 
30 - 34.9 24 (32.0) 21 (28.0) 
35 -39.9 9 (12.0) 13 (17.1) 
≥40 7 (9.3) 12 (16.0) 
Missing 1 1 
Number of drinks in last 30 days 0.80 
No drinks 53 (69.7) 53 (69.7) 
Within defined 
limits** 16 (20.1) 13 (17.1) 
More than limit 5 (6.6) 8 (10.5) 
Missing 2 (2.6) 2 (2.6) 
Current Smoker 0.49 
No 50 (65.8) 54 (71.1) 
Yes 26 (34.2) 22 (29.0) 
West Anniston resident 0.29 
No 6 (7.9) 10 (13.2) 
Yes 70 (92.1) 66 (86.8) 
* Not all percents add to 100% due to rounding
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Significant demographic differences were seen across liver disease categories with 
respect to age, gender, and race/ethnicity. Males were more likely than females to have TASH 
(55.7% vs. 45.6%, p<0.05) in ACHS, with gender differences found to be nonsignificant in ACHS-
II. In both studies, subjects with TASH were significantly more likely to be non-Hispanic white than 
subjects without liver disease (62.1% vs. 39.8% in ACHS and 57.0% vs. 38.2% in ACHS-II). The 
combined prevalence of liver disease was highest among males (67.4% in ACHS and 72.0% in 
ACHS-II) and non-Hispanic whites (70.2% in both cohorts).  These results are consistent with the 
increased susceptibility to fatty liver disease in Caucasians (compared to African Americans) and 
males as reported previously in other epidemiological studies90.  TASH was associated with 
significantly increased age compared to Other in ACHS (56.0±16.3 vs. 51.5±15.1), but not in 
ACHS-II. No intragroup differences were seen in other demographic or exposure variables 
including total PCBs (wet weight) or West Anniston residence, body mass index, alcohol 
consumption, or smoking status.   
Total lipids were significantly increased in both TASH and Other in ACHS (Table 6) while 
there were no significant intragroup differences for this parameter in ACHS-II (Table 9). Because 
both necrotic and apoptotic (M30) hepatocyte death contribute to total CK18 (M65), it is not 
surprising, based on the classification procedures, that CK18 M65 was significantly increased in 
both liver disease groups compared to None. However, the absolute M65 level was increased to a 
greater degree in Other compared to TASH, even though only M30 abnormality was used to 
discriminate between the two. 
Liver injury in Anniston is associated with increased pro-inflammatory cytokines and 
metabolic abnormalities. 
Steatohepatitis is associated with increased serum pro-inflammatory cytokines, which can 
result from and/or lead to liver injury and metabolic disease91, 92.  As shown in Table 14, IL-1β, IL-
6, IL-8, MCP-1, PAI-1, and TNFα were all numerically higher across liver disease categories 
(graphs), but only MCP-1 (p=0.01) and PAI-1 (p=0.001) reached statistical significance in the 
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Table 14 
Unadjusted ACHS Biomarker levels by liver disease status. 
Liver disease status 




(n = 294) (n = 359) (n = 85) (n = 738) 
Adiponectin ng/ml 
 Mean±SD 17.2±12.4 18.3±19.1 15.1±10.2 0.22 17.5±15.8 
Glucose, mg/dl 
 Mean±SD 105.1±40.4 108.2±40.9 115.7±53.9 0.13 107.8±42.5 
HOMA-B 
 Mean±SD 164.2±223.7 183.5±334.3 219.6±306.7 0.29 180.0±291.9
HOMA-IR 
 Mean±SD 3.9±5.4 5.1±8.4 6.4±8.3
a 0.01 4.8±7.4 
IL-1β  pg/ml 
Mean±SD 2.4±7.0 10.0±76.4 13.1±79.9 0.17 7.3±60.0 
 Not detectable 195 214 52 461 
IL-6 pg/ml 
Mean±SD 8.5±42.0 16.4±84.9 13.2±40.6 0.32 12.9±66.4 
Not detectable 35 23 4 62 
IL-8 pg/ml 
Mean±SD 78.7±199.0 101.4±257.4 86.7±304.5 0.49 90.7±242.1 
 Not detectable 0 1 0 1 
Insulin pg/ml 
Mean±SD 492.8±567.2 642.3±1067.2 757.7±918.7a 0.02 596.0±886.4
Not detectable 1 1 0 2 
LDL, mg/dl 
 Mean±SD 117.0±32.7 116.0±39.8 116.5±40.1 0.94 116.5±37.1 
Leptin ng/ml 
Mean±SD 30.5±27.0 29.3±39.7 26.1±25.1 0.57 29.4±33.6 
 Not detectable 0 1 0 1 
MCP-1 pg/ml 
Mean±SD 269.7±175.2 295.1±244.4b 314.9±193.6 0.01 294.6±194.1
Not detectable 0 1 0 1 
PAI-1 ng/ml 
 Mean±SD  49.0±19.4 54.9±21.4b 56.0±23.3a 0.001 52.7±21.1 
Resistin ng/ml 
 Mean±SD 41.0±31.7 44.1±29.8 37.8±19.1 0.15 42.1±29.6 
TNFα pg/ml 
Mean±SD 6.4±5.5 9.2±24.2 7.0±7.1 0.11 7.8±17.4 
 Not detectable 3 2 0 5 
Triglycerides, mg/dl 
Mean±SD 119.3±75.5 147.0±107.5b 160.6±130.7a 0.0002 137.5±100.3
P-value is one-way ANOVA, across all liver disease categories, unadjusted.  
a adj-p<=0.05 in pair-wise comparison of None vs. Other liver disease category.  
b adj-p<=0.05 in pair-wise comparison of None vs. TASH liver disease category.  
c adj-p<=0.05 in pair-wise comparison of TASH vs. Other liver disease category. 
46
unadjusted model. MCP-1 was higher in TASH than None (295.1±244.4 pg/ml vs. 269.7±175.2 
pg/ml, p=0.009). PAI-1 was increased in both TASH (54.9±21.4 ng/ml, p=.001) and Other 
(56.0±23.3 ng/ml, p=0.02) compared to None (49.0±19.4 ng/ml).   
NAFLD is also commonly associated with insulin resistance and hypertriglyceridemia 93. 
The mean HOMA-IR for the overall cohort was elevated (4.8±7.4) beyond one proposed cutoff for 
insulin resistance (HOMA-IR >4.65 or HOMA-IR >3.60 and BMI >27.5 kg/m2)94. HOMA-IR varied 
significantly across liver disease groups (p=0.01), and it was increased in Other compared to None 
(6.4±8.3 vs. 3.9±5.4, p=.017). While HOMA-IR was numerically higher in TASH (5.1±8.4) than 
None, this trend did not reach statistical significance. Fasting insulin varied in a pattern like that 
observed for HOMA-IR (Table 14), and likely accounted for the observed difference in HOMA-IR 
as glucose levels were not different between groups. Triglycerides varied by liver disease category 
(p=0.007) and were higher in both TASH (147.0±107.5 mg/dl, p=.001) and Other (160.6±130.7 
mg/dl, p=.002) vs. None (119.3±75.5 mg/dl). In summary, both TASH and Other were associated 
with increased PAI-1 and triglycerides. MCP-1 was also increased in TASH, while both HOMA-IR 
and insulin were increased in Other. 
In ACHS, TASH was associated with increased levels of IL-1β (p=0.04), IL-6 (p=0.03), and 
PAI-1 (p=0.03) in our unadjusted model (Table 15). Beta coefficients for other pro-inflammatory 
cytokines including IL-8, MCP-1, resistin, and TNFα were positive in TASH but did not reach 
statistical significance. TASH was also associated with increased HOMA-IR (p=0.001) with 
increased pancreatic insulin production (HOMA-B, p=0.003) and increased insulin levels (p=0.01) 
(Table 16) Other was associated with increased IL-6 (p=0.01), HOMA-IR (p=0.02), insulin (p=0.04), 
and decreased leptin (p=0.01). Thus, the liver disease categories remained associated with 
increased pro-inflammatory cytokines and hepatic insulin resistance after adjustment for 
confounders, although the specific cytokines varied slightly between models. This increases the 
certainty that the categorization procedures correctly identified liver disease. TASH appeared more 










PCB 0.01 0.05 0.90  
TASH vs. None 0.18 0.09 0.04 
 




PCB 0.05 0.05 0.33  
TASH vs. None 0.27 0.09 0.003 
Other vs. None 0.39 0.14 0.01 
IL-8 
PCB 0.08 0.07 0.25 
TASH vs. None 0.15 0.12 0.20 
Other vs. None -0.04 0.18 0.83 
MCP-1  
PCB 0.02 0.03 0.53 
TASH vs. None 0.01 0.05 0.91 
Other vs. None -0.07 0.08 0.36 
PAI-1 
PCB -0.01 0.02 0.51 
TASH vs. None 0.07 0.03 0.03 
Other vs. None 0.07 0.05 0.15 
TNFα  
PCB 0.04 0.03 0.26  
TASH vs. None 0.07 0.06 0.20 
  Other vs. None -0.04 0.09 0.65 
a Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity, 




Table 16  
Adjusteda beta coefficients of associations of ΣPCBs (wet weight) and liver status with 
metabolic biomarkers 
Cytokine/Adipokine β Standard Error p-Value 
Adiponectin  
PCB 0.01 0.03 0.69 
TASH vs. None -0.04 0.05 0.43 
Other vs. None -0.06 0.08 0.43 
Glucose  
PCB <0.001 0.01 1.00 
TASH vs. None 0.00 0.02 0.90 
Other vs. None 0.03 0.03 0.18 
Insulin 
PCB -0.07 0.04 0.04 
TASH vs. None 0.22 0.06 <0.001 
Other vs. None 0.19 0.09 0.04 
HOMA-B 
PCB -0.07 0.04 0.08 
TASH vs. None 0.20 0.07 0.003 
Other vs. None 0.13 0.10 0.22 
HOMA-IR 
PCB -0.08 0.04 0.03 
TASH vs. None 0.21 0.06 0.001 
Other vs. None 0.21 0.09 0.02 
Leptin  
PCB -0.14 0.04 <0.001 
TASH vs. None -0.06 0.06 0.32 
Other vs. None -0.24 0.09 0.01 
Resistin 
PCB 0.01 0.03 0.81 
TASH vs. None 0.06 0.05 0.20 
Other vs. None -0.06 0.07 0.41 
a Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity, 
diabetes, and alcohol use.  
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Liver injury in Anniston was validated by microRNA analysis and clinical liver function tests 
Analysis of serum microRNA was used to validate the findings of ACHS in a subset of the 
cohort, described as the ACHS miRNA cohort.  Demographic findings for this population are shown 
in Table 12.  This semi-balanced subgroup differs from the other two in several demographic 
characteristics. TASH participants tended to have higher BMI (kg/m2: 32.6 vs. 30.2, p = 0.045), 
total lipids (mg/dL: 659 vs. 606, p = 0.04) and insulin/HOMA-B/HOMA-IR (p = 0.01, 0.045, 0.01). 
They were more likely to be non-Hispanic white (58% vs. 41%, p = 0.03). Serum levels of 68 
microRNAs related to liver and other metabolic disease were quantified by Firefly assay and 
compared between CK18-defined TASH and NLD groups in this subcohort.   
Differential levels of several microRNAs related to liver injury were seen between two liver 
disease categories.  The well-characterized biomarker of liver injury, microRNA 122 (miR-122-5p), 
was significantly increased in the TASH group vs. the no liver disease (NLD) group.  Several other 
liver- and metabolic disease-associated microRNA were different between the two groups as well, 
including miR-22-3p, miR-320a, and miR-375 (significantly increased), and miR-223-3p was 
significantly decreased in TASH vs. NLD (Table 17). 
Several microRNA showed significant positive and/or negative associations with the 
individual isoforms of CK18, including miR-122, which was associated with an increase in CK18-
M30 and a smaller positive association with CK18-M65. Of the microRNA transcripts assayed, only 
miR-877-5p displayed a similar pattern.  Other microRNA showed either positive (hsa_miR_22_3p, 
hsa_miR_320a, hsa_miR_375, or negative (hsa_miR_21_5p, hsa_miR_375, hsa_miR_92a_3p) 
association with CK18-M65 alone.  Positive and negative associations (β-coefficients) for 
microRNA vs. CK-18 isoforms are shown in Table 18.   
Liver injury in ACHS-II was validated using clinical liver function tests (LFT). Clinical liver 
function tests including ALT, AST, Alkaline phosphatase, and total bilirubin were significantly 
elevated in the liver disease categories vs. control (Table 19).  It is interesting to note, however, 
that by standard cutoffs used by the NHANES laboratory, prevalence of ALT abnormality in ACHS2 
for females and males (respectively) would be 7.6% and 3.9% in the NLD category, 42% and 56% 
in the OLD category, and 22% and 8.2% in the TASH category, respectively.  By the cutoffs 
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Table 17 
ACHS validation - miRNA data by CK18 liver disease group 
Quantile-Normalized Data 
Adjusted for age, race, bmi, log(10)-total PCB, log(10)-lipids, plate 
Probe Fold Adj-P FDR Raw-P NLD TASH 
hsa_miR_122_5p 1.58 0.02 0.01 0.003 83.37 132.13 
hsa_miR_223_3p 0.91 0.33 0.06 0.047 533.99 485.08 
hsa_miR_22_3p 1.09 0.26 0.05 0.04 865.24 941.12 
hsa_miR_320a 1.09 0.04 0.01 0.01 1320.94 1444.48 
hsa_miR_375 1.18 0.12 0.03 0.02 6.94 8.19 
hsa_miR_92a_3p 0.93 0.02 0.01 0.003 1457.91 1357.75 
A subset of samples from ACHS Phase 1 were analyzed for levels of specific microRNA 
(miRNA) species associated with liver and/or metabolic disease.  Individuals with CK18-
indicated TASH (TASH) were compared to individuals with CK levels indicating no liver disease 
(NLD). Included in this table are those with a significant difference between groups (raw p-
value < .05).  
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Table 18 





Error Raw-P β 
Standard 
Error Raw-P 
hsa_miR_122_5p 1.00 0.33 0.003 0.20 0.09 0.02 
hsa_miR_21_5p 0.01 0.13 0.94 -0.19 0.08 0.02 
hsa_miR_22_3p 0.09 0.09 0.31 0.14 0.05 0.01 
hsa_miR_29a_3p -0.05 0.08 0.52 -0.10 0.05 0.06 
hsa_miR_29c_3p -0.10 0.10 0.36 -0.10 0.06 0.11 
hsa_miR_320a 0.09 0.07 0.19 0.10 0.04 0.04 
hsa_miR_375 0.09 0.15 0.55 0.20 0.09 0.03 
hsa_miR_503_5p -0.04 0.10 0.70 -0.12 0.06 0.05 
hsa_miR_877_5p 0.20 0.10 0.04 0.14 0.06 0.02 
hsa_miR_92a_3p -0.08 0.05 0.15 -0.09 0.03 0.003 
Several miRNA species showed significant positive or negative associations with either CK18 
M30 level or CK18 M65 level. 
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Table 19 
 ACHS-II  validation – LFTs by CK18 liver disease group 
Liver disease status 
 Characteristic None TASH Other P-value 
(n = 131) (n = 158) (n = 56) 
AST 25.9±8.1 29.0±12.1 42.2±27.4 <0.001 
ALT 22.8±8.6 29.6±9.8 38.3±19.3 <0.001 
Alk Phos 85.5±22.7 91.1±38.9 104.7±58.0 0.01 
Albumin 4.2±0.4 4.2±0.4 4.2±0.5 0.85 
Total Bilirubin 0.36±0.16 0.42±0.24 0.46±0.24 0.01 
Liver injury was validated in ACHS 2 (Phase 2) using the clinical liver injury biomarkers 
aspartate transaminase (AST), alanine transaminase (AST), alkaline phosphatase (Alk Phos), 
albumin, and total bilirubin. 
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suggested in Prati et al., (Table 20) prevalence of ALT abnormality in ACHS2 for females and males 
(respectively) would be 61% and 15% in the NLD category, 76% and 94% in the other liver disease 
(OLD) category, and 82% and 33% in the TASH category.  By either set of definitions, ALT performs 
better as a diagnostic tool for individuals with liver injury in which the predominant mechanism of 
cell death is apoptosis.   
Associations between ΣPCBs on Liver Disease as assessed by CK18, LFTs and miRNA 122 
Previous epidemiologic studies have demonstrated dose responses for PCBs in liver 
disease 95-99, and animal studies have demonstrated interactions between PCBs and diet-induced 
obesity in steatohepatitis22, 23.  Univariate analysis was performed in the ACHS-1 cohort to 
determine associations between ƩPCBs and the liver injury biomarkers used to derive the liver 
injury categories (Table 13). There were no significant associations between ƩPCB exposure 
variables (lipid-adjusted or wet weight) and either CK18 M65 or M30 in the population overall.    A 
sensitivity analysis was performed, excluding thirteen participants of 738 with total PCB wet weight 
values within four standard deviations of the mean.  In this sensitivity analysis alone, significant 
negative associations were found between both lipid-adjusted and wet-weight serum PCB content 
and CK18 M30, but not M65.   
Multinomial logistic regression was performed using multivariate models adjusted with or 
without additional confounders to investigate possible relationships between ƩPCBs and BMI and 
liver disease status (Table 21). Liver disease status was not associated with either ƩPCB levels or 
BMI whether alone or in combination. In both cohorts, there was no association between ƩPCBs 
or ƩPCB-O on liver disease status as determined by CK-18 (Table 22).  When taken together, these 
results demonstrate that these two summation techniques, ƩPCBs and ƩPCB-O, were not 
associated with CK-18-indicated liver disease status.  
In the ACHS microRNA subcohort, after adjustment for age and race there was no 
association between ƩPCB-O and miRNA 122.  Two other miRNA were significantly positively 
associated (hsa-let-7d-5p and hsa-miR-181d-5p) (Table 23).  In ACHS-II, after adjustment, there 
was were no associations between ƩPCB-O and clinical LFTs (data not shown). 
54
Table 20 








Men 18-21 ALT ≥ 37 IU/L ALT ≥ 70 IU/L 30 U/L 
Men >21 ALT ≥ 48 IU/L ALT ≥ 70 IU/L 30 U/L 
Women 18-21 ALT ≥ 30 IU/L ALT ≥ 70 IU/L 19 U/L 
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Table 23 
Significant associations of ∑PCBs and miRNA species 






0.07 0.03 0.03 
hsa_miR_181d_5p 
0.08 0.03 0.003 
After adjustment for lipids, age, race, and inter-plate variation, no significant relationship was 
found between the specific liver injury biomarker miRNA-122 and ∑PCBs .  Two other miRNA 
species, miRNA-let-7d and miRNA-181d, were positively associated with ∑PCBs. 
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Associations between individual PCB congeners and CK18-indicated liver disease in ACHS 
In the ACHS 1 cohort, TASH was positively associated with 10 PCB congeners (PCB 28, 
44, 49, 52, 66 101, 110, 128, 149, 151). Three congeners associated with TASH were also 
associated with Other (PCB 44, 49, 52). To explore the relationship between PCB levels and cell 
death mechanism, we examined associations between levels of individual congeners and absolute 
levels of CK18 M65 and M30. Thirteen congeners were positively associated with CK18 M65, while 
four PCBs were positively associated with M30 (Table 24). In ACHS1, consistent with the concept 
that TASH is ‘toxicant-associated’, more PCB congeners were associated with TASH than Other 
(10 vs. 3). The relationships between serum PCB concentration and CK18 M65/M30 were different 
for individual congeners than for summed groups. Although 13 congeners were positively 
associated with CK18 M65, ƩPCBs was not associated with this hepatocellular necrosis biomarker. 
While four congeners were positively associated with M30, ƩPCBs was inversely associated with 
this hepatocyte apoptosis biomarker.  
In the ACHS1 population, therefore, PCBs were associated with both liver disease status 
and mode of hepatocyte death.  Future experimental studies are required to evaluate the possible 
mechanistic role of PCBs in liver cell death. While animal studies have reported interactions 
between PCB exposures and diet-induced obesity in steatohepatitis 22, 23, no significant interaction 
was found between ƩPCBs and BMI on liver disease status in this study. However, this analysis 
may have been limited by the high prevalence of overweight/obesity and the elevated PCB levels 
in this population. 
Associations between TEQs for PCB congeners and other dioxin-like species on CK18-
indicated liver injury in ACHS-II 
Within the ACHS-II population, we estimated effects of dioxin-like chemicals on liver 
disease by using the TEQ protocol.  As mentioned previously, the effects of dioxin-like chemicals 
have historically been attributed to AhR-mediated mechanisms, and the TEQ, by estimating the 
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relationship between AhR induction and disease biomarkers. Associations between Total dioxin 
TEQ, TEQ by individual class (PCDD, PCDF, PCB), and TEQ for each dioxin-like chemical with a 
TEF available in the 2005 WHO evaluation were evaluated and are presented in Table 25.  Adjusted 
beta coefficients of significant associations of various TEQ summations and cytokeratin 18 
biomarkers are shown in Table 26. We did not find significant associations between log transformed 
mean of any TEQ sum and TASH status vs. None.  Non-Ortho PCB TEQ and Total Dioxins TEQ 
were significantly lower in the Other liver disease category compared to None. 
Associations between PCBs and other serum biomarkers 
PCB exposure has previously been associated with diabetes 100. However, less is known 
regarding the potential impact of PCBs on adipocytokines. For ACHS, the effects of lipid-adjusted 
ΣPCB levels on unadjusted adipocytokines and biomarkers of glucose and lipid metabolism are 
given as beta coefficients in Table 16. The pro-inflammatory cytokines TNFα (p<0.001) and IL-6 
(p=0.001), were positively associated with ΣPCBs in the unadjusted model. PCBs had no significant 
effects on IL-1β, IL-8, MCP-1, PAI-1, or resistin. HOMA-B (p<0.001) and insulin (p=0.03) levels 
were inversely associated with ΣPCB levels; while no effect was seen on HOMA-IR. Adiponectin 
was positively associated with PCBs (p=0.01) while no difference was seen in leptin. Regression 
curves presented in Figure 6 graphically depict the relationships between log-transformed insulin 
and leptin levels with log-transformed ƩPCBs in ACHS. 
For the ACHS-2 unadjusted model, biomarkers which varied significantly with changes to 
serum concentrations of all PCBs measured (ΣPCB), 35 ortho-substituted congeners (ΣPCB-O), 
or the non-dioxin-like congeners (ΣNDL) are shown in Table 27. In the same population and model, 
the biomarkers which varied significantly with changes to serum concentrations of tri/tetra-ortho 
substituted congeners (ΣPCB-TO), di-ortho substituted congeners (ΣPCB-DO), or mono-ortho 
substituted congeners (ΣPCB-MO) are shown in Table 28, while those which varied significantly 
with changes to serum concentrations of non-ortho substituted congeners (ΣPCB-NO), or dioxin-
like (ΣDL) are shown in Table 29. A summary of the congeners represented in each grouping is 
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Figure 6.  ƩPCBs were inversely associated with metabolic biomarkers in ACHS. Regression 
lines showing the change in insulin (Panel A) and leptin (Panel B) with increasing serum 
PCB load are shown for each liver disease group. 
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Table 27 
Unadjusted ACHS-II biomarker levels by sum of all PCBs (∑PCBs ) sum of 35 ortho-
substituted congeners (∑PCB-O), and all non-dioxin-like congeners (ƩNDL) 
β SE P-value 
∑PCBs Adiponectin (ug/ml) 0.07 0.03 0.03 
MCP-1 -0.07 0.03 0.01 
TNFa 0.07 0.04 0.04 
ALT (SGPT) -0.06 0.02 <.001 
ALK PHOS 0.04 0.01 0.02 
Albumin -0.01 0.00 0.04 
Insulin pmol/L -0.12 0.04 <.001 
HOMA-IR -0.10 0.04 0.01 
HOMA-B -0.13 0.05 0.01 
Hyaluronic Acid (ng/ml) 0.36 0.04 <.001 
Insulin -0.12 0.04 <.001 
CK18 M30 -0.08 0.03 0.00 
ƩPCB-O Adiponectin (ug/ml) 0.08 0.03 0.02 
MCP-1 -0.08 0.03 0.00 
ALT (SGPT) -0.07 0.02 <.001 
ALK PHOS 0.03 0.01 0.02 
Albumin -0.01 0.00 0.01 
Insulin pmol/L -0.13 0.04 <.001 
HOMA-IR -0.12 0.04 0.01 
HOMA-B -0.14 0.05 0.01 
Hyaluronic Acid (ng/ml) 0.37 0.04 <.001 
Insulin -0.13 0.04 <.001 
CK18 M30 -0.08 0.03 0.00 
CK18 M65 -0.04 0.02 0.04 
ƩNDL Adiponectin (ug/ml) 0.08 0.03 0.02 
MCP-1 -0.08 0.03 0.00 
ALT (SGPT) -0.06 0.02 <.001 
ALK PHOS 0.03 0.01 0.02 
Albumin -0.01 0.00 0.02 
Insulin pmol/L -0.13 0.04 <.001 
HOMA-IR -0.12 0.04 0.00 
HOMA-B -0.14 0.05 0.01 
Hyaluronic Acid (ng/ml) 0.37 0.04 <.001 
Insulin -0.13 0.04 <.001 
CK18 M30 -0.08 0.03 0.00 
CK18 M65 -0.04 0.02 0.04 
For the ACHS-II unadjusted model, biomarkers which varied significantly with 
changes to serum concentrations of all PCBs measured (ΣPCB), 35 ortho-substituted 
congeners (ΣPCB-O), or the non-dioxin-like congeners (ΣNDL) are shown. 
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Table 28 
Unadjusted ACHS-II biomarker levels by groups of ortho-substituted PCBs 
β SE P-value 
ƩPCB-TO Adiponectin (ug/ml) 0.08 0.03 0.01 
MCP-1 -0.08 0.03 0.00 
ALT (SGPT) -0.07 0.02 <.001 
ALK PHOS 0.03 0.01 0.03 
Albumin -0.01 0.00 0.01 
Insulin pmol/L -0.13 0.03 <.001 
HOMA-IR -0.13 0.04 0.00 
HOMA-B -0.13 0.05 0.01 
Hyaluronic Acid (ng/ml) 0.34 0.04 <.001 
Insulin -0.13 0.03 <.001 
CK18 M30 -0.07 0.03 0.01 
ƩPCB-DO Adiponectin (ug/ml) 0.07 0.03 0.03 
MCP-1 -0.09 0.03 0.00 
ALT (SGPT) -0.07 0.02 <.001 
ALK PHOS 0.03 0.01 0.02 
Albumin -0.01 0.00 0.02 
Insulin pmol/L -0.13 0.04 <.001 
HOMA-IR -0.12 0.04 0.01 
HOMA-B -0.13 0.05 0.01 
Hyaluronic Acid (ng/ml) 0.37 0.04 <.001 
Insulin -0.13 0.04 <.001 
CK18 M30 -0.09 0.03 0.00 
CK18 M65 -0.05 0.02 0.03 
ƩPCB-MO Adiponectin (ug/ml) 0.08 0.03 0.02 
MCP-1 -0.06 0.03 0.03 
TNFa 0.08 0.04 0.03 
ALT (SGPT) -0.08 0.02 <.001 
ALK PHOS 0.04 0.01 0.01 
Albumin -0.02 0.00 <.001 
Insulin pmol/L -0.11 0.04 0.00 
HOMA-B -0.14 0.05 0.01 
Hyaluronic Acid (ng/ml) 0.33 0.04 <.001 
Insulin -0.11 0.04 0.00 
Leptin 0.23 0.05 <.001 
CK18 M30 -0.08 0.03 0.00 
CK18 M65 -0.06 0.02 0.01 
For the ACHS-II unadjusted model, biomarkers which varied significantly with 
changes to serum concentrations of tri/tetra-ortho substituted congeners (ΣPCB-TO), di-ortho 




Unadjusted ACHS-II biomarker levels by groups of non-ortho-substituted and dioxin-like PCBs 
β SE P-value 
ƩPCB-NO AST (SGOT) -0.06 0.02 0.00 
ALT (SGPT) -0.08 0.02 <.001 
Albumin -0.02 0.01 <.001 
Total Bilirubin -0.07 0.03 0.02 
Direct Bilirubin -0.05 0.02 0.04 
Hyaluronic Acid (ng/ml) 0.22 0.05 <.001 
IL-6 0.14 0.06 0.01 
Leptin 0.27 0.06 <.001 
CK18 M30 -0.08 0.03 0.02 
CK18 M65 -0.06 0.03 0.02 
ƩDL TNFa 0.09 0.03 0.01 
AST (SGOT) -0.04 0.02 0.03 
ALT (SGPT) -0.08 0.02 <.001 
ALK PHOS 0.04 0.01 0.01 
Albumin -0.01 0.00 <.001 
Insulin pmol/L -0.10 0.03 0.00 
HOMA-B -0.14 0.04 0.00 
Hyaluronic Acid (ng/ml) 0.31 0.04 <.001 
Insulin -0.10 0.03 0.00 
Leptin 0.18 0.05 <.001 
CK18 M30 -0.07 0.02 0.00 
CK18 M65 -0.05 0.02 0.01 
For the ACHS-II unadjusted model, biomarkers which varied significantly with changes to 
serum concentrations of non-ortho substituted congeners (ΣPCB-NO), or dioxin-like (ΣDL) are 
shown. 
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In ACHS-II, significant positive relationships were observed between ƩPCBs and 
adiponectin, TNFα, alkaline phosphatase, and hyaluronic acid, while significant negative 
relationships were observed between ƩPCBs and MCP-1, ALT, Albumin, Insulin, HOMA-IR,  and 
HOMA-B.  Interestingly, while most of these relationships were conserved between ƩPCBs and 
other grouping structures, the positive relationship between summed PCBs and TNFα was 
observed only in the comparison with mono-ortho (β=0.08±0.04, p=0.03) and dioxin-like 
(β=0.09±0.03, p=0.01) PCBs, along with an additional positive relationship with IL-6 (β=0.14±0.06, 
p=0.01) observed in the dioxin-like group (Tables 27-29).  This suggests a relationship between 
the inflammatory processes contributing to PCB-related TASH and the structural characteristics of 
congeners within the exposure mixture. 
In the adjusted model, ΣPCBs remained associated with abnormal glucose metabolism. 
ΣPCBs were associated with decreased HOMA-IR (p=0.03) and insulin (p=0.04), with a trend 
towards decreased HOMA-B (p=0.08) (Table 30). ΣPCBs were also associated with decreased 
leptin (p<0.001). To investigate these associations further, we determined adjusted beta 
coefficients for individual PCB congeners and these biomarkers (Table 31). Significant inverse 
associations were seen between seven high molecular weight PCB congeners and both HOMA-IR 
and insulin. Twenty-six congeners (both low and high molecular weight) were inversely associated 
with leptin. Inverse associations were also found between HOMA-B and PCBs 180 and 194. ΣPCBs 
was no longer associated with increased pro-inflammatory cytokines in the adjusted model. Thus, 
PCBs appeared to modulate both liver cell death mechanism, intermediary metabolism, and 
adipokines. The liver-specific impact of PCBs on inflammation was less certain due to variability 
between the adjusted and unadjusted models. 
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Table 30 
ACHS adjusteda beta coefficients of associations of ΣPCBs (wet weight) with biomarkers
Cytokine/Adipokine β SE p-Value 
Glucose <0.001 0.01 1.00 
Insulin -0.07 0.04 0.04 
HOMA-B -0.07 0.04 0.08 
HOMA-IR -0.08 0.04 0.03 
IL-1β 0.01 0.05 0.90 
IL-6 0.05 0.05 0.33 
IL-8 0.08 0.07 0.25 
Leptin -0.14 0.04 <0.001 
MCP-1 0.02 0.03 0.53 
PAI-1 -0.01 0.02 0.51 
Resistin 0.01 0.03 0.81 
TNFα 0.04 0.03 0.26 
a Adjustments were made for lipid levels, age, body mass index, gender, race/ethnicity, 
diabetes, and alcohol use.  
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Table 31 
Adjusted beta coefficients of significant associations of PCB congeners with 
biomarkers of glucose metabolism 
HOMA-B HOMA-IR Insulin Leptin 























157 -0.08 -0.08 -0.13 
167 -0.06 




180 -0.08 -0.08 -0.08 -0.16 
183 -0.06 
187 -0.10 
189 -0.09 -0.16 
194 -0.07 -0.08 -0.08 -0.17 
195 -0.13 
196 -0.08 -0.08 -0.13 
199 -0.08 -0.07 -0.15 
206 -0.06 -0.13 
209 -0.114 
In ACHS-II, several individual congeners were associated with biomarkers or 
assessments of metabolic disease.  Leptin was negatively associated with most 
congeners, while insulin and HOMA-IR were primarily negatively associated with 
higher molecular weight congeners.   
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CHAPTER ONE: DISCUSSION 
To our knowledge, the 738 subjects in ACHS make this the largest environmental liver 
disease study ever undertaken using sensitive mechanistic biomarkers.  The overall liver injury 
prevalence of over 60% is among the highest ever reported for a residential cohort, and is well 
above estimates of NAFLD prevalence in the US and worldwide.  Importantly, this high 
prevalence was maintained across both phases, suggesting that the injury remains chronic and 
the biomarkers of that injury are persistent. Positive associations between TASH categorization 
and elevated pro-inflammatory cytokines, insulin resistance, and hypertriglyceridemia further 
support our conclusion that chronic steatohepatitis has occurred and is persistent in these 
subjects.   
The individuals comprising the ACHS and ACHS-II cohorts are highly contaminated with 
PCBs due to the proximity to a former PCB-manufacturing facility and exposure to PCB-
containing waste released into the environment. Most subjects within these cohorts were also 
overweight or obese, and the ACHS cohort was previously reported to have elevated prevalence 
of disease components of the metabolic syndrome, therefore, we expected to find increased 
prevalence of NASH, consistent with these reports, and we hypothesized that mechanism of 
hepatic injury would be consistent with TASH because of the toxicant exposure.  Liver injury in 
80% of ACHS and 73.8% of ACHS-II cases was associated with hepatocellular necrosis, a 
characteristic of TASH83, 84 but not of NASH, or ASH, which are associated with increased 
hepatocellular apoptosis91.   
The liver is the principal target organ for organochlorine toxicants such as PCBs101-103.  
Associations between PCBs and liver injury have been demonstrated in industrial exposures and 
in cases of accidental poisoning in humans, and chronic PCB exposure has been shown to cause 
steatohepatitis in laboratory animal models.  Attempts to demonstrate a straightforward 
71
relationship between environmental PCB exposure and liver injury in humans, however, has been 
frustrated, in part, by the lack of adequate biomarkers.  In 2010, our laboratory published an 
evaluation of the 2003-2004 NHANES data, which showed an association between serum levels 
of PCBs and elevations of the clinical liver injury biomarker ALT.  In this study, using upper limits 
defined in the 2003-2004 NHANES laboratory protocol104, 10.6% of subjects had ALT elevation 
not attributable to viral hepatitis, hemochromatosis, or alcohol abuse37.  Odds of inclusion in this 
group increased with increasing levels of serum PCBs, and inclusion was also associated with 
overweight/obesity and Hispanic/non-Hispanic White ethnicity, both of which are associated with 
increased NASH prevalence.  The association between PCBs and liver injury in this population 
persisted even after adjustment for BMI, however, the use of ALT in the NHANES population 
does not allow discrimination between NASH and TASH as potential etiologies for liver injury37.   
The use of CK18 M30 and M65 in the ACHS cohorts allowed dissection of these 
etiologies based on cell death mechanism. Our validation studies using alternative (miRNA) or 
approved clinical (ALT) diagnostic methods indicate significantly elevated markers of liver injury in 
the CK18-designated liver injury groups vs. NLD indicate that CK18 can detect liver injury in a 
population such as the ACHS cohorts, where TASH is suspected.  This capability is particularly 
important when one considers the findings of the ACHS-II clinical liver function tests, which 
indicate statistically significant but clinically irrelevant elevations in mean ALT within the TASH 
group.  Mean values for both NLD and “TASH” groups are well below the clinical cutoffs used in 
the 2003-2004 NHANES study as well as in most clinical applications.  Using the upper limits 
recommended in Prati   et al., 200263 (shown in Table 20), which redefined the cutoffs using a 
cohort at low risk for chronic HCV infection or NAFLD, a much larger proportion of the ACHS-II 
cohort has ALT values in the abnormal range (Figure 7), however, even by the Prati definitions, 
ALT abnormality was only detected in 33% of males within the TASH group.  This contrasts with 
females in the TASH group, 82% of whom had ALT abnormalities with the lower cutoff. Liver 
injury due to chronic TASH or TASH superimposed on NASH may not be detected in a clinical 
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Figure 7. Distribution of ALT levels in ACHS by liver disease category. 
Distribution of ALT levels for female (blue circles) and male (green squares) participants in the 
three CK18-defined liver disease categories, with lines indicating upper limits of normal based on 
the NHANES (black lines) or Prati definition (red lines). The upper limit of normal for females is 
the lower line in each color, while the upper limit of normal for males is the upper line in each 






setting using common screening methods, and this could delay identification therapeutic 
intervention. 
Neither ƩPCBs nor BMI was associated with liver disease in the ACHS cohorts, though 
ƩPCBs has been previously associated with liver disease in other epidemiologic studies 37, 95-99.  
Differences in methodologies and demographic/exposure variables might account for this 
discrepancy. However, exposures to 13 specific PCB congeners were associated with TASH and/or 
CK18 M65 elevation in the ACHS cohort. Of these, PCBs 66, 105, 149, 151, 172, 178, and 187 
were previously associated with increased ALT in NHANES97.  The present study using mechanistic 
biomarkers greatly extends this prior work. Some of the thirteen identified PCB congeners (PCBs 
28, 66, 105, and 128) have dioxin-like activity, while others have estrogenic (44, 49, 52, 101, 110) 
or phenobarbital-like (44, 49, 52, 101, 128, 149, 151, 187, 195) effects 105.  Perhaps activation of 
the AhR, estrogen receptor, or the constitutive androstane receptor (CAR) may be involved in PCB-
related TASH. While four congeners were associated with increased CK18 M30, an inverse 
association was observed between ΣPCBs and this apoptosis biomarker.  Notably, activation of 
the PCB receptor CAR, was found to be anti-apoptotic in a mouse model of cholestatic liver disease 
106.  This supports our clinical observation that some phenobarbital-like PCBs, which activate CAR, 
were associated with TASH106. Although not directly tested in this study, it is conceivable that PCBs 
could mediate a transition from NASH to TASH by decreasing apoptosis and promoting more pro-
inflammatory necrotic hepatocyte death. While PCBs were a ‘second hit’ in the transition from diet-
induced steatosis to more advanced liver disease in animal studies23, 107-109, a significant interaction 
between PCBs and BMI on liver disease status was not observed in the present study. Perhaps 
the high rates of overweight/obesity and elevated PCB levels in the cohort limited the ability to 
detect interactions occurring at lower exposures and body weights.   
In ACHS-II, the relationship between pro-inflammatory biomarkers and less ortho-
substituted congener groupings again suggests receptor-mediated disease processes, although 
the loss of significant relationships in the model adjusted for diabetes may indicate that modulation 
of inflammatory response in TASH may be an extrahepatic effect. 
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In ACHS, liver disease affected males (67.2%) and non-Hispanic whites (70.2%) 
disproportionately.  The sex difference is consistent with a recently published report documenting 
increased mortality from hepatic disease in men exposed to PCB through ingestion of contaminated 
rice oil110. Moreover, men and Caucasians have increased susceptibility to NAFLD90. Genetic 
polymorphisms may contribute to ethnic differences in NASH90, 111, 112.  For example, ethnic 
differences in the distribution of null alleles in the NASH susceptibility gene (patatin-like 
phospholipase domain containing protein 3 - PNPLA3), have been reported. We postulate that 
gene-environment interactions may also influence TASH; and that these interactions may have 
contributed to the ethnic differences observed in this study.  In addition to PNPLA3, candidate 
genes include the pregnane X receptor (PXR), which is a PCB receptor 19 with at least two 
polymorphisms previously associated with NAFLD severity 113. The observed gender differences 
could potentially be explained by estrogenic PCB congeners. 
While steatohepatitis has long been associated abnormal adipocytokines 83, 84 relatively 
less is known about the effects of PCBs on these biomarkers.  In a cohort of 992 elderly Swedish 
subjects, ƩPCBs was significantly associated with vascular cell adhesion protein 1 but not IL-6, 
MCP-1, or TNFα 114. However, Aroclor 1260 increased TNFα, IL-6, and PAI-1 23, 108 in mice fed high 
fat diet.  Adiponectin was inversely associated with PCB 28, 138, and 153 in a study of 98 Koreans 
115; but ƩPCBs was not associated with adiponectin levels in the Great Lakes Sport Fish Caught 
Consumers Study (n=413)116.  Leptin receptor expression was decreased in PCB-exposed children 
117; and PCB-exposures induced leptin resistance in the 3T3-L1 cell culture model while increasing 
both TNFα and IL-6 production 118; In the present study, ƩPCBs was associated with increased 
TNFα and IL-6, but only in the unadjusted model. While ƩPCBs was associated with increased 
adiponectin in the unadjusted model, it was associated with decreased leptin in the adjusted model. 
Importantly, in the adjusted model twenty-six PCB congeners were individually associated with 
decreased leptin. If PCBs decrease leptin expression while simultaneously inducing leptin 
resistance, this could be an important potential mechanism for PCB-related metabolic dysfunction. 
A high prevalence of diabetes (27%) has previously been reported in the ACHS49, and the 
impact of PCBs on diabetes has recently been reviewed100. In the present study, ƩPCBs was 
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associated with decreased HOMA-B in the unadjusted model with a trend (p=0.08) towards 
decreased HOMA-B in the adjusted model.  ƩPCBs and nine individual high molecular weight 
congeners were associated with decreased HOMA-IR in the adjusted model. ƩPCBs were inversely 
associated with insulin in both models. Adjustments were not made for diabetes medications, so it 
is difficult to draw firm conclusions from these data.  Nonetheless, these data are by and large 
consistent with the findings from our recently published mouse model. In that experiment, C57Bl/6 
male mice fed a 42% milk fat diet for 12 weeks with or without co-exposure to a high molecular 
weight PCB mixture (Aroclor 1260) at a dose designed to model ACHS108.  PCB treatment induced 
steatohepatitis, decreased HOMA-B and HOMA-IR but did not change glucose tolerance. Hepatic 
gluconeogenesis, glucose transporters, physical activity, food intake, and respiratory exchange 
rate appeared to be regulated, in part, by interactions between PCBs and the nuclear receptors Pxr 
and Car 108. These studies clearly demonstrate significant derangements in glucose metabolism 
occurring in the context of PCB-related liver disease. The mechanisms underpinning the 
complicated effects of PCBs on intermediary metabolism in steatohepatitis require further 
elucidation. However, based on the results of the present study, pancreatic β cell dysfunction, 
rather than insulin resistance (e.g., not Type II diabetes), may be involved in the diabetes 
associated with PCB exposures.  Importantly, such dysfunction would appear to occur in the 
absence of anti-islet antibodies (e.g. not Type I diabetes), suggesting the potential for Type 3c or 
pancreatogenic diabetes119 among the mechanisms of PCB-associated liver disease. 
CK18 is currently the most extensively validated serum biomarker for steatohepatitis as a 
stand-alone test correlating with histology 89, 120; and the addition of transaminases to CK18 in order 
to create a prediction model did not improve the diagnostic value of CK18 alone in NASH 89. In a 
multi-center validation study, the sensitivity and specificity of CK18 M30 for biopsy-proven NASH 
(vs. steatosis alone) were as high as 77% and 92% respectively depending on the test threshold 
89. While CK18 correlated with ALT 69, 89, it offered improved diagnostic accuracy over ALT for
histological NASH 89 and TASH 66. While CK18 is less well validated in TASH than NASH, it showed 
superior performance to ALT in previously published studies 66, 69.  
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This is the first analysis of liver disease in the ACHS, and the results have several 
limitations. The demographic and exposure characteristics of the ACHS cohort are not 
representative of the overall population, limiting the generalizability of the study results.  
Furthermore, the ACHS cohort likely had elevated exposures to unmeasured environmental 
chemicals, including additional dioxin-like PCBs, most notably PCB 126.  In a pilot study of 65 
ACHS participants, median concentrations of the dioxin-like congeners PCB 126 and 169 
approached the 95th percentile reported for the same age group in the general U.S. population for 
subjects age 40-59.  Importantly, dioxin-like PCBs were among the most potent environmental 
chemicals associated with the development of steatosis in rodent studies 121, and several dioxin-
like congeners were associated with TASH in ACHS.  PCB exposures may also have been 
accompanied by exposures to dioxins, dibenzofurans, metals, and other organics related to PCB 
production or releases from the nearby Anniston Army Depot Superfund Site or local ferro-
manganese smelting operations. Although the potentially confounding effects of alcohol were taken 
into consideration, viral hepatitis were not excluded.  Although CK18 is validated clinically, this may 
be the first application of CK18 in an epidemiological study.  The follow-up ACHS-II study 
addresses some of these limitations.  Additional measurements in ACHS-II will include evaluation 
of the relationships between CK-18 and individual congeners.  Future liver imaging and/or biopsies 
would help to confirm the study results. 
In summary, the 60.2% prevalence of liver disease in the PCB-exposed ACHS population 
is among the highest ever reported for a residential cohort.  Assessment of steatohepatitis in 
ACHS/ACHS-II population using the mechanistic liver injury biomarker CK18 revealed increased 
prevalence of hepatocellular necrosis, and clinical LFT analysis indicated the absence of 
transaminitis.   This pattern is characteristic of TASH, a specific subcategory of NAFLD 
associated with chemical exposures. The observed hepatocellular necrosis was associated with 
elevations in the pro-inflammatory cytokine IL-6 and metabolic abnormalities, also consistent with 
TASH. Assessment of the relationship between liver injury biomarkers and PCB exposure in this 
population indicated a relationship between total PCB load and biomarkers of metabolic 
dysfunction and fibrosis, however, increasing total PCB load was not associated with increases in 
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the liver injury biomarker CK18.  Interestingly, positive relationships with pro-inflammatory 
biomarkers IL-6 and TNFα were only seen with non-ortho and dioxin-like congener groupings. 
Exposures to ten individual PCB congeners were also associated with TASH. This suggests that 
congener structures within the mixture may contribute to TASH in different ways. Individuals in 
this cohort are exposed to PCBs at a level 2-3 times higher than the general U.S. population, and, 
importantly, acquire PCBs through environmental (rather than industrial) exposure.   
We therefore conclude that environmental PCB exposure is associated with increased 
liver injury. Individuals with TASH had corresponding elevations in other serum liver injury 
biomarkers, including miR-122, as well as indications of increased fibrosis and systemic 
inflammation. In the context of clinical hepatology practice, our findings suggest that a greater 
focus on the contribution of environmental chemical diseases is warranted, and the lack of 
correlation between clinical liver biomarkers and CK-18 and miR-122 findings suggests that 
standard screening practices may be insufficient to diagnose liver injury in some chemical-
exposed populations.  
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CHAPTER TWO: PCBS INDUCE DIFFERENTIAL TRANSCRIPTION IN LIVER TISSUE FROM 
A MOUSE MODEL OF CHRONIC PCB/DIETARY COEXPOSURE 
The implied mechanistic differences between obesity-related NASH and TASH suggest 
that widespread exposure to persistent organic pollutants may contribute to liver injury.  
Importantly, both dioxin-like and non-dioxin-like congeners appear to drive this difference, making 
it clear that an understanding of the underlying mechanism is needed make therapeutic decisions 
and to revise risk assessment in populations exposed to related chemicals. The apparent multi-
system effects of PCB exposure observed in the Anniston studies appear to converge on liver 
injury, but as PCB exposure in Anniston occurred in a complex coexposure environment, in the 
context of this epidemiological study, it is not straightforward to disentangle PCB effects from diet 
or metabolic disruption originating in organ systems outside the liver.  We hypothesized that 
direct PCB effects in the liver would induce transcriptional changes that could be mapped to 
pathways and processes related to NASH.  
A mouse model of diet-induced obesity and PCB coexposure has been evaluated in our 
laboratory, as previously reported23.  Notable findings from this study included the fact that 
exposure to PCBs decreased fasting glucose in control mice, but had had no discernable effect 
on histological or serological liver damage without dietary coexposure (high-fat diet, HFD).  With 
dietary coexposure, there was more histologically evident liver damage at a moderate exposure 
to PCBs (HFD-A20) than at high exposure (HFD-A200).  High fat diet increased body weight and 
fat pad weight at all three PCB exposure levels, though it was significantly less at the high dose.   
Therefore, HFD and PCB exposure contribute to the phenotype of liver damage and 
metabolic dysfunction in this mouse model.  Moreover, because the Anniston populations were 
observed to have high prevalence of obesity, serologic indicators of liver injury and elevations in 
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IL-6 and tPAI1 at PCB exposures at least 10-fold lower than the 200 mg/kg dose, the 
HFD+20mg/kg conditions most accurately models the PCB/dietary coexposures in Anniston.  We 
hypothesized, therefore, that HFD coexposures would modulate the PCB-dependent 
transcriptome (or vice versa), producing transcriptional changes related to the phenotype in this 
model and in ACHS.  We performed RNAseq analysis on RNA isolated from liver tissue in these 
animals, and performed in silico analysis of the differential transcriptome. Specifically, we 
expected to find that the genes differentially transcribed between CD/vehicle and CD/PCB 
treatment would be enriched in gene ontology terms related to insulin resistance, and genes 
differentially transcribed between CD/PCB and HFD/PCB would be enriched in terms related to 
liver diseases, metabolic diseases, and inflammation.
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CHAPTER TWO: MATERIALS AND METHODS 
Design of the animal study 
In this chronic (12-week) study, male C57Bl/6J mice (8 weeks old; The Jackson 
Laboratory, BarHarbor,ME, USA) were assigned to 6 study groups (n=10) as summarized in 
Figure 7.  Beginning at week 0, each group received one of two diets: control diet (CD, 10.2% 
kCal from fat; TD.06416 Harlan Teklad) or a high fat diet (HFD, 42% kCal from milk fat; TD.88137 
Harlan Teklad), and were allowed one week to acclimate.  Beginning at Week 1, each group 
received one of 3 exposures administered in corn oil by oral gavage: corn oil vehicle, Aroclor 
1260 (AccuStandard, CT, USA) (vs. corn oil alone) at 20 mg/kg or at 200 mg/kg.  Importantly, the 
20 mg/kg exposure was designed to mimic the highest human PCB exposures in the ACHS 
cohort, while the 200 mg/kg exposure was similar to that used in rodent carcinogenesis 
studies102.  The two doses of Aroclor 1260 were administered over a different time period in order 
to manage acute toxicity at the higher dose, with the 20 mg/kg dose administered once (Week 1) 
and the 200 mg/kg dose administered as four 50 mg/kg doses (Weeks 1, 3, 5, and 7).  
Mice were housed in a temperature- and light-controlled room (12 h light; 12 h dark) with 
food and water ad libitum. The animals were euthanized (ketamine/xylazine, 100/20 mg/kg body 
weight, i.p.) at the end of Week 12. Liver tissue was harvested and immediately disrupted in RNA 
Stat-60 reagent (AMS Biotechnology Limited, Abingdon UK) and stored on ice.   
Preparation of RNA samples and RNAseq analysis 
RNA was extracted by the RNA Stat-60 protocol according to manufacturer directions.  
For RNAseq analysis, RNA samples were multiplexed using sequence barcoding, and sequenced 
single ended to 75 base pair reads using a NextSeq500 to an approximate read count of 40 
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Figure 8. PCB exposure and high-fat diet induce phenotypic changes in C57/BL6 mice. 

























million reads per sample.  Base calling (assigning nucleobase identity to chromatogram peaks) 
for these files was accomplished using Illumina’s bcl2fastq software. All sequences produced 
were aligned to the mouse reference genome (GRCm38.83) using the alignment software 
TopHat, and transcript expression levels were calculated in FPKM (fragments per kilobase of 
transcript per million mapped reads) units using Cufflinks122.  The quantification was guided by 
transcriptome annotation for the mouse downloaded from NCBI.  Records corresponding to both 
mitochondrial and ribosomal RNA were removed (annotated as transcript_biotype rRNA or 
Mt_tRNA) to improve the accuracy of the transcriptome quantification.  Differential analyses 
(FPKM units averaged from 4 replicates of each test vs. DMSO-treated controls) were performed 
using CuffDiff. 
qPCR validation of selected targets 
Targets for validation were prototypical targets of the transcription factors AhR, CAR, and 
PXR.  From the isolated RNA samples, cDNA was generated using the QuantiTect Reverse 
Transcription kit (Qiagen #205313) according to manufacturer recommendations.  Multiplexed 
qPCR (target and GAPDH) was carried out on BioRad CFX384 system using the following 
TaqMan Gene Expression Array probes: Cyp1a2 (Applied Biosystems Mm00487224_m1/FAM), 
Cyp3a11 (Applied Biosystems Mm00731567_m1/FAM), Cyp2b10 (Applied Biosystems 
Mm01972453_s1/FAM) and GAPDH (Applied Biosystems, Mm99999915_g1/VIC).  
Pathway and enrichment analyses 
Initial analysis of the datasets were performed using the MetaCoreTM (Thompson 
Reuters) software suite.  For each treatment, the fold changes and p-values for each differentially 
transcribed gene (indexed by Ensembl ID) were uploaded into MetaCoreTM and recognized genes 
were associated with one or more MetaCoreTM-curated network objects.  Prefilters were applied 
to each dataset using a species (M. musculus) and tissue (liver) prefilter. Most of the raw 
Ensembl IDs for targets identified as differentially transcribed in each experimental comparison 
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were successfully mapped to network objects represented within the MetaCoreTM curated 
database (Table 32).  An additional species and tissue prefilter applied to each dataset resulted in 
object sets that were approximately 70% of the original size.  The number of objects which could 
be incorporated into one or more enrichment categories are also shown in Table 32.  The fewest 
objects were represented within disease enrichments (2-5% of each set), with the most 
represented in GO processes (approximately 90-95%).  There were no major discrepancies 
between groups in representation within specific MetaCoreTM ontologies. 
The experiments listed above were analyzed individually using the MetaCoreTM Enrichment 
Analysis Workflow tool.  Vehicle vs. PCB exposure within diet groups are represented by Groups 
1 and 2, while Group 3 compares CD to HFD at 0 (Vehicle), 20 mg/kg or 200 mg/kg.   
The four PCB exposures vs. vehicle control experiments were analyzed using the Toxicity 
Workflow (Liver Toxicity filter) and Biomarkers Analysis (Metabolic Disease filter) to explore 
enrichments specific to liver toxicity and metabolic disease, respectively. Genomic data from 
these experiments was matched to maps, networks and biomarker lists from the peer-reviewed 
literature database manually curated by Thomson Reuters.   
Because xenobiotic receptors such as PXR, CAR and AhR are transcription factors which 
are expected to mediate the transcriptional response to PCBs, as well as other xenobiotic and 
endobiotic molecules, we assessed the differential expression of MetaCoreTM-curated 
transcriptional targets of these receptors and their heterodimer complexes (PXR/RXR-alpha, 
CAR/RXR-alpha, and AhR/ARNT).   
Using the Build Network tool within MetaCoreTM, we analyzed connectivity between 
network objects in each dataset and specific transcription factors, with the ten transcription 
factors which could be expected to modulate transcription of the largest number of targets within 
each dataset ranked highest.   Because the xenobiotic receptors and heterodimer complexes are 
additionally expected to crosstalk with other transcription factors by protein-protein interactions, 
we built shortest-path networks showing the relationships between xenobiotic receptors and their 
binding partners which have defined relationships curated in MetaCoreTM. 
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Table 32
in vivo experiment dataset properties 
*The number associated with each comparison (column 1) is used throughout this section in the
pathway maps generated with MetaCore software. 
The six comparisons listed in column 2 were used to generate datasets of significantly 
differentially transcribed genes (column 3).  Changes to the overall sizes of the datasets were 
induced by import into the MetaCore pathway analysis software and reconciliation with the 
MetaCore curated database (column 4), and the application of prefilters excluding targets not 
associated with species (Mus musculus) or tissue (liver) (column 5).  Numbers of objects 
associated each of 4 core grouping mechanisms curated by MetaCore – maps, diseases, gene 


















































Group 1 (Dose within CD) 
1 CVvsC20 132 128 94 56 3 88 49
2 CVvsC200 1139 1088 825 327 17 736 306
Group 2 (Dose within HFD) 
3 HVvsH20 793 750 544 262 12 520 219
4 HVvsH200 410 388 280 142 13 262 125
Group 3 (Diet within dose) 
5 C20vsH20 1436 1365 996 456 27 899 406
6 C200vsH200 1446 1379 1007 487 30 936 419
7 CVvsHV 1877 1801 1376 620 38 1256 564
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CHAPTER TWO: RESULTS 
PCB exposure induced differential transcription with and without HFD coexposure 
Seven comparisons were made between the aggregated RNAseq data from each 
condition and its respective control using CuffDiff, as indicated in Table 32.  MetacoreTM 
enrichment analyses for the DTG sets resulting from each comparison are shown in Tables 33-
39.    
Chronic PCB exposure in the control-diet-fed animals explored the effects of systemic 
PCB exposure alone on liver tissue. In the CVvsC20 comparison, DTGs were enriched in 
diseases related to nutritional and metabolic disease, obesity and overnutrition, although these 
mice were fed regular synthetic diet (Table 33). Terms related to circadian rhythm were enriched 
among maps, networks and processes within this DTG set as well.  
The 200 mg/kg PCB exposure was a concentration based on rodent toxicity studies.  
Compared to vehicle, DTGs in this exposure were unsurprisingly enriched in terms related to 
previously reported sequelae of high-level PCB exposures: neoplastic disease biomarkers, 
immune-system and inflammatory process maps and networks.  Disruption of cell regulatory 
processes was also indicated at this exposure level.  Interestingly, processes and networks 
related to epithelial-mesenchymal transition and cell identity which are involved in both 
development and tissue remodeling (Wnt, TGFβ signaling), were over-represented in this dataset 
and, to a lesser extent, in the lower PCB exposure (Table 34). 
Our evaluation of chronic moderate and high PCB exposures in the high-fat diet fed 
animals explored the interaction between diet and exposure, to more faithfully reconstruct 
conditions in many human PCB exposures, including Anniston.  In the HVvsH20 and HVvsH200 
comparisons, we generated datasets with genes significantly differentially transcribed in 
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Table 33 
Enrichments for genes differentially transcribed in comparison CVvsC20 
Diseases p-value FDR 
Colonic Diseases 1.271E-11 1.169E-08
In-house Adverse Events 2.304E-11 1.169E-08
Drug-Related Side Effects and Adverse Reactions 2.949E-11 1.169E-08
Nutritional and Metabolic Diseases 3.875E-11 1.169E-08
Cardiovascular Diseases 7.116E-11 1.506E-08
Chemically-Induced Disorders 7.488E-11 1.506E-08
Obesity 1.554E-10 2.280E-08
Overnutrition 1.554E-10 2.280E-08
Vascular Diseases 1.712E-10 2.280E-08
Physiological Phenomena 2.045E-10 2.280E-08
Networks p-value FDR 
Neurophysiological process_Circadian rhythm 2.999E-04 3.029E-02
Development_Hedgehog signaling 3.478E-03 1.756E-01
Proliferation_Negative regulation of cell proliferation 1.424E-02 2.721E-01
Regulation of metabolism_Bile acid regulation of lipid metabolism 
and negative FXR-dependent regulation of bile acids concentration 1.795E-02 2.721E-01
Chemotaxis 2.210E-02 2.721E-01
Cell adhesion_Cell-matrix interactions 2.427E-02 2.721E-01
Cytoskeleton_Intermediate filaments 2.537E-02 2.721E-01
Reproduction_Progesterone signaling 2.560E-02 2.721E-01
Development_EMT_Regulation of epithelial-to-mesenchymal 
transition 3.091E-02 2.721E-01
Development_Neurogenesis_Axonal guidance 3.354E-02 2.721E-01
Maps p-value FDR 
Neurophysiological process_Circadian rhythm 1.656E-04 3.987E-02
Action of GSK3 beta in bipolar disorder 3.242E-04 3.987E-02
DNA damage_ATM/ATR regulation of G1/S checkpoint 8.741E-04 7.167E-02
Development_TGF-beta receptor signaling 3.202E-03 1.199E-01
Development_GM-CSF signaling 3.202E-03 1.199E-01
Development_WNT signaling pathway. Part 2 3.780E-03 1.199E-01
Development_YAP/TAZ-mediated co-regulation of transcription 4.416E-03 1.199E-01
Nicotine metabolism in liver 4.416E-03 1.199E-01
Immune response_IL-5 signaling via JAK/STAT 4.642E-03 1.199E-01
Effect of H. pylori infection on gastric epithelial cell proliferation 4.875E-03 1.199E-01
Processes p-value FDR 
cellular response to chemical stimulus 4.435E-17 1.807E-13
circadian rhythm 1.032E-15 2.103E-12
rhythmic process 1.591E-15 2.161E-12
cellular response to oxygen-containing compound 6.827E-13 6.955E-10
regulation of developmental process 6.009E-12 3.794E-09
regulation of cell differentiation 6.012E-12 3.794E-09
response to chemical 6.518E-12 3.794E-09
cellular response to organic substance 1.324E-11 6.743E-09
regulation of circadian rhythm 1.493E-11 6.759E-09
response to oxygen-containing compound 1.939E-11 7.900E-09
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20).  Top ten 
enrichments for each grouping, ranked from most to least significant by p-value 
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Table 34 
Enrichments for genes differentially transcribed in comparison CVvsC200 
Diseases p-value FDR 
Neoplasms 1.106E-19 1.136E-16
Pathological Conditions, Signs and Symptoms 1.280E-19 1.136E-16
Gastrointestinal Neoplasms 4.616E-19 2.488E-16
Neoplasms by Site 6.790E-19 2.488E-16
Respiratory Tract Neoplasms 7.238E-19 2.488E-16
In-house Adverse Events 9.070E-19 2.488E-16
Gastrointestinal Diseases 9.810E-19 2.488E-16
Drug-Related Side Effects and Adverse Reactions 2.239E-18 4.968E-16
Lung Neoplasms 4.384E-18 8.646E-16
Chemically-Induced Disorders 5.316E-18 9.436E-16
Networks p-value FDR 
Protein folding_Response to unfolded proteins 1.973E-08 3.058E-06
Protein folding_Folding in normal condition 1.576E-05 1.222E-03
Reproduction_Feeding and Neurohormone signaling 7.931E-05 3.470E-03
Development_EMT_Regulation of EMT 8.954E-05 3.470E-03
Signal transduction_WNT signaling 1.304E-04 4.041E-03
Inflammation_Amphoterin signaling 1.777E-04 4.207E-03
Cell cycle_G1-S Growth factor regulation 1.900E-04 4.207E-03
Apoptosis_Endoplasmic reticulum stress pathway 3.415E-04 6.617E-03
Signal Transduction_TGF-beta, GDF and Activin signaling 4.710E-04 8.112E-03
Inflammation_IL-6 signaling 6.253E-04 9.693E-03
Maps p-value FDR 
Immune response_HMGB1/RAGE signaling pathway 1.601E-06 1.242E-03
Immune response_IL-33 signaling pathway 4.092E-06 1.564E-03
Development_GM-CSF signaling 6.840E-06 1.564E-03
Development_Gastrin in cell growth and proliferation 8.063E-06 1.564E-03
CFTR folding and maturation (normal and CF) 1.214E-05 1.884E-03
Immune response_IL-4 signaling pathway 2.083E-05 2.323E-03
Immune response_TLR2 and TLR4 signaling pathways 2.326E-05 2.323E-03
Development_TGF-beta-dependent induction of EMT via RhoA,  
PI3K and ILK 2.395E-05 2.323E-03
Development_Growth factors in regulation of oligodendrocyte 
precursor cell survival 3.183E-05 2.745E-03
Apoptosis and survival_p53-dependent apoptosis 4.710E-05 3.655E-03
Processes p-value FDR 
negative regulation of biological process 6.174E-24 3.243E-20
regulation of response to stimulus 1.167E-23 3.243E-20
regulation of apoptotic process 1.725E-23 3.243E-20
regulation of programmed cell death 1.820E-23 3.243E-20
regulation of signal transduction 2.106E-23 3.243E-20
regulation of cell death 6.601E-23 8.472E-20
negative regulation of cellular process 8.781E-23 9.659E-20
response to organic substance 4.861E-22 4.679E-19
regulation of cell communication 1.172E-21 1.002E-18
regulation of signaling 3.931E-21 3.027E-18
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/vehicle and control diet/200 mg/kg PCB (CVvsC200).  Top 
ten enrichments for each grouping, ranked from most to least significant by p-value 
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Table 35 
Enrichments for genes differentially transcribed in comparison HVvsH20 
Diseases p-value FDR 
Drug-Related Side Effects and Adverse Reactions 1.034E-34 1.907E-31
Chemically-Induced Disorders 4.035E-34 3.721E-31
In-house Adverse Events 9.344E-33 5.744E-30
Pathologic Processes 4.832E-32 2.227E-29
Pathological Conditions, Signs and Symptoms 1.681E-31 6.122E-29
Ovarian Diseases 2.159E-31 6.122E-29
Adnexal Diseases 2.324E-31 6.122E-29
Gonadal Disorders 2.441E-30 5.627E-28
Ovarian Neoplasms 2.986E-30 6.117E-28
Phenomena and Processes 5.235E-30 9.653E-28
Networks p-value FDR 
Inflammation_IL-6 signaling 7.402E-09 1.147E-06
Blood coagulation 3.335E-08 2.584E-06
Development_Blood  vessel morphogenesis 2.242E-06 1.158E-04
Development_EMT_Regulation of EMT 1.976E-05 7.655E-04
Reproduction_Gonadotropin regulation 3.205E-05 9.937E-04
Cell adhesion_Attractive and repulsive receptors 1.921E-04 4.604E-03
Reproduction_FSH-beta signaling pathway 2.121E-04 4.604E-03
Cell cycle_G1-S Growth factor regulation 2.376E-04 4.604E-03
Signal transduction_ESR1-nuclear pathway 2.984E-04 5.138E-03
Inflammation_Kallikrein-kinin system 3.730E-04 5.781E-03
Maps p-value FDR 
Immune response_IL-6-induced acute-phase response in 
hepatocytes 5.092E-13 3.753E-10
Reproduction_Gonadotropin-releasing hormone (GnRH) signaling 9.800E-07 2.408E-04
Immune response_IL-6 signaling pathway via JAK/STAT 9.800E-07 2.408E-04
Blood coagulation_Blood coagulation 1.335E-06 2.460E-04
Immune response_IL-5 signaling via JAK/STAT 4.937E-06 7.277E-04
Mitogenic action of Estradiol / ESR1 (nuclear) in breast cancer 1.176E-05 1.444E-03
Signal transduction_mTORC2 downstream signaling 2.503E-05 2.636E-03
Blood coagulation_Platelet microparticle generation 4.165E-05 3.567E-03
Immune response_MIF-induced cell adhesion, migration and 
angiogenesis 4.763E-05 3.567E-03
Development_Ligand-dependent activation of the ESR1/AP-1 
pathway 4.840E-05 3.567E-03
Processes p-value FDR 
response to organic substance 1.741E-44 1.269E-40
response to chemical 5.052E-38 1.841E-34
cellular response to chemical stimulus 9.611E-37 2.336E-33
response to oxygen-containing compound 6.073E-33 1.107E-29
response to stress 9.920E-28 1.446E-24
response to organic cyclic compound 1.411E-27 1.714E-24
response to hormone 3.131E-25 3.261E-22
positive regulation of multicellular organismal process 6.891E-25 6.279E-22
response to lipid 2.898E-24 2.348E-21
cellular response to organic substance 7.733E-24 5.637E-21
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between high-fat diet/vehicle and high-fat diet/20 mg/kg PCB (HVvsH20).  Top ten 
enrichments for each grouping, ranked from most to least significant by p-value. 
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Table 36 
Enrichments for genes differentially transcribed in comparison HVvsH200 
Diseases p-value FDR 
Pathologic Processes 1.902E-22 2.574E-19
Pathological Conditions, Signs and Symptoms 3.351E-20 2.267E-17
Neoplasms, Ductal, Lobular, and Medullary 9.171E-20 4.136E-17
Neoplasms, Glandular and Epithelial 6.602E-19 2.233E-16
Neoplasms, Neuroepithelial 3.418E-18 9.250E-16
In-house Adverse Events 1.007E-17 2.022E-15
Digestive System Neoplasms 1.046E-17 2.022E-15
Drug-Related Side Effects and Adverse Reactions 1.713E-17 2.639E-15
Carcinoma 1.986E-17 2.639E-15
Stomach Diseases 1.996E-17 2.639E-15
Networks p-value FDR 
Reproduction_FSH-beta signaling pathway 1.355E-04 1.350E-02
Development_Regulation of angiogenesis 2.381E-04 1.350E-02
Development_EMT_Regulation of epithelial-to-mesenchymal 
transition 2.736E-04 1.350E-02
Apoptosis_Anti-apoptosis mediated by external signals via NF-kB 5.384E-04 1.758E-02
Protein folding_Response to unfolded proteins 5.940E-04 1.758E-02
Protein folding_Folding in normal condition 8.931E-04 2.203E-02
Signal transduction_WNT signaling 1.266E-03 2.677E-02
Proliferation_Negative regulation of cell proliferation 1.731E-03 3.162E-02
Apoptosis_Apoptotic nucleus 1.923E-03 3.162E-02
Proliferation_Positive regulation cell proliferation 2.434E-03 3.602E-02
Maps p-value FDR 
Development_Regulation of EMT 7.035E-06 3.737E-03
Immune response_IL-6-induced acute-phase response/hepatocytes 1.913E-05 3.737E-03
Development_Lipoxin inhibitory action on PDGF, EGF and LTD4 
signaling 1.913E-05 3.737E-03
CFTR folding and maturation (normal and CF) 3.154E-05 4.620E-03
Impaired Lipoxin A4 signaling in CF 6.244E-05 7.318E-03
Immune response_IL-5 signaling via JAK/STAT 2.709E-04 2.645E-02
Immune response_Oncostatin M signaling via JAK-Stat 3.581E-04 2.998E-02
Development_Regulation of lung epithelial progenitor cell 
differentiation 4.474E-04 3.277E-02
Regulation of Tissue factor signaling in cancer 5.602E-04 3.648E-02
Immune response_TNF-R2 signaling pathways 6.931E-04 3.750E-02
Processes p-value FDR 
response to organic substance 6.419E-23 3.433E-19
cellular response to chemical stimulus 3.993E-21 1.068E-17
response to oxygen-containing compound 1.463E-19 2.608E-16
regulation of signal transduction 3.241E-19 4.333E-16
response to hormone 7.205E-19 7.707E-16
negative regulation of cellular process 2.385E-18 2.105E-15
negative regulation of biological process 3.113E-18 2.105E-15
regulation of response to stimulus 3.148E-18 2.105E-15
response to organic cyclic compound 3.973E-18 2.361E-15
regulation of cell communication 5.115E-18 2.735E-15
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between high-fat diet/vehicle and high-fat diet/200 mg/kg PCB (HVvsH200).  Top 
ten enrichments for each grouping, ranked from most to least significant by p-value. 
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Table 37 
Enrichments for genes differentially transcribed in comparison CVvsHV 
Diseases p-value FDR 
Pathological Conditions, Signs and Symptoms 1.668E-40 3.561E-37
Pathologic Processes 1.095E-38 1.169E-35
Nutritional and Metabolic Diseases 2.753E-37 1.959E-34
Drug-Related Side Effects and Adverse Reactions 4.662E-36 2.489E-33
In-house Adverse Events 9.122E-36 3.895E-33
Chemically-Induced Disorders 1.856E-34 6.605E-32
Metabolic Diseases 6.604E-32 2.014E-29
Respiratory Tract Neoplasms 3.016E-29 7.174E-27
Physiological Phenomena 3.024E-29 7.174E-27
Phenomena and Processes 1.560E-28 3.330E-26
Networks p-value FDR 
Development_Regulation of angiogenesis 2.143E-05 3.387E-03
Cell adhesion_Platelet-endothelium-leucocyte interactions 4.700E-05 3.713E-03
Cell adhesion_Cell-matrix interactions 8.355E-05 4.400E-03
Chemotaxis 1.403E-04 5.542E-03
Cell adhesion_Leucocyte chemotaxis 4.519E-04 1.220E-02
Cell adhesion_Integrin-mediated cell-matrix adhesion 5.221E-04 1.220E-02
Cell cycle_G2-M 5.407E-04 1.220E-02
Apoptosis_Anti-Apoptosis mediated by external signals via 
PI3K/AKT 6.200E-04 1.224E-02
Signal Transduction_TGF-beta, GDF and Activin signaling 9.318E-04 1.560E-02
Translation_Translation initiation 9.871E-04 1.560E-02
Maps p-value FDR 
Transcription_Sirtuin6 regulation and functions 2.545E-09 2.146E-06
Immune response_IL-4-induced regulators of cell growth, survival, 
differentiation and metabolism 4.351E-07 1.834E-04
Cell cycle_Regulation of G1/S transition (part 1) 3.614E-06 1.015E-03
Cell cycle_ESR1 regulation of G1/S transition 7.096E-06 1.495E-03
Development_TFs in segregation of hepatocytic lineage 1.382E-05 2.115E-03
Protein folding and maturation_Angiotensin system maturation \ 
Human version 1.505E-05 2.115E-03
Cell adhesion_ECM remodeling 3.057E-05 3.018E-03
Cell cycle_Chromosome condensation in prometaphase 3.389E-05 3.018E-03
Role of ZNF202 in regulating gene expression in atherosclerosis 3.389E-05 3.018E-03
Cell adhesion_Integrin inside-out signaling in neutrophils 3.580E-05 3.018E-03
Processes p-value FDR 
response to organic substance 1.024E-38 9.358E-35
response to oxygen-containing compound 7.650E-31 3.335E-27
cellular response to chemical stimulus 1.095E-30 3.335E-27
single-organism metabolic process 8.462E-30 1.933E-26
response to endogenous stimulus 2.380E-28 4.349E-25
response to organic cyclic compound 7.309E-28 1.113E-24
response to stress 3.846E-27 5.021E-24
response to external stimulus 6.496E-27 7.419E-24
response to lipid 1.313E-26 1.333E-23
response to hormone 1.619E-26 1.391E-23
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/vehicle and high-fat diet/vehicle  (CVvsHV).  Top ten 
enrichments for each grouping, ranked from most to least significant by p-value. 
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Table 38 
Enrichments for genes differentially transcribed in comparison C20vsH20 
Diseases p-value FDR 
Drug-Related Side Effects and Adverse Reactions 9.926E-38 2.026E-34
Chemically-Induced Disorders 4.539E-37 4.632E-34
In-house Adverse Events 8.728E-37 5.938E-34
Pathological Conditions, Signs and Symptoms 2.331E-36 1.189E-33
Pathologic Processes 3.434E-36 1.402E-33
Fibrosis 1.512E-34 5.142E-32
Phenomena and Processes 6.761E-34 1.971E-31
Physiological Phenomena 2.105E-33 5.371E-31
Body Weight 4.840E-32 1.098E-29
Nutritional and Metabolic Diseases 7.909E-32 1.614E-29
Networks p-value FDR 
Development_Regulation of angiogenesis 1.829E-09 2.889E-07
Development_Blood  vessel morphogenesis 8.673E-06 6.851E-04
Development_EMT_Regulation of epithelial-to-mesenchymal 
transition 1.716E-05 9.036E-04
Inflammation_IL-6 signaling 1.992E-04 6.405E-03
Signal Transduction_BMP and GDF signaling 2.027E-04 6.405E-03
Inflammation_Amphoterin signaling 5.171E-04 1.191E-02
Regulation of metabolism_Bile acid regulation of lipid metabolism 
and negative FXR-dependent regulation of bile acids concentration 5.276E-04 1.191E-02
Apoptosis_Endoplasmic reticulum stress pathway 1.562E-03 3.086E-02
Cell adhesion_Attractive and repulsive receptors 1.912E-03 3.357E-02
Blood coagulation 2.654E-03 3.839E-02
Maps p-value FDR 
Transcription_Sirtuin6 regulation and functions 8.710E-09 7.003E-06
Immune response_IL-6-induced acute-phase response/hepatocytes 8.699E-08 3.497E-05
Development_β-adrenergic receptors/brown adipocyte 
differentiation 1.118E-06 2.997E-04
Development_TGF-beta-dependent induction of EMT via MAPK  2.196E-06 4.414E-04
Role of ZNF202 in regulating gene expression in atherosclerosis 4.150E-06 6.673E-04
Protein folding/maturation_Angiotensin system maturation \ Human 5.728E-06 7.675E-04
Protein folding/maturation_Angiotensin system maturation \ Rodent 1.793E-05 2.060E-03
Signal transduction_mTORC1 downstream signaling 3.867E-05 3.526E-03
Immune response_IL-6 signaling pathway via JAK/STAT 4.800E-05 3.526E-03
Apoptosis and survival_Role of PKR in stress-induced apoptosis 4.824E-05 3.526E-03
Processes p-value FDR 
response to oxygen-containing compound 1.007E-43 8.605E-40
response to organic substance 5.608E-42 2.397E-38
cellular response to chemical stimulus 1.522E-37 4.337E-34
response to organic cyclic compound 4.105E-34 8.772E-31
response to organonitrogen compound 2.307E-31 3.944E-28
response to chemical 2.647E-30 3.770E-27
response to external stimulus 3.106E-30 3.792E-27
response to nitrogen compound 4.595E-30 4.909E-27
single-organism metabolic process 1.205E-29 1.144E-26
response to lipid 2.262E-29 1.933E-26
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/20 mg/kg PCB  and high-fat diet/20 mg/kg PCB (C20vsH20).  
Top ten enrichments for each grouping, ranked from most to least significant by p-value. 
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Table 39 
Enrichments for genes differentially transcribed in comparison C200vsH200 
Diseases p-value FDR 
Pathologic Processes 2.843E-45 5.814E-42
Drug-Related Side Effects and Adverse Reactions 4.265E-40 4.139E-37
Pathological Conditions, Signs and Symptoms 6.071E-40 4.139E-37
In-house Adverse Events 4.134E-39 1.816E-36
Chemically-Induced Disorders 4.439E-39 1.816E-36
Nutritional and Metabolic Diseases 1.527E-31 5.204E-29
Metabolic Diseases 8.142E-31 2.379E-28
Vascular Diseases 2.710E-29 6.928E-27
Endocrine System Diseases 2.060E-28 4.681E-26
Cardiovascular Diseases 7.414E-28 1.516E-25
Networks p-value FDR 
Development_Regulation of angiogenesis 5.068E-06 4.739E-04
Chemotaxis 6.115E-06 4.739E-04
Immune response_Phagocytosis 1.356E-05 7.005E-04
Inflammation_IL-6 signaling 6.717E-05 2.603E-03
Cell adhesion_Attractive and repulsive receptors 1.385E-04 3.664E-03
Development_Blood  vessel morphogenesis 1.418E-04 3.664E-03
Cell adhesion_Leucocyte chemotaxis 2.759E-04 6.108E-03
Signal Transduction_Cholecystokinin signaling 1.198E-03 2.320E-02
Cell cycle_G1-S Interleukin regulation 1.407E-03 2.423E-02
Immune response_Phagosome in antigen presentation 1.960E-03 3.037E-02
Maps p-value FDR 
Immune response_IL-4-induced regulators of cell growth, survival, 
differentiation and metabolism 3.816E-07 3.114E-04
Immune response_IL-6-induced acute-phase response/hepatocytes 9.473E-07 3.865E-04
Immune response_IL-2 activation and signaling pathway 3.245E-06 6.912E-04
Development_Role of IL-8 in angiogenesis 3.388E-06 6.912E-04
Neurophysiological_Receptor-mediated axon growth repulsion 1.057E-05 1.539E-03
Immune response_Antigen presentation by MHC class II 1.161E-05 1.539E-03
Transcription_Role of AP-1 in regulation of cellular metabolism 1.320E-05 1.539E-03
Putative pathways for BPA-stimulated fat cell differentiation  1.999E-05 2.039E-03
Cell cycle_ESR1 regulation of G1/S transition 3.414E-05 3.095E-03
Signal transduction_mTORC1 downstream signaling 4.447E-05 3.629E-03
Processes p-value FDR 
response to organic substance 1.995E-37 1.674E-33
single-organism metabolic process 1.987E-32 8.334E-29
small molecule metabolic process 2.501E-31 6.994E-28
response to stress 1.066E-29 1.913E-26
lipid metabolic process 1.140E-29 1.913E-26
response to oxygen-containing compound 5.001E-29 6.993E-26
cellular response to chemical stimulus 8.298E-29 9.946E-26
response to organic cyclic compound 2.895E-27 3.036E-24
response to chemical 8.844E-27 8.245E-24
response to hormone 1.217E-26 1.021E-23
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/200 mg/kg PCB  and high-fat diet/200 mg/kg PCB 
(C200vsH200).  Top ten enrichments for each grouping, ranked from most to least significant 
by p-value. 
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HFD/PCB coexposure vs. HFD alone.  In the HVvsH20 comparison, enriched diseases were 
associated with gonadal and ovarian disease, including ovarian neoplasms.  Enriched networks 
and maps including both inflammatory and EMT-related categories (Table 35).   The HVvsH200 
comparison was notable for enrichments in inflammatory, immune-system and EMT-related 
networks and maps, and neoplastic diseases (Table 36).  Interestingly, both of the HFD+PCB 
groups were highly enriched in multiple processes related to xenobiotic responses (Tables 35-
36), while the CD+PCB groups were enriched in categories related to regulation of physiological 
processes (Tables 33-34). 
Transcriptional effects of HFD exposure were modulated by coexposure to PCBs 
Comparisons between CD and HFD at each level of PCB exposure (CVvsHV, C20vsH20, 
C200vsH200 comparisons) explored the transcriptional effects of HFD exposure without or with 
two levels of PCB coexposure (Tables 37-39).  Unsurprisingly, nutritional and metabolic disease 
biomarkers were over-represented in all three comparisons. Enriched processes for comparisons 
at all levels were associated with changes in cellular response to endobiotic and xenobiotic 
organic cyclic compounds, with responses to endogenous compounds (e.g., hormone, lipid, etc.) 
featuring prominently in the CVvsHV comparison (Table 37), and responses to organonitrogens 
and external stimulus encroaching in the moderate exposure (Table 38).  In a comparison 
between CD and HFD in the highest PCB exposure group, enrichments in process maps related 
to pro-inflammatory and anti-inflammatory cytokine signaling were over-represented (Table 39). 
The sets of genes differentially transcribed by moderate and high PCB exposures within each diet 
partially overlapped 
Figure 9 shows the relative size of the targets differentially transcribed in a comparison 
between vehicle and moderate (gold) or vehicle and high (red) PCB exposure in animals on 
control diet (Panel A) or HFD (Panel B). The overlapping areas indicate targets which are shared 
between moderate and high PCB exposure levels within a single diet condition.  On control diet, a 
94
 
Figure 9. Moderate and high PCB exposures produce overlapping DTG sets (vs. vehicle) 
In an evaluation of PCB transcriptional effect, comparison between PCB exposure and control 
(vehicle) produced sets of significantly differentially transcribed genes (DTGs), which are shown 
for control diet (CD, Panel A) and high fat diet (HFD, Panel B).  The number of targets which were 
differentially affected at both 20 mg/kg Aroclor 1260 and 200 mg/kg Aroclor 1260 are shown in 
the intersecting regions.  Targets which were differentially regulated at only moderate (gold) or 
high (red) dose are shown in the non-intersecting regions.   For CD, high PCB exposure resulted 
in a larger DTG set than moderate PCB exposure.  For HFD, moderate PCB exposure resulted in 




larger number of targets were significantly differentially transcribed in response to chronic high 
PCB exposure (CVvsC200 comparison) than chronic moderate PCB exposure (CVvsC20 
comparison).  In the HFD groups, this pattern was reversed, with a smaller number of genes 
(both absolute and relative) differentially transcribed with the high PCB exposure (HVvsH200 
comparison) and a larger number in the moderate PCB exposure (HVvsH20 comparison).   
Enrichment analysis of DTGs common between moderate and high PCB exposure within 
the CD group are shown in Table 40.  Targets perturbed in both exposures were over-
represented in circadian rhythm-related categories within networks and processes, while 
processes involving response to endogenous and exogenous molecules comprised the 
remainder of the most ten enriched processes.  Interestingly, hedgehog signaling and WNT 
signaling, both involved in development and remodeling, were differentially regulated in both 
moderate and high PCB exposures within this diet group.  In the HFD-fed groups, enrichment 
analysis of DTGs common between both moderate and high PCB exposures were enriched in 
several networks and maps involved in development and EMT, particularly WNT signaling (Table 
41).  Hormone signaling pathways including FSH, progesterone and gonadotropin were also 
identified as commonly engaged networks.   
HFD coexposure at different PCB doses resulted in DTG sets with large areas of overlap 
When high fat diet was compared to control diet within each PCB exposure level 
(CDvsHFD, C20vsH20, C200vsH200), three large sets of differentially transcribed genes were 
identified, with substantial overlap (Figure 10).  In the vehicle-treated comparison (black) the 
entire DTG set can be described as diet-dependent, and the overlapping areas between this and 
other sets can be described as targets which are differentially transcribed with HFD exposure in 
the presence or absence of Aroclor 1260 coexposure.  The top enrichments for the DTGs 
produced are shown in Tables 42-46. The moderate (gold) and high (red) PCB coexposure-
dependent DTGs are represented by the sections of those sets that do not overlap with the 
vehicle-treated comparison.   
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Table 40 
Common targets between moderate/high PCB exposure levels within the control diet groups 
Diseases p-value FDR 
In-house Adverse Events 3.271E-07 1.434E-12
Colonic Diseases 3.480E-07 9.982E-08
Drug-Related Side Effects and Adverse Reactions 3.774E-07 2.375E-12
Endocrine System Diseases 9.532E-07 2.795E-05
Chemically-Induced Disorders 1.422E-06 2.626E-12
Cardiovascular Diseases 1.731E-06 1.550E-08
Neoplasms, Bone Tissue 3.722E-06 2.101E-05
Vascular Diseases 4.292E-06 1.097E-08
Diabetes Mellitus, Type 2 4.349E-06 4.745E-04
Eye Diseases 6.021E-06 5.913E-04
Networks p-value FDR 
Reproduction_Progesterone signaling 2.405E-03 1.465E-01
Regulation of metabolism_Bile acid regulation of lipid metabolism 
and negative FXR-dependent regulation of bile acids concentration 3.806E-03 1.465E-01
Signal transduction_WNT signaling 7.644E-03 2.304E-02
Immune response_IL-5 signalling 1.238E-02 1.980E-01
Reproduction_Feeding and Neurohormone signaling 1.374E-02 1.489E-02
Development_Hedgehog signaling 2.575E-02 3.305E-01
Development_Ossification and bone remodeling 3.250E-02 3.387E-01
Cell adhesion_Glycoconjugates 3.519E-02 3.387E-01
Muscle contraction 4.152E-02 7.278E-02
Neurophysiological process_Circadian rhythm 4.519E-02 7.038E-02
Maps p-value FDR 
Development_WNT signaling pathway. Part 2 6.710E-04 4.347E-02
Nicotine metabolism in liver 7.887E-04 4.347E-02
Immune response_IL-5 signaling via JAK/STAT 8.307E-04 4.347E-02
Action of GSK3 beta in bipolar disorder 2.524E-03 8.628E-02
Immune response_IL-27 signaling pathway 2.748E-03 8.628E-02
Regulation of lipid metabolism_FXR-dependent negative-feedback 
regulation of bile acids concentration 4.564E-03 1.090E-01
DNA damage_ATM/ATR regulation of G1/S checkpoint 4.858E-03 9.421E-02
Development_EPO-induced Jak-STAT pathway 6.121E-03 1.201E-01
Regulation of metabolism_Bile acids FXR regulation/ glucose and 
lipid metabolism 7.886E-03 1.376E-01
Regulation of GSK3 beta in bipolar disorder 9.852E-03 8.940E-02
Processes p-value FDR 
cellular response to chemical stimulus 1.811E-12 6.576E-12
cellular response to organic substance 1.056E-09 1.657E-09
response to stimulus 5.204E-09 1.921E-06
cellular response to oxygen-containing compound 5.723E-09 4.689E-06
circadian rhythm 1.362E-08 1.522E-06
response to chemical 2.079E-08 8.674E-07
response to organic substance 5.529E-08 2.305E-14
rhythmic process 9.143E-08 4.206E-07
response to organic cyclic compound 1.641E-07 2.153E-10
cellular response to organic cyclic compound 2.955E-07 8.475E-05
Top ten enrichments for each grouping, ranked from most to least significant by p-value 
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Table 41 
Common targets between moderate/high PCB exposure levels within the high-fat diet groups 
Diseases p-value FDR 
Hypoxia 1.987E-16 2.285E-13
Neoplasms, Ductal, Lobular, and Medullary 4.844E-16 2.785E-13
Physiological Phenomena 1.831E-15 7.121E-15
Ovarian Neoplasms 1.840E-15 2.478E-15
Ovarian Diseases 2.609E-15 3.432E-16
Adnexal Diseases 2.675E-15 3.432E-16
In-house Adverse Events 2.932E-15 2.308E-17
Vascular Diseases 3.321E-15 5.733E-15
Drug-Related Side Effects and Adverse Reactions 4.143E-15 7.903E-19
Signs and Symptoms, Respiratory 4.344E-15 4.996E-13
Networks p-value FDR 
Reproduction_FSH-beta signaling pathway 2.903E-05 3.056E-03
Reproduction_Progesterone signaling 5.023E-05 3.056E-03
Proliferation_Positive regulation cell proliferation 6.596E-05 3.056E-03
Inflammation_IL-6 signaling 1.805E-04 9.444E-04
Signal transduction_ESR1-membrane pathway 2.894E-04 6.880E-03
Development_Regulation of angiogenesis 3.587E-04 6.880E-03
Signal transduction_WNT signaling 3.775E-04 6.880E-03
Development_EMT_Regulation of EMT 3.960E-04 6.880E-03
Cell cycle_G1-S Growth factor regulation 7.198E-04 1.112E-02
Reproduction_Gonadotropin regulation 8.224E-04 1.143E-02
Maps p-value FDR 
IL-6-induced acute-phase response/hepatocytes 7.330E-06 3.084E-05
Lipoxin inhibitory action-PDGF/EGF/LTD4 signaling 7.330E-06 1.646E-03
Impaired Lipoxin A4 signaling in CF 2.013E-05 3.013E-03
Development_WNT signaling pathway. Part 2 5.040E-05 5.658E-03
Effect of H. pylori infection on gastric epithelial cell proliferation 7.811E-05 7.015E-03
Development_Gastrin in cell growth and proliferation 1.077E-04 7.580E-03
Development_Regulation of EMT 1.254E-04 7.580E-03
Ovarian cancer (main signaling cascades) 1.351E-04 7.580E-03
Development_Beta-adrenergic receptors transactivation of EGFR 1.753E-04 8.333E-03
Development_Ligand-dependent activation/ESR1/AP-1 pathway 1.856E-04 8.333E-03
Processes p-value FDR 
response to organic substance 2.006E-20 5.752E-23
cellular response to chemical stimulus 2.280E-20 4.951E-17
regulation of signal transduction 4.488E-19 6.498E-16
regulation of cell communication 1.713E-18 1.860E-15
regulation of signaling 3.782E-18 3.286E-15
regulation of response to stimulus 1.437E-17 1.041E-14
response to chemical 2.895E-17 8.033E-20
response to oxygen-containing compound 3.049E-17 1.468E-15
positive regulation of cell communication 2.363E-16 1.140E-13
positive regulation of signaling 2.696E-16 1.171E-13
Top ten enrichments for each grouping, ranked from most to least significant by p-value 
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Figure 10. Comparison of PCB/Diet interactions. 
For each PCB exposure, control and high fat diet were compared to generate a differentially 




Enrichment analysis of common targets for all PCB exposure levels within diet 
comparisons (Table 42) showed nutritional, metabolic, and endocrine-related diseases among the 
highly-enriched disease biomarkers, and IL-6 signaling among the engaged maps and processes. 
Processes related to lipid and steroid metabolism, endobiotic and xenobiotic response were also 
commonly engaged in these comparisons.   
Differentially regulated targets within vehicle vs. PCB comparisons were enriched in liver and 
metabolic disease biomarkers 
Because the animal model phenotype suggested liver and metabolic disease processes 
at work, we further explored liver toxicity analysis and biomarker analysis for nutritional and 
metabolic disease within these datasets. In an evaluation of liver toxicity endpoints in the control 
diet groups, there were no significantly enriched pathways for the moderate exposure group 
(Table 43), however, the high exposure was significantly (FDR < 0.05) enriched in pathways 
related to ischemia and hypoxia (Table 44).  In the high fat diet groups, significantly enriched 
categories within the liver toxicity analysis were cholestasis and steatosis pathways for moderate 
exposure (Table 45) and steatosis, fibrosis, and liver hypertrophy in the high exposure group 
(Table 46). Targets affected within the steatosis category are shown in Table 47, and included 
LIPE, ELOVL6, FADS3, GPAM, and several cytochrome P450s including members of the Cyp4A 
and Cyp2C subfamilies.  
One liver injury pathway map which was highly enriched in DTGs from several of the 
conditions was IL-6-mediated acute-phase response in hepatocytes (Figure 11).  Several 
immediate effectors of acute phase response down-stream of IL-6 signaling were up-regulated, 
particularly in the HVvsH20 condition, including serum amyloid proteins (A1, A2, and A3 
isoforms), serum amyloid P-component, and fibrinogen components (alpha, beta, and gamma), 
shown in Figure 12.  Engagement of this pathway of local hepatic inflammatory response is 
consistent with histological findings in this animal model, as well as serological findings of 




Common targets between all PCB exposure levels within diet comparisons 
Diseases p-value FDR 
Pathological Conditions, Signs and Symptoms 6.116E-27 8.706E-24 
Pathologic Processes 1.071E-26 8.706E-24 
Drug-Related Side Effects and Adverse Reactions 2.676E-24 1.450E-21 
In-house Adverse Events 1.478E-23 4.980E-21 
Chemically-Induced Disorders 1.531E-23 4.980E-21 
Nutritional and Metabolic Diseases 2.480E-23 6.722E-21 
Metabolic Diseases 1.164E-22 2.704E-20 
Phenomena and Processes 5.832E-22 1.185E-19 
Physiological Phenomena 1.705E-21 3.081E-19 
Endocrine System Diseases 4.360E-21 7.089E-19 
Networks p-value FDR 
Development_Regulation of angiogenesis 3.424E-07 5.000E-05 
Inflammation_IL-6 signaling 5.307E-06 3.874E-04 
Development_Blood  vessel morphogenesis 3.416E-05 1.662E-03 
Translation_Translation initiation 2.444E-04 8.920E-03 
Translation_Elongation-Termination 1.509E-03 4.405E-02 
Signal Transduction_Cholecystokinin signaling 4.062E-03 8.473E-02 
Cell cycle_Meiosis 4.062E-03 8.473E-02 
Reproduction_Feeding and Neurohormone signaling 4.882E-03 8.910E-02 
Cell cycle_G0-G1 7.245E-03 1.109E-01 
Blood coagulation 7.594E-03 1.109E-01 
Maps p-value FDR 
Cholesterol Biosynthesis 7.453E-06 4.636E-03 
Cell cycle_Role of Nek in cell cycle regulation 3.880E-05 1.207E-02 
IL-6-induced acute-phase response/hepatocytes 7.792E-05 1.616E-02 
Effect of H. pylori infection on gastric epithelial cell proliferation 1.643E-04 2.555E-02 
Transcription_Sirtuin6 regulation and functions 3.062E-04 3.809E-02 
Role of ZNF202 in regulation of expression of genes involved in 
atherosclerosis 
7.644E-04 7.149E-02 
Development_Beta adrenergic receptors in brown adipocyte 
differentiation 
8.592E-04 7.149E-02 
Expression targets of Tissue factor signaling in cancer 9.195E-04 7.149E-02 
Signal transduction_mTORC1 downstream signaling 1.456E-03 9.691E-02 
Regulation of Tissue factor signaling in cancer 1.719E-03 9.691E-02 
Processes p-value FDR 
lipid metabolic process 1.500E-25 9.695E-22 
response to organic cyclic compound 7.688E-24 2.484E-20 
response to oxygen-containing compound 1.649E-23 3.553E-20 
single-organism metabolic process 4.262E-23 6.635E-20 
small molecule metabolic process 5.133E-23 6.635E-20 
response to organic substance 8.934E-21 9.623E-18 
response to external stimulus 2.110E-20 1.948E-17 
response to drug 4.389E-20 3.546E-17 
steroid metabolic process 5.788E-20 3.908E-17 
single-organism process 6.046E-20 3.908E-17 
Top ten enrichments for each grouping, ranked from most to least significant by p-value 
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Table 43 
Enrichments for liver and metabolic disease endpoints in comparison CVvsC20 
Liver Toxicity Endpoint Processes p-value FDR 
Steatosis, development_liver 4.866E-02 5.422E-01
Fibrosis, development_liver 7.746E-02 5.422E-01
Hypertrophic organ growth_liver 1.679E-01 7.837E-01
Cell cycle, processes involved in G0-phase 3.450E-01 7.870E-01
Cell cycle, processes involved in G1-phase 4.245E-01 7.870E-01
Cholestasis, development_liver 4.409E-01 7.870E-01
Cell cycle, processes involved in G2-phase 4.702E-01 7.870E-01
Peroxisomal proliferation, induction_liver 5.235E-01 7.870E-01
Cell cycle, processes involved in S-phase 5.474E-01 7.870E-01
Apoptosis via Mitochondrial membrane dysfunction 6.746E-01 7.870E-01
Liver-Specific Maps p-value FDR 
Neurophysiological process_Circadian rhythm 1.030E-04 9.994E-03
DNA damage_ATM/ATR regulation of G1/S checkpoint 6.179E-04 2.997E-02
Development_TGF-beta receptor signaling 2.286E-03 6.552E-02
Development_WNT signaling pathway. Part 2 2.702E-03 6.552E-02
Signal transduction_mTORC2 downstream signaling 5.471E-03 1.061E-01
Development_Signaling of β-adrenergic receptors via Beta-arrestins 7.044E-03 1.125E-01
DNA damage_ATM / ATR regulation of G2 / M checkpoint 8.240E-03 1.125E-01
Development_SSTR1 in regulation of cell proliferation and migration 1.019E-02 1.125E-01
DNA damage_Brca1 as a transcription regulator 1.088E-02 1.125E-01
Regulation of lipid metabolism_FXR-dependent negative-feedback 
regulation of bile acids concentration 1.159E-02 1.125E-01









Nutrition Disorders 3.774E-03 2.600E-02
Insulin Resistance 7.968E-03 4.448E-02
Nutritional and Metabolic Disease Maps p-value FDR 
Development_Signaling of β-adrenergic receptors via Beta-arrestins 2.670E-03 9.095E-02
Regulation of lipid metabolism_FXR-dependent negative-feedback 
regulation of bile acids concentration 4.437E-03 9.095E-02
Bile acids regulation of glucose and lipid metabolism via FXR 7.673E-03 9.830E-02
Transcription_Androgen Receptor nuclear signaling 9.590E-03 9.830E-02
Development_IGF-1 receptor signaling 1.214E-02 9.958E-02
Unsaturated fatty acid biosynthesis 1.699E-02 1.161E-01
Transcription_Transcription regulation of aminoacid metabolism 7.854E-02 2.751E-01
Triacylglycerol metabolism p.2 8.456E-02 2.751E-01
Role of Diethylhexyl Phthalate and Tributyltin in fat cell 
differentiation 9.055E-02 2.751E-01
Vitamin B6 metabolism 9.353E-02 2.751E-01
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20).  Top ten 
enrichments for each grouping, ranked from most to least significant by p-value 
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Table 44 
Enrichments for liver and metabolic disease endpoints  in comparison CVvsC200 
Liver Toxicity Endpoint Processes p-value FDR 
Ischemia-induced cellular changes_liver 1.588E-03 2.179E-02
Hypoxia, development 2.421E-03 2.179E-02
Apoptosis via Mitochondrial membrane dysfunction 5.073E-02 2.521E-01
Fibrosis, development_liver 7.399E-02 2.521E-01
Steatosis, development_liver 8.062E-02 2.521E-01
Hypertrophic organ growth_liver 8.403E-02 2.521E-01
Phospholipidosis, development_liver 1.391E-01 3.576E-01
Cholestasis, development_liver 1.710E-01 3.848E-01
Cell cycle, processes involved in G1-phase 3.839E-01 7.678E-01
Cell cycle, processes involved in G2-phase 5.009E-01 8.667E-01
Liver-Specific Maps p-value FDR 
Immune response_TLR2 and TLR4 signaling pathways 1.658E-05 5.109E-03
Apoptosis and survival_p53-dependent apoptosis 3.762E-05 5.109E-03
G-protein signaling_Proinsulin C-peptide signaling 5.040E-05 5.109E-03
Signal transduction_mTORC2 upstream signaling 5.539E-05 5.109E-03
Apoptosis and survival_Endoplasmic reticulum stress response 
pathway 9.226E-05 5.608E-03
Immune response_IL-1 signaling pathway 9.229E-05 5.608E-03
Immune response_TLR5, TLR7, TLR8,TLR9 signaling pathways 1.064E-04 5.608E-03
Immune response_IL-18 signaling 1.600E-04 7.170E-03
Histamine H1 receptor signaling/immune response 1.749E-04 7.170E-03
Development_ERBB-family signaling 2.779E-04 9.580E-03
Nutritional and Metabolic Disease Biomarkers p-value FDR 
Obesity 3.371E-07 2.174E-05
Overnutrition 3.371E-07 2.174E-05
Nutrition Disorders 3.925E-06 1.688E-04
Vascular Calcification 9.711E-05 3.132E-03
Frontotemporal Dementia 5.455E-04 1.173E-02
Frontotemporal Lobar Degeneration 5.455E-04 1.173E-02
Hyperinsulinism 9.153E-04 1.687E-02
Diabetes Mellitus, Type 1 1.805E-03 2.911E-02
Insulin Resistance 4.129E-03 5.918E-02
Calcinosis 5.304E-03 6.842E-02
Nutritional and Metabolic Disease Maps p-value FDR 
G-protein signaling_Proinsulin C-peptide signaling 1.347E-06 2.102E-04
Development_Activation of ERK by Alpha-1 adrenergic receptors 4.336E-06 2.431E-04
Immune response_IL-18 signaling 4.675E-06 2.431E-04
Development_IGF-1 receptor signaling 1.332E-05 5.196E-04
Putative pathways for BPA-stimulated fat cell differentiation 5.286E-05 1.649E-03
Apoptosis and survival_Ceramides signaling pathway 1.942E-04 5.049E-03
Development_β adrenergic receptors in brown adipocyte 
differentiation 1.109E-03 2.471E-02
Transcription_Transcription regulation of aminoacid metabolism 1.875E-03 3.656E-02
Transcription_Sirtuin6 regulation and functions 2.481E-03 4.221E-02
Membrane-bound ESR1: interaction with growth factors signaling 2.706E-03 4.221E-02
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20).  Top ten 
enrichments for each grouping, ranked from most to least significant by p-value 
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Table 45 
Enrichments for liver and metabolic disease endpoints  in comparison HVvsH20 
Liver Toxicity Endpoint Processes p-value FDR 
Cholestasis, development_liver 6.523E-04 9.480E-03
Steatosis, development_liver 1.053E-03 9.480E-03
Fibrosis, development_liver 1.364E-02 6.576E-02
Progression of oxidative stress 1.461E-02 6.576E-02
Inflammation, development 2.248E-02 8.092E-02
Hypertrophic organ growth_liver 1.108E-01 3.323E-01
Hypoxia, development 4.259E-01 1.000E+00
Apoptosis via Mitochondrial membrane dysfunction 5.346E-01 1.000E+00
Ischemia-induced cellular changes_liver 8.177E-01 1.000E+00
Apoptosis via Death Domain receptors cascades 8.298E-01 1.000E+00
Liver-Specific Maps p-value FDR 
IL-6-induced acute-phase response/hepatocytes 4.661E-13 1.571E-10
Immune response_IL-6 signaling pathway via JAK/STAT 9.310E-07 1.569E-04
Signal transduction_mTORC2 downstream signaling 2.422E-05 2.721E-03
MIF-induced cell adhesion, migration and angiogenesis 4.658E-05 3.231E-03
Development_Ligand-dependent activation-ESR1/AP-1 pathway 4.793E-05 3.231E-03
Development_Beta-adrenergic receptors transactivation of EGFR 8.020E-05 4.505E-03
Transcription_Role of AP-1 in regulation of cellular metabolism 9.590E-05 4.617E-03
Glutathione metabolism 1.810E-04 7.624E-03
Development_VEGF signaling and activation 2.163E-04 8.100E-03
Immune response_IL-1 signaling pathway 2.509E-04 8.457E-03
Nutritional and Metabolic Disease Biomarkers p-value FDR 
Nutrition Disorders 9.404E-08 7.284E-06
Obesity 1.539E-07 7.284E-06
Overnutrition 1.539E-07 7.284E-06




Lipid Metabolism Disorders 4.613E-04 8.188E-03
Colorectal Neoplasms, Hereditary Nonpolyposis 6.567E-04 1.036E-02
Hyperlipidemias 1.077E-03 1.472E-02
Nutritional and Metabolic Disease Maps p-value FDR 
Ligand-dependent activation of the ESR1/AP-1 pathway 1.295E-05 7.881E-04
β adrenergic receptors/brown adipocyte differentiation 1.397E-05 7.881E-04
Transcription_Role of AP-1 in regulation of cellular metabolism 1.681E-05 7.881E-04
Glutathione metabolism 2.174E-05 7.881E-04
Putative pathways for stimulation of fat cell differentiation by 
Bisphenol A 6.243E-05 1.811E-03
Immune response_IL-18 signaling 3.418E-04 8.259E-03
Transcription_Sirtuin6 regulation and functions 5.104E-04 1.057E-02
Development_α-1 adrenergic receptors signaling via Cyclic AMP 7.107E-04 1.288E-02
Insulin, IGF-1 and TNF-alpha in brown adipocyte differentiation 9.726E-04 1.567E-02
Regulation of metabolism_Bile acids regulation of glucose and lipid 
metabolism via FXR 2.027E-03 2.939E-02
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20).  Top ten 
enrichments for each grouping, ranked from most to least significant by p-value 
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Table 46 
Enrichments for liver and metabolic disease endpoints in comparison HVvsH200 
Liver Toxicity Endpoint Processes p-value FDR 
Hypertrophic organ growth_liver 1.768E-03 2.109E-02
Fibrosis, development_liver 2.343E-03 2.109E-02
Steatosis, development_liver 5.006E-03 3.004E-02
Cell cycle progression of Mitosis 8.310E-02 3.725E-01
Apoptosis via Mitochondrial membrane dysfunction 1.035E-01 3.725E-01
Cholestasis, development_liver 1.580E-01 4.741E-01
Hypoxia, development 3.809E-01 9.793E-01
Inflammation, development 4.762E-01 9.971E-01
Cell cycle, processes involved in S-phase 5.009E-01 9.971E-01
Cell cycle, processes involved in G1-phase 6.586E-01 9.971E-01
Liver-Specific Maps p-value FDR 
Development_Regulation of EMT 3.347E-06 8.870E-04
Immune response_IL-6-induced acute-phase response in 
hepatocytes 1.092E-05 1.447E-03
Immune response_Oncostatin M signaling via JAK-Stat 2.479E-04 2.190E-02
Signal transduction_mTORC2 downstream signaling 4.219E-04 2.795E-02
Development_IGF-1 receptor signaling 8.743E-04 4.215E-02
Development_WNT signaling pathway. Part 2 9.544E-04 4.215E-02
Development_Ligand-dependent activation - ESR1/AP-1 pathway 1.180E-03 4.469E-02
Cell cycle_ESR1 regulation of G1/S transition 1.376E-03 4.557E-02
Development_Beta-adrenergic receptors transactivation of EGFR 1.895E-03 5.580E-02
Transcription_Sirtuin6 regulation and functions 2.236E-03 5.926E-02
Nutritional and Metabolic Disease Biomarkers p-value FDR 
Obesity 8.546E-05 2.606E-03
Overnutrition 8.546E-05 2.606E-03
Vascular Calcification 1.017E-04 2.606E-03
Nutrition Disorders 1.032E-04 2.606E-03
Frontotemporal Dementia 1.580E-04 2.659E-03
Frontotemporal Lobar Degeneration 1.580E-04 2.659E-03
Zellweger Syndrome 1.506E-03 2.165E-02
Peroxisome biogenesis disorders 1.715E-03 2.165E-02
Diabetes Mellitus, Type 2 2.031E-03 2.279E-02
Calcinosis 2.557E-03 2.582E-02
Nutritional and Metabolic Disease Maps p-value FDR 
Development_IGF-1 receptor signaling 2.504E-04 2.165E-02
Development_Ligand-dependent activation - ESR1/AP-1 pathway 5.388E-04 2.165E-02
Transcription_Sirtuin6 regulation and functions 6.629E-04 2.165E-02
Retinol metabolism 1.066E-03 2.612E-02
Unsaturated fatty acid biosynthesis 4.752E-03 9.314E-02
Galactose metabolism 6.265E-03 1.023E-01
Regulation of metabolism_Bile acids regulation of glucose and lipid 
metabolism via FXR 1.028E-02 1.439E-01
Transcription_Androgen Receptor nuclear signaling 1.407E-02 1.724E-01
Signal transduction_PTMs in BAFF-induced signaling 1.857E-02 2.022E-01
Amitraz-induced inhibition of Insulin secretion 2.424E-02 2.127E-01
Enrichment is based on the significantly differentially transcribed genes (p<.05) in a 
comparison between control diet/vehicle and control diet/20 mg/kg PCB (CVvsC20).  Top ten 


























ENSMUSG00000026072  Il1r1  0.58 
ENSMUSG00000017057  Il13ra1  0.71 
ENSMUSG00000030748  Il4ra  0.57
ENSMUSG00000027947  Il6ra  -0.67
ENSMUSG00000029304  Spp1  0.48 
ENSMUSG00000024620  Pdgfrb  -0.53
ENSMUSG00000028599  Tnfrsf1b  0.58
ENSMUSG00000021250  Fos  1.27 
Liver toxicity analysis  for each comparison indicated gene sets associated with liver toxicity 
endpoints including steatosis and fibrosis.  Differentially regulated gene targets are indicated. 
For each target, the fold change vs. control is shown. 
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Figure 11. IL-6-mediated acute-phase response in hepatocytes. 
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of IL-6-
mediated acute-phase response in hepatocytes.  In particular, components of the AP-1 complex 
(c-Jun, c-Fos) were differentially regulated in the CVvsC200 comparison (2), the HVvsH20 
comparison (3), and the HVvsH200 comparison (4), along with changes in transcription of HNF1-
alpha targets IBP1, G6PT and Fibrinogen alpha.  The HVvsH20 condition was associated with 
differential transcription of the most targets associated with this pathway, in particular, targets of 
STAT3 transcriptional activation.  An increase in local inflammation associated with this condition 






Figure 12. IL-6/STAT-3 signaling pathways. 
 PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of IL-6-
signaling pathways. In particular, components of the AP-1 complex (c-Jun, c-Fos) were differentially 
regulated in the CVvsC200 comparison (2), the HVvsH20 comparison (3), and the HVvsH200 
comparison (4). Image generated using MetaCoreTM from Thomson Reuters. 
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Both the lack of transcription-level changes in biomarkers of liver disease in the CVvsC20 
comparison and the relative abundance of changes in the HVvsH20 comparison vs. either of the 
higher PCB exposure groups is in keeping with the histological severity of liver disease in these 
groups23.  Few common targets were seen in this enrichment, which may suggest pleiotropic 
effects on hepatocyte toxicity, as well as complex interactions between nutrition/PCB 
coexposures on disease mechanisms. 
Among nutritional and metabolic disease enrichments, the pattern presented by the 
individual comparisons was far more cohesive, with over-nutrition/obesity in the top enrichments 
for every comparison.  Fold changes of differentially transcribed genes associated with over-
nutrition/obesity for each vehicle vs. PCB comparison are listed in Table 48.  Other metabolic 
diseases that were of interest to us and highly enriched in one or more datasets were type 2 
diabetes mellitus (Table 49), metabolic syndrome (Table 50), and insulin resistance (Table 51).  
In each of these disease categories, the condition with the most changes vs. vehicle control was 
the HVvsH20 condition.  These changes included down-regulation of fatty acid synthetase and 
beta 2-adrenergic receptor, polymorphisms of which have been associated with metabolic 
disease123, 124.  Down-regulation of GLUT4 reduces insulin-sensitive glucose uptake in non-
hepatocyte liver cells and other insulin-sensitive tissues125.  Metabolic disease enrichments for 
the CVvsC20 and CVvsC200 group indicated changes to PPAR-alpha and LXR-mediated 
glucose and lipid homeostasis, including alterations in expressions of the Tribbles-3 
pseudokinase, which contributes to insulin resistance126  and down-regulation of Cyp7a1, which 
could lead to cholesterol accumulation. 
MetaCoreTM network analysis of dose-within-diet comparisons did not appear to indicate 
enrichment in transcriptional targets of the xenobiotic transcription factors AhR, PXR, or CAR 
Because xenobiotic receptors AhR, PXR, and CAR are classically associated with 
transcriptional response to PCBs and other chemicals, we used MetaCoreTM to evaluate over-
representation of curated transcriptional targets of these receptors.  The direct transcriptional 







CVvsC20  CVvsC200  HVvsH20  HVvsH200 
Metabolic Disease Biomarkers: Obesity 
ENSMUSG00000020917  Acly -0.72
ENSMUSG00000031278  Acsl4 -0.47 1.05 
ENSMUSG00000035783  Acta2 -0.96 -0.71
ENSMUSG00000026883  Dab2ip 0.65
ENSMUSG00000042429  Adora1 0.81 -0.64 -0.66
ENSMUSG00000022994  Adcy6 -0.69
ENSMUSG00000005580  Adcy9 -0.92 -0.73
ENSMUSG00000046532  Ar -0.86 -1.11 
ENSMUSG00000027792  Bche -0.67
ENSMUSG00000055116  Arntl 2.19 1.04
ENSMUSG00000045730  Adrb2 -1.04 -1.49 
ENSMUSG00000082361  Btc 1.10
ENSMUSG00000002944  Cd36 -0.75 0.74 -0.89 
ENSMUSG00000039804  Ncoa5 -0.65
ENSMUSG00000029238  Clock  0.77
ENSMUSG00000000326  Comt 0.62 
ENSMUSG00000056054  S100a8 1.44 1.49 1.62
ENSMUSG00000056071  S100a9 1.39 1.69 1.58





ENSMUSG00000028001  Fga 1.06 
ENSMUSG00000033831  Fgb 1.02 




ENSMUSG00000041798  Gck -0.98 -1.01 -0.63




ENSMUSG00000038894  Irs2 0.57 0.83
ENSMUSG00000025780  Itih5 0.60 1.01 
ENSMUSG00000055148  Klf2 -1.38 -0.74 
ENSMUSG00000032796  Lama1 -0.63
ENSMUSG00000053846  Lipg -1.08 -0.78 -1.66 -0.94















ENSMUSG00000015312  Gadd45b 2.17 1.23 1.05
ENSMUSG00000038039  Gcc2 0.69
ENSMUSG00000026864  Hspa5 -1.17
ENSMUSG00000074896  Ifit3 1.13 0.67
ENSMUSG00000052684  Jun 1.15 0.62 0.80
ENSMUSG00000049723  Mmp12 -0.97
ENSMUSG00000003849  Nqo1  0.47 -1.28 




ENSMUSG00000020641  Rsad2 0.89 0.72
ENSMUSG00000057465  Saa2 -1.37 2.06 2.62
ENSMUSG00000041567  Serpina12 -1.04 0.65 
ENSMUSG00000032902  Slc16a1 0.59 
ENSMUSG00000020027  Socs2 1.10 0.71




Metabolic disease analysis for each comparison indicated gene sets associated with endpoints 
including obesity/overnutrition.  Differentially regulated gene targets are indicated. For each 







CVvsC20  CVvsC200  HVvsH20  HVvsH200 
ENSMUSG00000024052  Lpin2 -0.73
ENSMUSG00000015568  Lpl 0.72 0.91 
ENSMUSG00000027253  Lrp4 -0.73 -0.53 
ENSMUSG00000040584  Abcb1a -2.05
ENSMUSG00000024589  Nedd4l 1.14 0.60 0.86 
ENSMUSG00000026822  Lcn2 1.18 1.47
ENSMUSG00000032715  Trib3 1.21 0.91 -0.59 
ENSMUSG00000024413  Npc1 0.68
ENSMUSG00000030659  Nucb2 0.82 
ENSMUSG00000029304  Spp1 0.48 
ENSMUSG00000038508  Gdf15 1.52 1.22 1.08
ENSMUSG00000055866  Per2 -1.39 -0.74
ENSMUSG00000033871  Ppargc1b 0.86




ENSMUSG00000027540  Ptpn1 0.61 
ENSMUSG00000021876  Rnase4 0.66 
ENSMUSG00000022883  Robo1 -0.80 -1.82 
ENSMUSG00000028150  Rorc -0.74 0.88 0.53
ENSMUSG00000074115  Saa1 -1.44 2.34 2.41
ENSMUSG00000075701  Selenos -0.47
ENSMUSG00000060807  Serpina6 -0.97 -1.02 
ENSMUSG00000053113  Socs3 1.08 
ENSMUSG00000025006  Sorbs1 0.64 -0.50 





ENSMUSG00000055254  Ntrk2 -1.28 -2.03 0.72
ENSMUSG00000027962  Vcam1 0.63 -0.85 
ENSMUSG00000020484  Xbp1 0.71 
ENSMUSG00000028978  Nos3 -0.87







Input IDs  Gene Symbol  CVvsC20 CVvsC200 HVvsH20  HVvsH200
Metabolic Disease Biomarkers: Type 2 Diabetes Mellitus 
ENSMUSG00000035783 Acta2 -0.96 -0.71
ENSMUSG00000026883 Dab2ip  0.65
ENSMUSG00000035561 Aldh1b1 -0.68
ENSMUSG00000026289 Atg16l1 -0.57
ENSMUSG00000024391 Apom 0.76 
ENSMUSG00000019947 Arid5b 0.51
ENSMUSG00000046532 Ar -0.86 -1.11 
ENSMUSG00000032066 Bco2 -0.45
ENSMUSG00000027792 Bche -0.67
ENSMUSG00000055116 Arntl 2.19 1.04
ENSMUSG00000033863 Klf9 0.91 0.80
ENSMUSG00000045730 Adrb2 -1.04 -1.49 
ENSMUSG00000082361 Btc  1.10
ENSMUSG00000027381 Bcl2l11 0.91
ENSMUSG00000022637 Cblb  0.62
ENSMUSG00000035042 Ccl5 -0.97
ENSMUSG00000002944 Cd36 -0.75 0.74 -0.89 
ENSMUSG00000039804 Ncoa5 -0.65
ENSMUSG00000000326 Comt 0.62 
ENSMUSG00000068742 Cry2  0.48
ENSMUSG00000019997 Ctgf -0.85 -0.63
ENSMUSG00000025003 Cyp2c39 -2.02
ENSMUSG00000003053 Cyp2c29 2.75 1.31
ENSMUSG00000056054 S100a8 1.44 1.49 1.62
ENSMUSG00000056071 S100a9 1.39 1.69 1.58
ENSMUSG00000028914 Casp9  0.64
ENSMUSG00000072082 Ccnf 0.46 
ENSMUSG00000027533 Fabp5 0.80 
ENSMUSG00000054191 Klf1 -0.73
ENSMUSG00000041112 Elmo1 0.87
ENSMUSG00000042787 Exog -0.92 -0.88
ENSMUSG00000019768 Esr1 0.57 0.69
ENSMUSG00000010663 Fads1 -0.64
ENSMUSG00000039529 Atp8b1 0.42 
ENSMUSG00000044167 Foxo1 -0.53
ENSMUSG00000048756 Foxo3 -0.79
ENSMUSG00000049721 Gal3st1  1.51
ENSMUSG00000029992 Gfpt1 -0.75 -0.56
ENSMUSG00000028645 Slc2a1  0.93
ENSMUSG00000018566 Slc2a4 -1.78










Input IDs  Gene Symbol  CVvsC20 CVvsC200 HVvsH20  HVvsH200 
ENSMUSG00000043013 Onecut1 0.96
ENSMUSG00000091971 Hspa1a -3.95949
ENSMUSG00000041798 Gck -0.98 -1.01 -0.63
ENSMUSG00000032115 Hyou1 -1.35 0.52 -0.75
ENSMUSG00000026185 Igfbp5 -1.14 -1.39 -0.97 -0.54
ENSMUSG00000026072 Il1r1 0.58 
ENSMUSG00000027947 Il6ra -0.67
ENSMUSG00000038894 Irs2 0.57 0.83
ENSMUSG00000020653 Klf11 1.13 0.73
ENSMUSG00000052040 Klf13 -0.72
ENSMUSG00000055148 Klf2 -1.38 -0.74 
ENSMUSG00000032796 Lama1 -0.63
ENSMUSG00000020593 Lpin1 -0.76 -1.96 -0.70
ENSMUSG00000024052 Lpin2 -0.73
ENSMUSG00000015568 Lpl 0.73 0.91 
ENSMUSG00000035202 Lars2 -1.38 -1.58
ENSMUSG00000026688 Mgst3 -1.19
ENSMUSG00000049723 Mmp12 -0.97
ENSMUSG00000021025 Nfkbia -0.51 -0.46 
ENSMUSG00000032715 Trib3 1.21 0.91 -0.59 
ENSMUSG00000024413 Npc1  0.68
ENSMUSG00000030659 Nucb2 0.82 
ENSMUSG00000023034 Nr4a1 -0.63 0.94
ENSMUSG00000096054 Syne1 0.62
ENSMUSG00000041827 Oasl1  1.15
ENSMUSG00000000168 Dlat -0.76
ENSMUSG00000029304 Spp1 0.48 
ENSMUSG00000028211 Trp53inp1 1.08
ENSMUSG00000044254 Pcsk9 -0.99 -1.20
ENSMUSG00000028525 Pde4b  0.73
ENSMUSG00000038508 Gdf15 1.52 1.22 1.08
ENSMUSG00000019577 Pdk4 1.04 1.37
ENSMUSG00000025509 Pnpla2  0.85
ENSMUSG00000020893 Per1 -0.97
ENSMUSG00000033871 Ppargc1b  0.86
ENSMUSG00000032462 Pik3cb  0.89
ENSMUSG00000041417 Pik3r1 -0.47
ENSMUSG00000045038 Prkce -0.53
ENSMUSG00000000440 Pparg  0.62
ENSMUSG00000027540 Ptpn1 0.61 
ENSMUSG00000028150 Rorc -0.74 0.88 0.53
ENSMUSG00000015843 Rxrg  0.83
ENSMUSG00000043895 S1pr2  1.20
ENSMUSG00000074115 Saa1 -1.44 2.34 2.41
ENSMUSG00000041567 Serpina12 -1.04 0.65 
ENSMUSG00000019970 Sgk1 0.77







CVvsC20 CVvsC200 HVvsH20  HVvsH200 
ENSMUSG00000020027 Socs2 1.10 0.71
ENSMUSG00000053113 Socs3 1.08 
ENSMUSG00000025006 Sorbs1 0.64 -0.50 
ENSMUSG00000037465 Klf10 0.86 -0.54 -1.29
ENSMUSG00000028599 Tnfrsf1b 0.58
ENSMUSG00000022797 Tfrc -0.80
ENSMUSG00000028128 F3 1.32 0.85 
ENSMUSG00000020123 Avpr1a 0.98 -1.29 0.72 
ENSMUSG00000027962 Vcam1 0.63 -0.85 
ENSMUSG00000024924 Vldlr -2.54
ENSMUSG00000028978 Nos3 -0.87
ENSMUSG00000041653 Pnpla3 -1.78 -1.17
Metabolic disease analysis for each comparison indicated gene sets associated with endpoints 
including diabetes mellitus.  Differentially regulated gene targets are indicated. For each 





Input IDs  Gene Symbol  CVvsC20  CVvsC200  HVvsH20  HVvsH200 
Metabolic Disease Biomarkers: Metabolic Syndrome 
ENSMUSG00000031278  Acsl4 -0.47 1.05
ENSMUSG00000024391  Apom 0.76
ENSMUSG00000055116  Arntl 2.2 1.04 
ENSMUSG00000045730  Adrb2 -1.04 -1.49




ENSMUSG00000019768  Esr1 0.57 0.69




ENSMUSG00000020429  Igfbp1 -0.46 1.08
ENSMUSG00000020427  Igfbp3 0.44
ENSMUSG00000026185  Igfbp5 -1.14 -1.39 -0.97 -0.54
ENSMUSG00000027947  Il6ra -0.674195
ENSMUSG00000020593  Lpin1 -0.76 -1.96 -0.70
ENSMUSG00000015568  Lpl 0.72 0.91
ENSMUSG00000059436  Max -0.55 
ENSMUSG00000032715  Trib3 1.21 0.91 -0.59
ENSMUSG00000027820  Mme 0.73 -0.81
ENSMUSG00000019577  Pdk4 1.04 1.37





ENSMUSG00000027368  Dusp2 -1.27 
ENSMUSG00000020580  Rock2 -0.42
ENSMUSG00000074115  Saa1 -1.44 2.34 2.41
ENSMUSG00000041567  Serpina12 -1.04 0.65
ENSMUSG00000012428  Steap4 -0.62 1.22
ENSMUSG00000028978  Nos3 -0.87 
ENSMUSG00000041653  Pnpla3 -1.78 -1.17










ENSMUSG00000057465  Saa2 -1.37 2.06 2.62
ENSMUSG00000028599  Tnfrsf1b  0.58
Metabolic disease analysis for each comparison indicated gene sets associated with endpoints 
including metabolic syndrome.  Differentially regulated gene targets are indicated. For each 







CVvsC20 CVvsC200 HVvsH20  HVvsH200
Metabolic Disease Biomarkers: Insulin resistance 
ENSMUSG00000031278  Acsl4 -0.47 1.05 
ENSMUSG00000035783  Acta2 -0.96 -0.71
ENSMUSG00000024391  Apom 0.76 
ENSMUSG00000027792  Bche -0.67
ENSMUSG00000055116  Arntl 2.19 1.04
ENSMUSG00000045730  Adrb2 -1.04 -1.49 
ENSMUSG00000036098  Myrf 0.51 
ENSMUSG00000035042  Ccl5 -0.97
ENSMUSG00000002944  Cd36 -0.75 0.74 -0.89 
ENSMUSG00000029238  Clock  0.77
ENSMUSG00000068742  Cry2  0.48
ENSMUSG00000072082  Ccnf 0.46 
ENSMUSG00000041220  Elovl6 -0.89 -0.53
ENSMUSG00000019768  Esr1 0.57 0.69
ENSMUSG00000010663  Fads1 -0.64
ENSMUSG00000024664  Fads3 -0.91 -0.56 -0.91
ENSMUSG00000044167  Foxo1 -0.53
ENSMUSG00000048756  Foxo3 -0.79
ENSMUSG00000028001  Fga 1.06 
ENSMUSG00000033831  Fgb 1.02 
ENSMUSG00000033860  Fgg 0.96 
ENSMUSG00000049721  Gal3st1 1.51
ENSMUSG00000029992  Gfpt1 -0.75 -0.56
ENSMUSG00000018566  Slc2a4 -1.78 
ENSMUSG00000021670  Hmgcr -0.73
ENSMUSG00000043013  Onecut1 0.96
ENSMUSG00000041798  Gck -0.98 -1.01 -0.63
ENSMUSG00000020429  Igfbp1 -0.46 1.08
ENSMUSG00000020427  Igfbp3  0.44
ENSMUSG00000026185  Igfbp5 -1.14 -1.39 -0.97 -0.54
ENSMUSG00000027947  Il6ra -0.67
ENSMUSG00000038894  Irs2 0.57 0.83
ENSMUSG00000020593  Lpin1 -0.76 -1.96 -0.70
ENSMUSG00000024052  Lpin2 -0.73
ENSMUSG00000015568  Lpl 0.72 0.91 
ENSMUSG00000054612  Mgmt -1.03 
ENSMUSG00000059436  Max -0.55
ENSMUSG00000054764  Mtnr1a 1.51





Input IDs  Gene Symbol  CVvsC20 CVvsC200 HVvsH20  HVvsH200
ENSMUSG00000032715  Trib3 1.21 0.91 -0.59 
ENSMUSG00000027820  Mme 0.73 -0.81 
ENSMUSG00000019577  Pdk4  1.04  1.37
ENSMUSG00000025509  Pnpla2  0.85
ENSMUSG00000055866  Per2 -1.39 -0.74
ENSMUSG00000032462  Pik3cb  0.89
ENSMUSG00000041417  Pik3r1  -0.47
ENSMUSG00000042632  Pla2g6  0.98
ENSMUSG00000023913  Pla2g7  0.65
ENSMUSG00000000440  Pparg   0.62
ENSMUSG00000027540  Ptpn1 0.61 
ENSMUSG00000027368  Dusp2 -1.27
ENSMUSG00000020580  Rock2 -0.42
ENSMUSG00000074115  Saa1 -1.44 2.34 2.41
ENSMUSG00000075701  Selenos -0.47
ENSMUSG00000041567  Serpina12 -1.04 0.65 
ENSMUSG00000060807  Serpina6 -0.97 -1.02 
ENSMUSG00000053113  Socs3 1.08 
ENSMUSG00000012428  Steap4 -0.62 1.22 
ENSMUSG00000028599  Tnfrsf1b  0.58
ENSMUSG00000027962  Vcam1 0.63 -0.85 
ENSMUSG00000044786  Zfp36 -0.53
ENSMUSG00000028978  Nos3 -0.87
ENSMUSG00000041653  Pnpla3 -1.78 -1.17
ENSMUSG00000008845  Cd163 0.84 1.32
ENSMUSG00000048376  F2r 0.44 
ENSMUSG00000044674  Fzd1  0.53
ENSMUSG00000030748  Il4ra  0.57
ENSMUSG00000021871  Pnp  0.61 
ENSMUSG00000033871  Ppargc1b  0.86
ENSMUSG00000033220  Rac2  0.56
ENSMUSG00000015843  Rxrg  0.83
ENSMUSG00000057465  Saa2 -1.37 2.06 2.62
Metabolic disease analysis for each comparison indicated gene sets associated with endpoints 
including insulin resistance.  Differentially regulated gene targets are indicated. For each 
comparison, fold change vs. control is shown. 
119
proportion of the DTG sets.  Comparison of these results to outputs of the same network frame 
showing DTG sets in vitro primary hepatocyte exposure to prototypical ligands for these 
receptors, however, indicates that the sets of direct transcriptional targets as curated by 
MetaCoreTM are probably not comprehensive (data not shown).  Other software tools may be 
needed to further explore these relationships.   
Analysis of dose-within-diet comparisons indicated enrichment in disease-associated transcription 
factors 
Transcription factor analysis for the CVvsC20, CVvsC200, HVvsH20 and HVvsH200 are 
shown in Tables 52-55.  These analyses are based on gene ontology, therefore the transcription 
factors ranked highest in the list of engaged transcription factors were those with the most 
literature-based relationships among the DTGs in each dataset.  Many of these connections are 
based on chromatin immunoprecipitation studies or computational binding site prediction, and are 
of unspecified effect, however, when only the defined relationships (activation or inhibition via 
transcriptional regulation) were considered, we were able to develop a percent activation for each 
listed transcription factor under each condition: the number differentially regulated in a direction 
consistent with TF activation/total differentially regulated.  These are listed in Tables 56 and 57.  
Overall, transcription factors tended to increase in percent activation with increasing PCB 
concentration and decrease with HFD exposure.  Interestingly, transcription factors which were 
targets of PXR regulation by binding showed evidence of increased activation at the 20 mg/kg 
exposure, compared to the 200 mg/kg exposure, shown in Figure 13. PXR targets of regulation 
by protein-protein interaction.  
Specific targets within pathways engaged in these experiments are related to metabolic 
syndrome components, including fatty liver disease and diabetes, as well as liver damage and 
regeneration pathways. 
Several of the targets differentially regulated under one or more of the experimental 






op ten transcription factor enrichm


















































; 3.449e-12), circadian regulation of gene 
expression (19.4%





















; 2.013e-13), negative regulation of cellular 
process (84.4%
; 7.367e-12), negative regulation of biological process (84.4%












; 3.802e-15), circadian rhythm
 (35.5%




; 2.982e-11), circadian regulation of gene expression (19.4%
























; 4.566e-11), regulation of developm
ental process (69.0%























; 1.282e-10), regulation of developm
ental process (66.7%
















; 1.495e-11), response to oxygen-containing com
pound (60.7%
; 6.514e-10), circadian regulation 


















; 6.790e-11), negative regulation of gene expression (59.3%
; 8.863e-11), n
egative regulation of 
cellular m
acrom














; 2.637e-13), circadian regulation of gene 
expression (23.1%
; 5.579e-10), negative regulation of gene expression (57.7%




















; 2.376e-13), response to oxygen-containing com
pound (66.7%

















































































op ten transcription factor enrichm


























negative regulation of biological process (49.1%
; 3.269e-14), negative regulation of cellular process (46.7%
; 
3.566e-14), positive regulation o
f biological process (50.9%
; 1















negative regulation of biological process (59.8%
; 2.064e-18), negative regulation of cellular process (56.3%
; 
1.927e-17), regulation of apoptotic process (32.2%
; 4.137e-17), regulation of program
m
ed cell death (32.2%
; 















regulation of apoptotic process (41.1%
; 9.997e-24), regulation of program
m
ed cell death (41.1%
; 1.594e-23), 







regulation of apoptotic process (46.2%
; 9.045e-28), regulation of program
m
ed cell death (46.2%
; 1.488e-27), 
regulation of cell death (46.9%
; 9.259e-27), regulation of cell com
m
unication (57.7%












regulation of cell death (42.0%
; 1.379e-19), regulation of apop
totic process (40.3%
; 1.898e-19), regulation of 
program
m
ed cell death (40.3%
; 2
.785e-19), negative regulation of biological process (66.4%
; 3.771e-18), 













regulation of apoptotic process (50.0%
; 2.902e-28), regulation of program
m
ed cell death (50.0%
; 4.657e-28), 
regulation of cell death (50.9%
; 2.054e-27), negative regulatio
n of biological process (76.8%
; 1.145e-26), 














; 9.314e-21), positive regulation of m
etabolic 
process (57.4%
; 6.092e-20), regulation of m
acrom
olecule biosynthetic process (63.0%
; 6.818e-19), regulation of 
cellular biosynthetic process (63.9%














; 1.262e-21), positive regulation of m
etabolic 
process (59.0%















regulation of apoptotic p
rocess (47.1%
; 1.991e-23), regulation of program
m
ed cell death (47.1%
; 2.993e-23), 
regulation of cell death (48.1%
; 8.857e-23), positive regulation of m
etabolic process (60.6%










response to organic substance (62.4%
; 1.132e-21), positive regulation of m
etabolic process (59.4%
; 2.226e-20), 




; 1.163e-18), response to lipid (37.6%
; 3.606e-













































































op ten transcription factor enrichm


























response to organic substance (47.0%
; 3.429e-19), response to oxygen-containing com
pound (35.4%
; 1.098e-
18), response to organonitrogen com
pound (26.3%
; 4.006e-17), response to extracellular stim
ulus (19.7%
; 








regulation of apoptotic p
rocess (45.3%
; 1.557e-28), regulation of cell death (46.8%
; 2.561e-28), regulation of 
program
m
ed cell death (45.3%
; 2
.621e-28), negative regulation of cell death (36.0%
; 6.566e-25), negative 








response to organic substance (66.7%




regulation of cell death (49.6%












regulation of cell death (43.7%
; 2.988e-21), regulation of apop
totic process (42.0%
; 3.922e-21), regulation of 
program
m
ed cell death (42.0%
; 5.874e-21), response to organic substance (57.1%








regulation of cell death (50.0%
; 8.565e-28), regulation of apoptotic process (46.6%
; 7.797e-26), regulation of 
program
m
ed cell death (46.6%
; 1
.231e-25), positive regulation o
f biological process (77.1%














response to organic substance (66.4%




response to oxygen-containing co
m
pound (51.3%
; 2.433e-25), response to chem
ical (73.5%
; 1.489e-24), 






response to organic substance (68.6%
; 2.067e-28), response to oxygen-containing com
pound (54.3%
; 1.411e-
26), regulation of cell death (51.4%
; 2.464e-26), regulation of apoptotic process (49.5%
; 4.376e-26), regulation 
of program
m









regulation of cell death (54.9%
; 3.336e-29), regulation o
f apoptotic process (52.0%
; 6.901e-28), regulation of 
program
m
ed cell death (52.0%
; 1.084e-27), response to organic substance (67.6%
















regulation of cell death (55.1%
; 2.578e-28), regulation of apop
totic process (53.1%
; 5.735e-28), regulation of 
program
m
ed cell death (53.1%
; 8.944e-28), response to oxygen-containing com
pound (56.1%
; 1.138e-26), 









cellular response to chem
ical stim
ulus (68.8%
; 8.421e-30), response to organic substance (71.9%
; 2.788e-29), 
response to organic cyclic com
pound (51.0%
; 6.592e-29), response to oxygen-containing com
pound (57.3%
; 















































































op ten transcription factor enrichm


























negative regulation of cellu
lar process (66.4%
; 7.735e-20), negative regulation of biological process (66.4%
; 
1.009e-17), regulation of cell death (39.7%
; 6.005e-17), response to horm
one (31.9%















; 9.952e-20), positive regulation of m
etabolic 
process (60.5%
; 2.515e-18), response to organic substance (61.6
%
; 4.053e-18), regulation of cell death 
(46.5%








response to endogenous stim
ulus (52.4%
; 8.326e-21), negative regulation of cellular process (73.8%
; 
6.342e-20), response to organic substance (64.3%
; 1.169e-19), negative regulation of biological process 
(75.0%







regulation of cell death (50.6%
; 5.417e-20), response to organic substance (64.2%
; 6.069e-19), response to 
endogenous stim
ulus (50.6%














response to organic substance (68.0%
; 2.838e-20), response to endogenous stim
ulus (53.3%
; 2.041e-19), 
negative regulation of cell death (42.7%
















response to organic substance (69.2%




21), positive regulation of m
etabolic process (65.4%
; 3.572e-20), response to chem
ical (76.9%
; 7.676e-20), 










response to organic su
bstance (70.1%




20), regulation of cell death (51.9%
; 4.482e-20), response to chem
ical (76.6%











regulation of cell death (53.9%
; 2.327e-21), response to organic substance (67.1%
; 7.032e-20), regulation 
of apoptotic process (50.0%
; 1.274e-19), regulation of program
m
ed cell death (50.0%













response to organic substance (76.0%




25), response to endogenous stim
ulus (58.7%
; 1.692e-23), response to horm
one (48.0%
; 7.672e-23), 
















; 5.873e-22), positive regulation of m
etabolic 
process (68.1%
; 1.405e-20), response to organic substance (69.4
%
; 1.574e-20), regulation of cell death 
(54.2%






ther significantly enriched transcription factors included A


































































Percent activation for engaged transcription factors identified in all conditions 













CREB1 31 16% 48 52% 168 13% 93 24% 
c-Myc 25 32% 72 32% 116 28% 62 18% 
p53 19 37% 68 60% 92 34% 50 46% 
SP1 23 30% 69 59% 109 32% 58 43% 
HIF1A 21 38% 54 63% 62 34% 44 48% 
RelA (p65 NF-
kB subunit) 
16 25% 53 64% 69 38% 43 56% 
c-Jun 14 50% 37 73% 71 38% 35 49% 
C/EBPbeta 14 64% 34 56% 58 47% 41 61% 
ESR1 (nuclear) 18 33% 52 54% 84 33% 50 50% 
GCR 16 56% 47 43% 60 27% 37 68% 
Androgen 
receptor 
13 15% 37 54% 89 25% 33 24% 
C/EBPalpha 13 46% 25 60% 47 38% 33 39% 
PPAR-gamma 9 78% 30 57% 36 28% 15 47% 
HNF4-alpha 14 50% 29 62% 45 33% 30 53% 
Oct-3/4 12 42% 54 50% 56 39% 31 39% 
YY1 7 29% 19 42% 33 15% 15 27% 
FKHR 7 43% 24 63% 24 21% 18 50% 
STAT3 10 50% 44 45% 62 48% 37 57% 
Relative activation of the most enriched transcription factors (second column for each 
comparison) was determined by comparing the proportion of differentially transcribed targets in 
which the direction of transcription was concordant with activation of the transcription factor, 
based on the MetaCore curated TFtarget relationship and normalized to the total number of 
targets for that TF differentially transcribed in our experiment (first column for each comparison).  
This table shows % engagement for TFs which were enriched in all group 1-2 comparisons. 
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Table 57 
Percent activation for engaged transcription factors identified in 1-3 conditions 













SP3 6 33% 25 52% 38 37% 0 - 
TCF7L2 (TCF4) 7 43% 0 - 41 34% 0 - 
c-Fos 9 33% 0 - 35 49% 22 55% 
SMAD3 8 38% 0 - 0 - 0 - 
PPAR-alpha 8 50% 0 - - - 14 43% 
IRF8 8 13% 0 - - - 0 - 
SMAD2 5 20% 0 - - - - - 
NRF2 6 83% 0 - - - - - 
AP-2A 8 25% 0 - - - - - 
SRF 5 40% 26 42% 0 - - - 
NRSF 4 25% 0 - - - - - 
SMAD4 5 100% 0 - - - - - 
NANOG 0 - 27 48% 45 31% 23 26% 
E2F1 0 - 21 81% 37 35% 0 - 
GATA-3 0 - 9 33% 26 15% 0 - 
SOX2 0 - 18 39% 0 - 24 33% 
NF-kB 0 - 27 70% 28 32% 0 - 
KLF4 0 - 20 55% 29 62% 0 - 
p63 0 - 25 52% 0 - - - 
NF-kB1 (p50) 0 - 13 62% 0 - - - 
HSF1 0 - 27 26% 0 - - - 
PU.1 0 - 26 65% 0 - - - 
AHR 0 - 0 - 33 12% 18 22% 
HNF3-beta 0 - 0 - 26 15% 19 47% 
FOXO3A 0 - 0 - 29 28% 23 57% 
EGR1 10 50% 0 - 32 47% 21 43% 
VDR 0 - 0 - 26 27% 16 50% 
STAT1 0 - 0 - 0 - 20 70% 
STAT6 0 - 0 - 0 - 16 0% 
SREBP1 (nuclear) 0 - 0 - 0 - 14 7% 
IRF4 0 - 0 - 0 - 16 38% 
Relative activation of the most enriched transcription factors (second column for each 
comparison) was determined by comparing the proportion of differentially transcribed targets in 
which the direction of transcription was concordant with activation of the transcription factor, 
based on the MetaCore curated TFtarget relationship and normalized to the total number of 
targets for that TF differentially transcribed in our experiment (first column for each comparison).  
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Trib3/NIPK, Arntl, and claudin-1. Associated pathway maps are shown in Figures 14-16, 
respectively.  
The Tribbles 3 pseudokinase (NIPK or TRIB3) interrupts insulin signaling by binding and 
preventing phosphorylation of AKT, thereby promoting gluconeogenic down-stream targets such 
as PEPCK and diminishing the activity of GSK3B and associated glycogen synthesis127, 128 
(Figure 14). TRIB3 can also dephosphorylate several MAP kinases and AMPK.  TRIB3 is 
activated by PPARα and by endoplasmic reticulum stress (PERK-eIF2alpha-ATF4-CHOP arm of 
the unfolded protein response),129 thereby providing a mechanism by which ER stress can 
modulate the transduction energy and growth factor signaling to intermediary metabolic and 
developmental transcriptional outputs.  The human TRIB3 polymorphism Q84R, which enhances 
its inhibition of AKT, has been linked to increased prevalence of insulin resistance and associated 
cardiovascular risk130. TRIB3 is up-regulated in obesity and metabolic syndrome.   
The arylhydrocarbon receptor nuclear translocator-like (Arntl) forms a heterodimer with 
CLOCK, an active complex driving transcription of circadian output genes such as the Period 
(Per1, 2, etc.) and Cryptochrome (Cry1, 2, etc.) genes (Figure 15). Another target up-regulated in 
all four comparisons was nuclear factor interleukin-3 (Nfil-3, or E4BP4), which encodes a protein 
that represses expression of the Period genes131, 132.  Processes related to circadian rhythm and 
control of rhythmic processes were enriched with moderate PCB exposure in our model.  Again, 
disruption of normal circadian rhythm may be both cause and effect in metabolic disease133, 134. 
The oscillatory patterns of circadian clock output genes (BMAL/CLOCK target genes) are 
disrupted in response to nutritional challenges135, 136.  Disrupted sleep patterns due to sleep 
apnea137 or shift work138 are also associated with metabolic disease progression.  Another target 
of circadian rhythm circuitry is Kruppel-like factor 9 (KLF9), a transcription factor which expressed 
in epithelial cells and regulates daytime-specific expression of differentiation-related targets (Ell3) 
as well as targets related to glucocorticoid signaling (Fkbp5)139.  
Other targets associated with cell differentiation/identity, epithelial-to-mesenchymal 
transition and regenerative processes were differentially regulated, particularly within the 
moderate exposure models.  These included up-regulated cell adhesion proteins such as claudin-
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Figure 14. Nipk/Trib3 signaling pathway downstream of PPAR-alpha. 
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of 
signaling pathways downstream of PPAR-alpha.  In particular, the tribbles pseudokinase 
(Nipk/Trib3) differentially regulated in all comparisons: CVvsC20 (1), CVvsC200 (2), HVvsH20 (3), 
HVvsH200 (4), C20vsH20 (5), C200vsH200 (6), and CVvsHV (7).  Notably, transcription was 
upregulated in both control diet comparisons and in CVvsHV and downregulated in other 




Figure 15. Arntl/Bmal1 pathway related to circadian signaling. 
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of 
signaling pathways related to circadian signaling.  In particular, the arylhydrocarbon receptor 
nuclear translocator-like (Arntl/Bmal1)  was differentially regulated in comparison CVvsC20 (1), 
CVvsC200 (2), and C20vsH20 (5).  Clock output targets such as Per1/2, and Cry1/2 were 
differentially regulated in comparisons HVvsH20 (3), HVvsH200 (4), and CVvsHV (7), as well as 





1, endothelin-1, and vimentin, changes in which signal epithelial-to-mesenchymal or 
mesenchymal-to-epithelial transitions in hepatocytes140 (Figure 16).  Other differentially regulated 
targets in this category, including Frizzled, bone morphogenic protein 2 (BMP-2, a TGFβ-family 
member), Kruppel-like factors 10/11 (KLF-10, KLF-11: TGFβ-inducible growth regulators) and ID-
1/2 (inhibitor of DNA binding) are components of multiple development and differentiation 
pathways such as WNT (Frizzled), Hedgehog (BMP2), TGFβ (BMP2, TIEG), and Hippo (ID-1/2). 
Alterations in cell identity that accompany EMT are classically associated with neoplastic liver 
disease141, however there is evidence to link alterations in Hedgehog142, 143,  TGFβ144, WNT145, 146, 
and Hippo147 signaling to the progression of steatohepatitis and fibrosis. 
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Figure 16. Claudin-1 and e-cadherin pathways related to EMT. 
PCB exposure and PCB/HFD coexposures induced transcriptional changes in elements of 
signaling pathways related to epithelial to mesenchymal transition.  The cell adhesion molecules 
claudin-1 and e-cadherin were differentially regulated in all or most conditions CVvsC20 (1), 
CVvsC200 (2), a HVvsH20 (3), HVvsH200 (4), C20vsH20 (5), C200vsH200 (6) and CVvsHV (7).  
Image generated using MetaCoreTM from Thomson Reuters. 
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CHAPTER TWO: DISCUSSION 
PCB exposure induced transcriptional changes in mouse liver, and higher PCB exposure 
substantially increased the number of genes differentially transcribed compared to lower PCB 
exposure in the absence of dietary coexposure, the pathway characteristics of which are 
summarized in Figure 17.  The addition of HFD as a coexposure greatly affected the number of 
differentially transcribed genes produced by PCB exposure:  increasing the number and changing 
the distribution of engaged pathways. HFD itself produces many transcriptional changes in 
mouse liver, as have previously been described.  PCB exposure modulates this effect, resulting in 
sets of differentially transcribed genes which overlap substantially.  In the CVvsC20 comparison, 
nutritional and metabolic disease biomarkers were over-represented, and along with 
cardiovascular and vascular disease categories (also metabolic syndrome components), 
occupied five of the top ten most enriched categories in this group.  It is interesting that these 
indicators were enriched in regular defined diet-fed animals exposed to PCBs, and that the 
difference between vehicle and moderate PCB exposure was lost in HFD coexposure.  This 
suggests that PCB and HFD exposure may converge on pathways regulating nutritional 
homeostasis, and that PCBs may contribute to metabolic dysregulation even in the absence of 
HFD. 
With or without HFD coexposure, exposure to PCBs at 200 mg/kg increases enrichment 
in biomarkers of neoplastic disease.  This is consistent with findings in previously reported rodent 
toxicity studies.  Cancer outcomes have been a historic focus of PCB research, mainly due to the 
presence of dioxins and dioxin-like PCBs and dibenzofurans within the exposure mixture.  Dioxins 
are potent carcinogens in mice, and have been classified as human carcinogens.  Other than a 
















victims, however, the evidence linking PCB to cancer in humans has been underwhelming110. 
Interestingly, other than ovarian neoplasms in the HVvsH20 comparison, neoplastic disease 
categories were not in the top 10 disease enrichments by biomarker for either of the moderate 
exposure groups.   
Our 20 mg/kg PCB exposure was based on the highest serum PCB level reported in the 
Anniston population23, 79, which itself has a mean several times higher than that of the US 
average148.  The moderate PCB dose, therefore, is more representative of environmentally-
relevant human exposures, and we find that the distribution of diseases in these enrichments 
reflects this.  Our analysis of the differential transcriptomes produced by liver tissue in these 
experiments in some ways recapitulated the proteomic and metabolic phenotype assessments.  
Within the HVvsH20 comparison, however, the most highly enriched disease category was IL-6 
signaling (Table 45 and Figures 11-12).  This is consistent with the findings of Wahlang et al., 
which indicated that the increased liver injury observed in the HVvsH20 model was not due to 
increased steatosis, but due to increased inflammation23. Increases in serum IL6 and tPAI1 
protein were observed in the HFD/moderate exposure.  In our transcriptomic analysis of liver 
tissue, pathways involving hepatocyte acute-phase response triggered by IL6 were observed in 
the moderate exposure (comparison HVvsH20). 
  We also saw enrichment in pathways and processes associated with control of circadian 
rhythm and rhythmic processes with moderate PCB exposure.  Interestingly, in a 2015 report 
using metabolic cages to carry out metabolic phenotyping on PCB-exposed mice, our laboratory 
showed increased movement during the light (typical sleep) cycle in transgenic mice chronically 
exposed to 20mg/kg Aroclor 1260.  These differences were observed only in mice with ablated 
constitutive androstane receptor (CAR) or pregnane and xenobiotic receptor (PXR), with a 
nonsignificant increase in wild-type mice.  HFD feeding alone has been reported to alter the 
oscillatory patterns of circadian rhythm output genes in wild-type mice (Nampt, Acss2/ACSA-
downreg in all CDvsHFD comparisons, Cyp2a5)136, but not the core clock genes, which are more 
resistant to reprogramming by nutritional challenge135, 136.  We also found differences in the 
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transcription of clock output genes with HFD and HFD/PCB coexposure, but with moderate PCB 
exposure alone, we saw differences in transcription of the core clock genes as well, suggesting 
that PCB exposure and nutritional coexposures may impact these systems by different and 
potentially interacting mechanisms.  
Although neoplastic disease biomarkers may not be captured by enrichment analysis in 
more realistic models of human environmental exposure, processes such as cell adhesion, cell-
cell communication, and pathways dictating cell identity changes through the processes of 
development and remodeling are over-represented in these models.  The liver has extraordinary 
regenerative potential requiring plasticity in development and differentiation pathways even in 
adult hepatic tissue.  Multiple pathways involved in development as well as repair were engaged 
in these models, including TGF-beta signaling, Wnt/β-Catenin signaling, Hedgehog signaling, and 
Hippo signaling.  Because these pathways are involved in development and regeneration, they 
also share common processes related to cell identity, orientation, and cell-cell recognition.  
Although pathway analysis shows engagement of these pathways in our animal model of 
environmental liver disease, it is unclear whether this engagement indicates regenerative 
response to ongoing PCB/HFD-dependent liver damage or modulation of basal or HFD-driven 
liver regeneration through xenobiotic receptor mediated PCB effect.       
Responses to endogenous and exogenous organic compounds were over-represented 
among engaged processes both in the presence and absence of HFD coexposure.  Responses 
to xenobiotics are thought to be mediated by xenobiotic receptors, of which AhR, PXR, and CAR 
are the prototypical example.  In addition, xenobiotic receptors may also be activated by 
endogenous molecules, and crosstalk at multiple levels with receptors transducing hormone and 
metabolite sensing to control of intermediary metabolic processes.  Among the direct 
transcriptional targets of these receptors with defined relationships curated by MetaCoreTM, few 
were differentially regulated, however, MetaCoreTM software does not offer a comprehensive 
database of interactions for these receptors, and even some prototypical transcriptional effects of 
receptor-target interactions, such as Mus musculus PXR transcriptional activation of Cyp3a11, 
are not among the curated dataset.  Canonical prototypical targets of PXR, including Cyp3a11, 
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were up-regulated in the CVvsC20 condition.  Alternative pathway analysis tools may offer more 
insight into the direct transcriptional effects of xenobiotic receptors in this model. It is interesting 
to note, however, that transcription factors which directly interact with and are inhibited by PXR 
showed a pattern consistent with increased engagement in the moderate exposure compared to 
the high exposures.  Since these protein-protein interactions are ligand-dependent, it suggests 
that PXR (and potentially other xenobiotic receptors) may indeed be engaged, and that the 
mechanism of their effect in PCB-associated liver injury requires further study.   
In summary, our RNAseq and subsequent pathway analysis of liver tissue from an animal 
model of PCB/HFD coexposure revealed several transcriptional changes which may be related to 
the observed phenotypic differences between groups.  In particular, the enrichments in nutritional 
disease terms observed in the control diet animals exposed to PCBs may explain some of the 
differences in glucose handling which were previously reported for this experiment.23  
Enrichments in IL-6 signaling with the moderate PCB/HFD coexposure may explain the increased 
histological evidence of liver injury observed only in this condition, while differential transcription 
affecting pathways involved in development and regeneration, as well as cell adhesion and cell-
cell recognition may provide some insight into differences in regenerative/fibrotic processes 
observed in the animal model.
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CHAPTER THREE 
PCB EXPOSURE INDUCES A DIFFERENTIAL TRANSCRIPTOME WHICH PARTIALLY 
OVERLAPS WITH THAT OF PROTOTYPICAL XENOBIOTIC RECEPTOR LIGANDS IN A 
MOUSE PRIMARY HEPATOCYTE MODEL 
Xenobiotic receptors are transcription factors which allow an organism to respond to 
chemical changes in the environment with appropriate metabolic adaptations. Although these 
changes are often circumscribed in the literature as encounters with environmental toxicants, it is 
important to recognize that xenobiotic receptors often respond to endobiotic signals as well, and 
are intimately involved in intermediary metabolism and inter-tissue communication along with the 
metabolism of xenobiotics. Even the arylhydrocarbon receptor (AhR), a classic focus of 
xenobiotic and toxicant research, affects149 and is affected by150, hormonal signaling pathways 
and the metabolic products of gut commensals. It is not surprising, therefore, that AhR and other 
xenobiotic receptors such as the pregnane and xenobiotic receptor (PXR) and the constitutive 
androstane receptor (CAR), have been implicated in metabolic derangements associated with 
toxicant exposures.  Such derangements may manifest clinically and experimentally as 
components of metabolic syndrome, including steatohepatitis.   
Nuclear receptors including PXR, CAR, farnesoid X receptor (FXR) and the liver X 
receptor (LXR) are known to cross-talk at multiple levels, from common ligands151, binding 
partners, and cofactors152 to conserved response elements characterized by a DR4153 or other 
shared motifs.  This last intersection is most intriguing because while PXR and CAR are known to 
be sensors and effectors in xenobiotic metabolism, induction of the sterol-sensor LXR and the 
bile acid receptor FXR directly induce lipogenic gene targets, a phenomenon which is known to 




pharmacotherapy, has been shown to lead to nonalcoholic fatty liver disease (NAFLD)154. 
Considering the interplay of these factors, it is not surprising that PXR, CAR, and LXR have been 
implicated along with the AhR in toxicant-associated steatohepatitis. 
 
A further degree of complexity arises when we consider the effects of toxicant mixtures such as 
PCBs, which can be expected to affect several of these sensors simultaneously. PCBs are 
always encountered and bioaccumulated as mixtures of congeners, and persist at detectable 
levels in the serum of every adult in the United States37.  The distribution of congeners found in 
the adipose tissue and serum of humans contains species which are known to modulate the 
activity of AhR, PXR, CAR19, 34, 35, 155 and other receptors, and may, through crosstalking 
pathways, affect the transcriptional function of LXR. Because each of these receptors modulates 
gene targets related to steatohepatitis, an understanding of the contribution of each of these 
transcription factors to the overall PCB-modified transcriptome would assist with both risk 
assessment and the rational development of therapies. 
 Other groups have elucidated the subsets of the transcriptome modulated by AhR, PXR, 
and CAR individually in response to prototypical ligands.  Findings have been intriguing for 
several reasons. Both in vivo and in vitro experiments suggest that for both AhR and PXR, 
differential transcription of target genes appears to be ligand-specific156.  Additionally, for primary 
hepatocytes, variations in cell isolation and culture techniques including culture time and plating 
substrate may drastically affect the expression levels of prototypical targets of AhR, CAR and 
PXR.  In light of this, we sought to consolidate our assessment into a single primary murine 
hepatocyte model, examining the relationships between prototypical ligand responses and 
response to PCBs using RNAseq.  We further sought to evaluate the PCB-dependent 
transcriptional output of this model for components of metabolic pathways related to steatosis and 
for gene ontology (GO) term enrichments within hepatic and metabolic disease categories.
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CHAPTER THREE: MATERIALS AND METHODS 
Animals and primary cell isolation procedure 
Male C57BL6 mice 8-10 weeks of age were purchased from Jackson Labs and allowed to 
acclimate for 1 week on a defined control diet (Harlan Teklad Cat TD.06416).  Mice were deeply 
anesthetized with ketamine/xylazine, and the liver was flushed by retrograde perfusion first with a 
washing solution for 6 minutes, then with a buffered collagenase solution for 10 minutes. After 
perfusion, the liver was isolated and the gallbladder removed in a dish of ice-cold FBS-
supplemented Waymouth’s media.  The liver was finely minced and the resulting suspension 
filtered through a 70 µm cell strainer.  Cells were immediately centrifuged, washed twice with ice 
cold HBSS, and selected by densitiy gradient centrifugation.  The cell pellet was then 
resuspended in cold, supplemented Waymouth’s media, and viability and cell count were 
determined.  Cells were plated on collagen-coated 12-well plates and allowed to adhere.  
Adherent cells were exposed for 6 hours to 4 µl/well vehicle (DMSO) or test substance solubilized 
in DMSO:  Aroclor 1260 at 5 µg/ml or a prototypical ligand for mPXR – summarized in Table 58 
(10 µM pregnane carboxynitrile, PCN), mCAR (10 µM, TCPOBOP), LXR (1 µM GW3965 
hydrochloride, GW) or AhR (50 µM benzathracene, BA). After exposure, media was removed and 
RNA was isolated by the RNAStat60 manufacturer’s protocol. 
RNAseq and gene transcription analysis 
RNA samples were multiplexed using sequence barcoding, and sequenced single ended to 75 
base pair reads using a NextSeq500 to an approximate read count of 40 million reads per 
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Table 58  
Treatment summary 
Exposure Anticipated Target 
DMSO Control 
Benzanthracene (BA), 50 µM AhR 
Pregnane Carboxynitrile (PCN), 10µM mPXR 
GW3965 1µM LXR 
TCPOBOP µM mCAR 
Aroclor 1260 (PCB) 5µg/ml -- 
Isolated primary mouse hepatocytes were exposed to Aroclor 1260 (a representative PCB 
mixture) or prototypical ligand for the above anticipated targets for 6h. 
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sample.  The bcl files produced were basecalled using Illumina’s bcl2fastq software. All 
sequences produced were aligned to the mouse reference genome (GRCm38.83) using the 
alignment software TopHat, and transcript expression levels were calculated in FPKM units using 
Cufflinks122.  The quantification was guided by transcriptome annotation for the mouse 
downloaded from NCBI.  Records corresponding to both mitochondrial and ribosomal RNA were 
removed (annotated as transcript_biotype rRNA or Mt_tRNA) to improve the accuracy of the 
transcriptome quantification.  Differential analyses (FPKM units averaged from 4 replicates of 
each test vs. DMSO-treated controls) were performed using CuffDiff. 
Pathway and GO enrichment term analysis 
For each treatment, the fold changes and p-values for each differentially transcribed gene 
(indexed by Ensembl ID) were uploaded into MetaCoreTM (Thompson Reuters) and recognized 
genes were associated with one or more MetaCoreTM-curated network objects.  Experiments 
were analyzed using the MetaCoreTM Enrichment Analysis Workflow tool, using a species (M. 
musculus) and tissue (liver) prefilter. With prefilters, the number of tags/genes was reduced to 87 
targets (from 119). 
qPCR validation of selected targets:  
Targets for validation were selected based on RNAseq-indicated up-regulation and 
relevance to implicated transcription factors, pathways and disease processes.  cDNA was 
generated using the QuantiTect Reverse Transcription kit (Qiagen #205313) according to 
manufacturer recommendations.  Multiplexed qPCR (target and GAPDH) was carried out on 
BioRad CFX384 system using the following TaqMan Gene Expression Array probes: Cyp1a2 
(Applied Biosystems Mm00487224_m1/FAM), Cyp3a11 (Applied Biosystems 
Mm00731567_m1/FAM), Cyp2b10 (Applied Biosystems Mm01972453_s1/FAM) and GAPDH 
(Applied Biosystems, Mm99999915_g1/VIC).  
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CHAPTER THREE: RESULTS 
Aroclor1260 exposure at 5 ug/mL for 6h induced differential transcription in primary mouse 
hepatocytes  
Under these conditions, 123 targets were significantly differentially transcribed with 
Aroclor 1260 treatment vs. DMSO control (Figure 18 and Table 59).  Among these, 68 were 
down-regulated (FC > 0.5), with 13 genes showing greater than 1-fold reduction in transcription.   
Aroclor 1260 exposure resulted in up-regulation (FC < 0.5) of 55 genes, with 3 genes up-
regulated more than 1-fold.   
In this model, the Aroclor 1260-dependent DTG sets partially overlapped with DTG sets produced 
by exposure to ligands for AhR, PXR, CAR, and LXR 
Of the 123 targets within the PCB-DTG set, 41 (33%) were not shared with the DTG sets 
produced by the prototypical ligands investigated, as shown in Figure 19.  Most (67.5%) of the 
genes within the PCB-DTG set overlapped with DTG sets produced by prototypical ligands for 
murine AhR, PXR, CAR, and/or LXR, as shown in Figure 20.  The largest areas of overlap as a 
proportion of the total PCB-DTG set occurred with the PXR agonist PCN (65 targets in common 
with PCB exposure) and the AhR agonist BA (64 targets in common with PCB exposure). These 
two prototypical ligands produced by far the largest differential transcriptomes: 672 and 720 total 
DTGs, respectively, and the proportion of these transcriptomes which were also modulated by 
PCBs was relatively small (9.7% and 8.9%, respectively).  The smallest area of overlap occurred 
between PCB and GW3960, a specific inducer of LXR, with only 14 targets differentially 
transcribed under both conditions.  Although the direct murine CAR agonist TCPOBOP produced 
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Figure 18. Histograms of differential transcriptomes produced by PCB/prototypical ligand exposure. 
The differential transcriptome produced by Aroclor 1260 exposure in this model included both up-
regulated and downregulated targets, with fold changes ranging from  -3.73 to +1.3 (Panel A).  
Differential transcriptome FC ranges for prototypical ligands are shown in Panels B-E. 
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Table 59 
Targets differentially regulated with Aroclor 1260 Exposure
Ensembl ID Name FC Ensembl ID Name FC
ENSMUSG00000026442 Nfasc -3.73 ENSMUSG00000035171 -0.61
ENSMUSG00000002489 Tiam1 -2.51 ENSMUSG00000011305 Plin5 -0.59
ENSMUSG00000076434 Wfdc3 -2.45 ENSMUSG00000100798 Gm19589 -0.59
ENSMUSG00000034780 B3galt1 -1.81 ENSMUSG00000036941 Elac1 -0.56
ENSMUSG00000032315 Cyp1a1 -1.78 ENSMUSG00000045502 Hcar2 -0.53
ENSMUSG00000084923 Gm15611 -1.57 ENSMUSG00000028088 Fmo5 -0.53
ENSMUSG00000069919 Hba-a1 -1.47 ENSMUSG00000035202 Lars2 -0.52
ENSMUSG00000038156 Spon1 -1.43 ENSMUSG00000032310 Cyp1a2 -0.52
ENSMUSG00000050097 Ces2b -1.41 ENSMUSG00000059325 Hopx -0.51
ENSMUSG00000097461 Gm26735 -1.20 ENSMUSG00000030643 Rab30 -0.51
ENSMUSG00000076431 Sox4 -1.17 ENSMUSG00000019832 Rab32 -0.49
ENSMUSG00000004038 Gstm3 -1.10 ENSMUSG00000019726 Lyst -0.49
ENSMUSG00000050069 Grem2 -1.00 ENSMUSG00000039270 Megf9 -0.47
ENSMUSG00000041992 Rapgef5 -0.99 ENSMUSG00000049404 Rarres1 -0.46
ENSMUSG00000030909 Anks4b -0.97 ENSMUSG00000019866 Aim1 -0.46
ENSMUSG00000053168 -0.96 ENSMUSG00000012428 Steap4 -0.45
ENSMUSG00000052305 Hbb-bs -0.96 ENSMUSG00000023073 Slc10a2 -0.43
ENSMUSG00000101206 Gm5266 -0.95 ENSMUSG00000018102 Hist1h2bc -0.42
ENSMUSG00000064128 Cenpj -0.92 ENSMUSG00000038332 Sesn1 0.42
ENSMUSG00000091572 Vmn2r3 -0.92 ENSMUSG00000021190 Lgmn 0.45
ENSMUSG00000052131 Akr1b7 -0.90 ENSMUSG00000056204 Pgpep1 0.45
ENSMUSG00000031169 Porcn -0.89 ENSMUSG00000000303 Cdh1 0.46
ENSMUSG00000057068 Fam47e -0.86 ENSMUSG00000041483 Zfp281 0.46
ENSMUSG00000021260 Hhipl1 -0.84 ENSMUSG00000022512 Cldn1 0.49
ENSMUSG00000041132 N4bp2l1 -0.84 ENSMUSG00000037260 Hgsnat 0.50
ENSMUSG00000055312 Them7 -0.84 ENSMUSG00000016382 Pls3 0.50
ENSMUSG00000038403 Hfe2 -0.83 ENSMUSG00000024773 Atg2a 0.51
ENSMUSG00000078612 -0.81 ENSMUSG00000021998 Lcp1 0.51
ENSMUSG00000020000 Moxd1 -0.80 ENSMUSG00000035671 Zswim4 0.51
ENSMUSG00000030107 Usp18 -0.79 ENSMUSG00000030790 Adm 0.51
ENSMUSG00000061540 Orm2 -0.76 ENSMUSG00000047777 Phf13 0.52
ENSMUSG00000030089 Slc41a3 -0.75 ENSMUSG00000024042 Sik1 0.52
ENSMUSG00000057425 Ugt2b37 -0.75 ENSMUSG00000068876 Cgn 0.52
ENSMUSG00000028359 Orm3 -0.74 ENSMUSG00000024014 Pim1 0.53
ENSMUSG00000022032 Scara5 -0.72 ENSMUSG00000032350 Gclc 0.54
ENSMUSG00000063659 Zbtb18 -0.71 ENSMUSG00000019854 Reps1 0.54
ENSMUSG00000046027 Stard5 -0.71 ENSMUSG00000020034 Tcp11l2 0.55
ENSMUSG00000032715 Trib3 -0.69 ENSMUSG00000025351 Cd63 0.56
ENSMUSG00000022244 Amacr -0.67 ENSMUSG00000078866 Gm14420 0.56
ENSMUSG00000020553 Pctp -0.67 ENSMUSG00000000957 Mmp14 0.57
ENSMUSG00000046794 Ppp1r3b -0.66 ENSMUSG00000024486 Hbegf 0.58
ENSMUSG00000003762 Adck4 -0.65 ENSMUSG00000019960 Dusp6 0.59
ENSMUSG00000056148 Rdh9 -0.65 ENSMUSG00000028381 Ugcg 0.60
ENSMUSG00000073565 Prr16 -0.65 ENSMUSG00000025779 Ly96 0.61
ENSMUSG00000036181 Hist1h1c -0.64 ENSMUSG00000052609 Plekhg3 0.61
ENSMUSG00000030827 Fgf21 -0.63 ENSMUSG00000027954 Efna1 0.61
ENSMUSG00000031482 Slc25a15 -0.63 ENSMUSG00000021765 Fst 0.61
ENSMUSG00000107198 Gm19619 -0.63 ENSMUSG00000024810 Il33 0.62
ENSMUSG00000022946 Dopey2 -0.62 ENSMUSG00000040152 Thbs1 0.64







Table 59 (Continued) 
 
Targets differentially regulated with Aroclor 1260 Exposure
























Gene targets differentially regulated with Aroclor 1260 
exposure are shown.  FC = fold change compared to DMSO 
control.   
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investigated.    This  uniquely  regulated  section  of  the  PCB‐dependent  transcriptome 
included unique of CREB1, SP1, and c‐Myc. Several of the differentially transcribed targets, 
including  SOX‐4,  Ptpre  (Receptor‐type Protein  Tyrosine Phosphatase  epsilon)  and  Sik‐1 
(salt‐inducible kinase 1) are implicated in regulation of hepatic intermediary metabolism. 
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Figure 20. A portion of the PCB-DTG overlapped with DTGs for AhR, PXR, CAR, and LXR 
prototypical ligands. The differential transcriptome produced by Aroclor 1260 (PCB) exposure in 
this model overlapped with the differential transcriptome produced by each of the 4 prototypical 
ligands studied.  The largest differentially-transcribed gene (DTG) sets were produced by A. 
pregnane carboxynitrile (PCN), a pregnane and xenobiotic receptor agonist and B. 
Benzanthracene (BA), an arylhydrocarbon receptor agonist.  These two prototypical ligands also 
produced the largest areas of overlap with PCB exposure (65 and 64 common DTGs, respectively).  
Two other prototypical ligands produced smaller total DTG sets. C. GW3965, a LXR agonist, 
produced a total differential transcriptome of 78 genes, 14 of which were also affected by PCB 
exposure.  D. TCPOBOP, a direct constitutive androstane receptor (CAR) agonist, caused 
differential transcription of the smallest number of total genes (56), 20 of which were shared with 
PCB exposure.  PCB exposure regulated a larger proportion of the total CAR differential 
transcriptome, however, than any other prototypical ligand studied (36%, vs 8% of BA-DTGs, 9% 
of PCN-DTGs, and 18% of LXR-DTGs). 
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the smallest differential transcriptome (56 targets), 20 targets within this set were also targets of 
differential regulation by Aroclor 1260 exposure.   
The direction of change in these common DTGs varied between treatment with Aroclor 
and prototypical ligands, but agreed with the direction of PXR and AhR differential transcription in 
most cases, as expected (Table 60), with more shared targets down-regulated than up-regulated. 
Of the 65 targets shared between PCB and PCN, 87.7% agreed in direction. Exceptions included 
the gene target Usp18, which was moderately up-regulated in the PXR prototypical ligand 
condition and down-regulated with both Aroclor 1260 treatment and CAR prototypical ligand 
treatment.  Of the 64 targets shared between PCB and BA, 85.9% agreed in direction. The six 
genes up-regulated with BA and down-regulated with Aroclor 1260 were all differentially regulated 
by at least one other transcription factor, and in fact, two of the three DTGs common to all 5 
conditions were represented in this group (Cyp1a1 and Lars2).  DTGs shared between 
GW3965/PCB and TCPOBOP/PCB included both up-regulated and down-regulated targets.  In 
both cases, the up-regulated target sets were entirely concordant (6/6 for GW3965 and 10/10 for 
TCPOBOP, concurrently up-regulated/shared).  87.5% of genes were concordantly down-
regulated between GW3965 and PCB, while only half of the shared targets of TCPOBOP down-
regulated with PCB exposure agreed in direction.  Although a tremendous amount of overlap 
existed between the conditions investigated, we were surprised to find that 41 DTGs (33.3%) 
were unique to Aroclor exposure and are not shared with other prototypical ligand treatment 
(Figure 19 and Appendix Table 1), with 21 up-regulated and 20 down-regulated. 
As expected, exposure to each of the prototypical ligands resulted in up-regulation of the 
corresponding prototypical target (Table 61).  With Aroclor 1260 exposure, however, no 
significantly different transcription occurred (vs. DMSO control) in any prototypical target other 
than Cyp1a2, which was significantly down-regulated. This finding validates previous reports that 
while PCB exposure leads to induction of CAR, PXR, AhR and LXR prototypical targets in vivo23, 
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Aroclor1260 differentially transcribed genes are significantly enriched in pathway maps involved 
in cell identity and development, and in GO terms related to liver, endocrine, and metabolic 
disease 
Initial output of in silico analysis using the MetaCoreTM Enrichment analysis workflow 
identified 9 pathway maps significantly (FDR < .05) over-represented in the Aroclor1260 
differentially transcribed gene set, shown in Table 62.  Within these pathways, network objects 
related to differentiation or epithelial to mesenchymal transition (EMT) were enriched, particularly 
E-cadherin, vimentin, and claudin-1, which appeared separately or together in half of the top 10 
enriched pathways. Pathways related to EMT were enriched for the PCB-DTG members. Figure 
21 illustrates elements of this pathway.   
Components of the PCB-DTG set were enriched in GO terms related to liver (31/4260 
curated network objects, p = 6.0 E-05, FDR = 4.7 E-04), pancreatic (27/3463 curated network 
objects, p = 6.8e-5, FDR = 5.2 e-4) and metabolic (29/3584 curated network objects, p = 1.6 e-5, 
FDR = 2.0 e-4) disease biomarkers.  Within these sets, E-cadherin, vimentin and claudin-1 
figured prominently, as did HB-EGF, AMACR, and osteopontin. 
Aroclor1260 DTGs contain known or putative targets of transcription factors with known 
involvement in fatty liver disease and metabolic dysfunction. Transcription factor analysis of 
Aroclor 1260 indicated that large subsets of the PCB-DTGs set were predicted to be influenced 
by specific transcription factors including CREB-1, SP-1 and cMyc.  Nuclear receptors such as 
HNF4-α and PPAR-γ, with known roles in steatosis and steatohepatitis, were also found to 
modulate the transcription of targets within this set.  Significantly overconnected transcription 
factors are listed in Table 63.  Notably, several of these transcription factors are direct or down-
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Figure 21. Pathways related to EMT were enriched in genes in the PCB-DTG set.  The cell 
adhesion molecules claudin-1 and E-cadherin, as well as vimentin were important components of 
this pathway as well as others related to cell differentiation and tissue regeneration pathways. 
Image generated using MetaCoreTM from Thomson Reuters. 
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Table 63 





CREB1 33 3.050E-105 212.83 
SP1 23 8.940E-73 176.55 
c-Myc 21 2.420E-66 168.36 
p53 20 3.910E-63 164.12 
C/EBPbeta 19 6.230E-60 159.76 
Androgen receptor 17 1.530E-53 150.68 
c-Jun 15 3.570E-47 141.01 
ESR1 (nuclear) 14 5.360E-44 135.93 
PPAR-gamma 14 5.360E-44 135.93 
HNF4-alpha 14 5.360E-44 135.93 
NANOG 13 7.920E-41 130.65 
C/EBPalpha 13 7.920E-41 130.65 
STAT3 12 1.150E-37 125.15 
HIF1A 12 1.150E-37 125.15 
GATA-3 12 1.150E-37 125.15 
ATF-4 12 1.150E-37 125.15 
c-Fos 11 1.660E-34 119.4 
RelA (p65 NF-kB subunit) 11 1.660E-34 119.4 
Bcl-6 10 2.340E-31 113.37 
SMAD3 10 2.340E-31 113.37 
VDR 10 2.340E-31 113.37 
IRF1 10 2.340E-31 113.37 
SMAD2 10 2.340E-31 113.37 
Oct-3/4 10 2.340E-31 113.37 
JunD 9 3.250E-28 107.02 
GCR 9 3.250E-28 107.02 
FKHR 9 3.250E-28 107.02 
PPAR-alpha 8 4.430E-25 100.27 
TCF7L2 (TCF4) 8 4.430E-25 100.27 
p63 8 4.430E-25 100.27 
Transcription regulation pathway analysis was performed on the PCB-DTG 
dataset without prefilters. 
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CHAPTER THREE: DISCUSSION 
Classically, the transcriptional effects of PCB exposure have been attributed entirely to 
ligand-dependent activation of AhR, PXR and CAR.  We expected that the subset of genes 
differentially transcribed with Aroclor1260 exposure in this acute primary hepatocyte model would 
overlap almost entirely with the transcriptional output of prototypical ligands for these three 
receptors.  We were therefore surprised to discover that fully 1/3 of DTGs were unique to 
Aroclor1260 in this system, possibly due to the transcriptional effects of another xenobiotic 
receptor or by an indirect mechanism.  Our laboratory has recently reported that EGFR is also a 
target of inhibition by both Aroclor1260 and individual PCB congeners.  PCBs therefore would be 
expected to function as an indirect CAR activator in both mice and humans by the same 
mechanism as phenobarbital21.   
The canonical cytochrome P450 targets of CAR and PXR activation cyp2b10 and 
cyp3a11 did not appear among the RNA-seq derived PCB-DTG gene set, while cyp1a1 and 
cyp1a2 (prototypical targets of AhR induction) were both down-regulated in the PCB-DTG set.  
Interestingly, cyp1a1 and cyp1a2 were also down-regulated by PCN treatment in this model.  
Regulation of cyp1a1 was particularly complex: up-regulated by inducers of CAR and LXR as well 
as AhR and down-regulated by PXR induction. We conclude that differential regulation of the 
proportion of PCB-DTGs overlapping with targets of the evaluated receptors is complex and may 
be influenced by the combined effects of these and other xenobiotic receptors. 
The targets most strongly up-regulated with Aroclor 1260 exposure, slc34a2 (+1.34-fold 
vs. control) and spred3 (+1.31-fold vs. control) were uniquely up-regulated by PCBs in this model.  
Although slc34a2 was also a target differentially regulated by PCN exposure, it was down-
regulated in that condition and unchanged with exposure to other prototypical ligands. The targets
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 most strongly down-regulated with Aroclor 1260 exposure, nfasc (-3.73-fold vs. control) Tiam1(-
0.51-fold vs. control) and wfdc3 (-2.45-fold vs. control) were also strongly down-regulated by PCN 
treatment (-4.20, -2.73, and -2.13-fold vs. control, respectively).  PXR is involved in differential 
regulation of transcription related to PCB exposure, however, it seems more involved in inhibition 
of these targets than induction. 
Several of the genes differentially transcribed with PCB exposure in this model are 
differentially transcribed in the incidence or progression of liver disease or liver disease 
biomarkers.  Osteopontin (Spp), which was up-regulated with PCB (+0.93-fold vs. control) is up-
regulated in NASH fibrosis has been shown to oppose EMT in liver progenitor cells157.  Four And 
A Half LIM Domains 3 (FHL3), which was up-regulated with PCB (+0.91-fold vs. control) affects 
transcription of tPAI1, a fibrosis biomarker up-regulated in PCB-exposed humans. RAB31, a 
member RAS Oncogene Family, which was up-regulated with PCB (+0.84-fold vs. control), is 
associated with invasive/metastatic characteristics and worse prognosis in HCC.158.  Semaphorin 
3E (Sema3e), which was up-regulated in PCB exposure (+0.77 vs. control) is expressed by 
damaged hepatocytes and secreted, inducing contraction of sinusoidal epithelial cells and 
activation of stellate cells. Chronic exposure to Semaphorin 3E in a mouse model of CCl4-induced 
chronic heptatitis lead to disorganized sinusoidal regeneration and exacerbated fibrosis.159 
Cytochrome P450 1a1 (Cyp1a1), which was down-regulated (-1.78-fold vs. control) is a 
prototypical target of the arylhydrocarbon receptor and is up-regulated in animal models of 
TCDD-induced nonalcoholic steatohepatitis.160 Interestingly, in this model, although it was up-
regulated by prototypical ligands of LXR and CAR in addition to AhR, it was strongly down-
regulated by PXR ligand exposure. Carboxyesterase 2 (Ces2b), which was down-regulated in our 
model (-1.41-fold vs. control), and in the livers of NASH patients.  Experimental ablation of Ces2b 
in a mouse model causes ER stress in hepatocytes and stimulates lipogenesis in an SREBP-1-
dependent manner.161 Aldo-keto reductase family 1, member B7 (Akr1b7), which was down-
regulated in our model (-0.90-fold vs. control) is enriched in adipose stromal vascular fraction, but 
not in mature adipocytes.  In a mouse model, Akr1b7 KO increased basal adiposity (adipocyte 
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hyperplasia and hypertrophy) with diet-independent development of liver steatosis and insulin 
resistance.162 Hemochromatosis, type 2 (Hfe2), which was down-regulated in our model (-0.83 vs. 
control), is expressed at significantly lower levels in NAFLD patients vs. those with no disease.  
Because Hfe2 is involved in iron-sensing pathways, it is hypothesized that lower levels of Hfe2 
are related to the dysregulated iron-sensing pathways leading to iron overload in NAFLD.163 
Thrombospondin-1 (Thbs1), was up-regulated in our model (+0.64 vs. control).  Transcription of 
Thrombospondin-1 is increased in individuals with chronic liver disease and in mouse models of 
liver fibrosis.164 Interleukin 33 (Il33) was up-regulated in our model (+0.62 vs. control), and is 
elevated in the serum of NASH patients, increasing with increasing histologic severity.165 
Several of the genes differentially transcribed with PCB exposure in this model affect 
pathways of interest. Sprouty-related protein with EVH-domain 3 (Spred-3), which was up-
regulated with PCB (+1.31-fold vs. control) potently inhibits ERK1/2 signaling166, 167. Four And A 
Half LIM Domains 3 (FHL3) physically interacts with SMAD proteins (TGFβ) pathway.168 RAB31 
is associated with modulation of EGFR trafficking.  It physically interacts with EGFR and its 
overexpression increases early-late endosome trafficking and degradation of EGFR.169, 170 T 
lymphoma invasion and metastasis 1 (Tiam1), which is strongly down-regulated with PCB (-2.51-
fold vs. control) is differentially regulated in hepatocellular carcinoma and pancreatic cancer 
tissues.171, 172  In pancreatic cancers, the Par3 interacts with Tiam1 to affect tight junctions by 
downregulating Claudin-1 and Occludin.172  Tiam1 is also a target suppressed by several 
miRNAs.173, 174 Sustained ectopic exposure to Sema3E (up-regulated by PCB exposure in this 
model) has been found to result in disorganized regeneration of liver sinusoids, contributing to 
fibrosis, in a mouse model of liver regeneration.159 SRY (sex determining region Y)-box 4 (Sox-4), 
was down-regulated with PCB exposure in our model (-1.17-fold vs. control).  In HepG2 cells, 
inhibition of Sox-4 blocks caspase-1-dependent apoptosis.175 Glutathione S-transferase, mu 3 
(Gstm3), which was down-regulated with PCB exposure in our model (-1.10-fold vs. control) is 
involved in glutathione-dependent clearance of xenobiotics (Phase II metabolism).176  Protein 
Tyrosine Phosphatase, Receptor Type E (Ptpre) was up-regulated with PCB exposure, and 
functions to modulate insulin signaling in hepatocytes and skeletal muscle by suppressing 
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phosphorylation of targets down-stream of insulin signaling such as Akt, ERK and GSK3.177 
Porcupine homologue (Porcn), which was down-regulated (-0.89-fold vs. control) is an ER protein 
essential for the processing of Wnt proteins, and its inhibition inhibits Wnt signaling.178 
Lastly, several of the genes differentially transcribed with PCB exposure in this model are 
affected by pathways of interest. Na+-Pi Cotransporter NaPi-IIb is regulated by glucocorticoid, 
estrogen, EGF, aging,179 dietary phosphate status, hormones like parathyroid hormone, 1,25-
OH2 vitamin D3 or FGF23180. Expression of Gstm is induced by wnt/β-catenin activation and 
inhibited with Ras activation.181 Aldo-keto reductase family 1, member B7 (Akr1b7) is induced in 
the liver by activation of FXR182 CAR, PXR, and LXR via direct interaction with DR4 elements in 
the promoter, and that the influence of PXR/LXR is additive.183 
The MetaCoreTM curated GO processes most significantly enriched in genes affected by 
Aroclor 1260 exposure included several recurring objects with roles in Wnt signaling, cell 
adhesion and/or EMT: pathways which are altered in the progression of fatty liver disease184.  Of 
these, up-regulation of Claudin-1 was unique to Aroclor 1260 exposure and although more than 
one prototypical ligand induced differential expression of E-cadherin (PCN and BA), it was up-
regulated only with PCB exposure. Vimentin, in contrast, was up-regulated with PCN and 
TCPOBOP as well as PCB exposure.  Importantly, EMT in hepatocytes is characterized by a 
decrease in E-cadherin and claudin-1, corresponding to increased inhibition by SNAIL/SLUG 
signaling down-stream of TGFβ.  EMT in hepatocytes is characterized by decreases in E-
cadherin and claudin-1, and increased Vimentin, however, with PCB exposure, we saw increases 
in expression of both epithelial (E-cadherin and Claudin-1) biomarkers, along with increased 
Vimentin (a mesenchymal biomarker).  Although decreases in expression are associated with 
mesenchymal change, exogenously expressed Claudin-1 promotes the acquisition of 
mesenchymal characteristics in hepatocellular carcinoma185.  Decreased Claudin-1 and E-
cadherin in Increases in Claudin-1 expression characterize HUVEC cells undergoing 
differentiation to endodermal and hepatic stages.186 
In the context of liver damage and regeneration, the designation of “epithelial” or 
“mesenchymal” refers not to the inflexible characteristic of lineage (origin) but rather, the plastic 
159
cellular organization and metabolic commitments underlying tissue-level function187.  Epithelial 
cells are characterized by tight cell-cell contacts and apico-basal polarity.  In epithelioid adult liver 
parenchymal cells, (hepatocytes and cholangiocytes), these characteristics are critical to their 
function as a selectively permeable, transformative metabolic layer receiving input from 
enterohepatic circulation (sinusoidal/basolateral) and contributing modified output to systemic 
circulation and the biliary system (cannalicular/apical). The levels, ratio, and distribution of 
claudins, members of the main transmembrane protein family forming hepatocyte intercellular 
tight junctions form the structural underpinning of this polarity/permeability, and so define specific 
identity and function of the cell.   
In contrast, traits associated with mesenchymal cells include a lack or loss of polarity and 
loss or differential organization of the protein architecture required to maintain cell-cell and cell-
ECM contacts. A transition from epithelial to mesenchymal or mesenchymal to epithelial qualities 
involves the gradual loss of characteristic markers of one state and gain of markers characteristic 
of the other, with transitioning cells often expressing some of each.  In this case, high E-cadherin 
and claudin would be indicative of epithelioid character, while Vimentin is typically a 
mesenchymal marker140.   
In summary, in primary hepatocytes, differential transcription induced by PCB exposure 
cannot be completely explained by direct ligand-induced transcriptional activity of the AhR, PXR, 
or CAR by congeners within the Aroclor 1260 mixture.  This is surprising, considering the vast 
amount of research that has focused on these three receptors as mediators of PCB effect.  AhR 
and PXR had the largest areas of overlap, however, the direction of differential transcription was 
often opposite between Aroclor 1260 DTGs and the DTGs produced by treatment with these 
prototypical ligands, particularly PXR.  LXR, which is unlikely to be bound by congeners within the 
mixture, is likely to crosstalk with PXR and CAR at the level of chromatin binding, as it recognizes 
the same DR-4 motif response element.  LXR is often implicated as a key transcription factor 
involved in the development of steatosis leading to steatohepatitis, however, transcriptional 
changes due to direct ligand activation of LXR did not have a large overlap with the Aroclor 1260-
dependent differential transcriptome either.  We conclude from the information in this model that 
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other transcription factors are likely responsible for a large portion of the transcriptional changes 
observed with PCB exposure. 
Transcription factors that appear to be involved in PCB-dependent transcription are often 
directly or indirectly influenced by EGFR-mediated cell signaling via phosphorylation, consistent 
with our recent report that PCBs inhibit EGFR signaling20. MetaCoreTM pathway analysis of the 
PCB-DTG set indicated enrichment in biomarkers associated with liver disease, and components 
pathways known to be involved in the progression of fatty liver disease.  Targets uniquely 
modified by PCB exposure in this model include markers of epithelioid character and hepatocyte 
polarity, as well as ECM modifiers. Together, these suggest that at least some of the diseases 
associated with PCB exposure are due to differential transcription mediated by one or more 




The study of human disease related to environmental exposures requires a 
multidisciplinary approach unique in biomedical research.  It requires a balance between overly 
reductionist approaches that ignore poorly understood pathways and massive, non-mechanistic 
association studies which muddy the waters and yield unapproachable data.  The experimental 
approaches to PCB research suffer from both problems, resulting in a body of literature that is 
measured “by the pound, not by the page”39: a massive body of exposure data with mechanistic 
assumptions based on changes to one or two transcriptional targets of one or two xenobiotic 
receptors.  The overall result of this status is that even 80 years after publication of the first paper 
linking PCB exposure to human disease, the mechanisms of PCB-related diseases are poorly 
understood.  
The Cave laboratory began with a study of the people exposed to PCBs – every adult in 
the US population, represented by the massive, cross-sectional National Health and Nutrition 
Evaluation Survey, or NHANES.  That study demonstrated that PCBs are ubiquitous and 
associated with liver injury in the general population37.  A logical next step was then an 
epidemiological evaluation of liver disease in a population with a relatively high exposure to 
environmental PCBs – that of Anniston, Alabama, already under investigation to determine 
whether PCB exposure was associated with multiple metabolic diseases.   
Both the positive and negative findings of our study were striking and novel – although 
nonalcoholic fatty liver disease in Anniston was clearly elevated compared to expected 
prevalence in the general US and worldwide population, the mechanistic biomarkers employed 
showed that the overall level of the PCB exposure represented by the sum of all congeners was 
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not correlated with the severity of liver injury or inclusion in a liver disease category in the overall 
population.   
We considered two potential reasons for this observation which were not mutually 
exclusive.  First, the Anniston population represents a complex, but not atypical, exposure 
situation, which was one of the acknowledged limitations of the study.  Chemical exposures alone 
included not only PCBs, but also heavy metals and pesticides, many of which are associated with 
liver or metabolic disease37, 121, 188, while nutritional coexposures inferred from the high 
prevalence of obesity/overweight in this population could contribute independently to fatty liver 
disease. A second possibility is that, like other endocrine/metabolism-disrupting chemical 
exposures189, increasing PCB dose could result in a nonmonotonic dose-response (NMDR) with 
respect to damage biomarkers – not steadily increasing or decreasing with increasing exposure 
concentration.  At the cellular level, differential engagement of crosstalking mechanisms may 
result in different output at different exposures.  At the organismal level, PCB effects on multiple 
systems must be considered: suppressive effects on inflammatory pathways could lead to higher 
overall liver damage indicators at a lower exposure level, interference with circadian control could 
contribute to hyperphagy and decreased energy expenditure, while effects on hormonal signaling 
could communication between concerted systems.  For this last consideration, nutritional 
coexposures play a role as well: direct effects of PCBs to reduce insulin output could limit the 
compensatory role of the pancreas in glucose allostasis, putting more stress on connected 
systems including the liver. 
The animal study previously reported by Wahlang   et al.23 was an attempt to 
disambiguate the effects of PCB exposure level and nutritional coexposure in an animal model of 
chronic PCB/HFD coexposure.  We integrated our epidemiological study with our animal model 
by comparing serology and phenotype in both studies.  The condition represented by animals 
coexposed to HFD and moderate PCBs (20 mg/kg) was designed to most closely model the 
Anniston exposure, and, indeed, the phenotype of animals within this condition approximated the 
findings in Anniston with respect to physical characteristics of metabolic syndrome and 
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serological evidence of liver injury, inflammation, and metabolic dysfunction.  The exposure to 
higher levels of PCBs in this animal model did not result in additional histological evidence of liver 
injury, suggesting that it was possible to observe nonmontonic dose responses to PCBs with 
respect to serological biomarkers of liver injury. 
One of the major findings of the Wahlang et al. study was that Aroclor 1260 exposure 
contributed to liver injury not by exacerbating steatosis, but by increasing inflammation, 
particularly in the HVvsH20 model.  Our original hypothesis was that, at higher levels of Aroclor 
1260 exposure, the concentration of trace dioxin-like PCBs within the mixture would reach a 
“tipping point” that would quell immune response in our inflammation-primed HFD-fed mice.  
Previous reports suggested that the ED50 for Aroclor 1260 immunotoxicity (in mice) was 360 
mg/kg190, still higher than our highest in vivo dose.  We saw differences in the moderate vs. high 
dose with regards to transcriptional output of IL-6JAKSTAT-3 signaling, which plays a role in 
chronic inflammation.  
Inflammatory response is a process that is both context-modulated and dynamic, 
involving initiation and resolution processes that confound a simple understanding of “pro-
inflammatory” and “anti-inflammatory” signaling molecules.  IL-6, which is produced by many cell 
types, including hepatocytes and Kupffer cells (liver-resident macrophages), is often categorized 
as a “pro-inflammatory” cytokine, and was elevated in both the ACHS cohort and in the in vivo 
moderate dose + HFD.  Certainly, IL-6 is elevated in inflammation and has down-stream effects 
that promote inflammation; on the other hand, IL-6 has distinctly “anti-inflammatory” effects in the 
liver as well, particularly to oppose exaggerated cytokine release from neighboring Kupffer cells.  
Components of IL-6 signaling pathways were more enriched in the moderate PCB/HFD 
model (Figure 22).  IL-6 signaling mediators down-stream of STAT-3 transcriptional regulation 
leading to cell differentiation pathways (cFos and cJun – 1.23-fold and 0.64-fold increased, 
respectively), were also affected with the high PCB exposures (cJun only: 0.80-fold, p=0.00005 
and 1.15-fold, p=0.00005 in the high PCB exposure with HFD and CD, respectively). Another 
group of STAT-3 targets with PCB-dependent transcriptional changes were the suppressors of 











moderate PCB/HFD exposure).  SOCS3 is an important player in the attenuation of IL-6-mediated 
STAT-3 signaling.  Potently up-regulated by active STAT-3, SOCS3 binds to and inhibits 
JAK2/gp130 kinases, which couple IL-6 to STAT-3 signaling.  SOCS3 also independently 
contributes to hepatic insulin resistance and metabolic dysfunction by binding to and inhibiting 
both insulin receptor and its down-stream mediator IRS-1191 and well as leptin receptor192.  
SOCS3 was only up-regulated in the moderate PCB/HFD exposure, while in the high PCB/HFD 
exposure, SOCS2 was up-regulated as well (0.71-fold, p=0.00005). 
In addition to transcriptional changes down-stream of STAT-3 signaling, the 
HFD/moderate exposure animals had decreased transcription of IL-6 receptor alpha (IL-6Rα: -
0.67-fold, p=0.0000).  IL-6Rα plays an important role in mechanisms contributing to chronic 
STAT-3 activation and related metabolic dysfunction and chronic inflammation.  Of interest is the 
relationship between IL-6Rα and EGFR.  Independent of EGF activation, EGFR forms a complex 
with both IL6Rα and STAT-3 in a mechanism which potentiates STAT-3 phosphorylation even in 
the presence of SOCS-3193.  EGFR/IL-6Rα-mediated STAT-3 activation contributes to chronic IL-
6 expression by hepatocytes193. Expression of EGFR itself was down-regulated in HFD alone (-
0.85-fold, p=0.0027), but was up-regulated in both the moderate and high PCB + HFD exposures 
(1.15-fold, p=0.00005 and 0.78-fold, p=0.0011, respectively).  If protein levels were similarly 
affected, this might represent a mechanism by which PCBs and HFD contribute to chronic IL-6 
release.  Alternatively, liver-specific knockout of IL-6Rα has been shown to enhance the release 
of IL-6 and TNFα from Kupffer cells (liver-specific tissue-resident macrophages), preventing the 
IL-6-mediated down-regulation of these cytokines.  Abrogation of this receptor in liver 
parenchymal cells also reduces insulin-stimulated glucose uptake in white adipose tissue and 
skeletal muscle, contributing to systemic insulin resistance194. Therefore, by altering IL-6 signaling 
within hepatocytes, PCBs may affect not only the transduction of inflammatory signals in the liver, 
but also signals coordinating metabolic response between tissues.  Future studies may be able to 
pinpoint whether PCB-mediated EGFR/IL-6Rα/STAT-3 perpetuation of STAT-3 signaling and/or 
IL-6Rα inhibition contribute to systemic IL-6 elevation, which has been associated with T2DM and 
many other metabolic diseases. 
166
 
Another factor contributing to increased systemic IL-6 may be hyaluronic acid, an 
extracellular matrix protein which was significantly increased with PCB exposure in sera from the 
ACHS-II cohort.  Hyaluronic acid binds and stabilizes extracellular IL-6, resulting in increased 
serum protein levels without affecting IL-6 mRNA transcription195.  Multiple factors contributing to 
high chronic systemic IL-6 may therefore represent a self-sustaining system by which PCBs 
exacerbate pre-existing metabolic dysfunction. Chronic IL-6 elevation may also represent a point 
of convergence for liver injury mechanisms, agreeing well with the “multiple-hits hypothesis”. 
PCB exposure did not contribute to increased steatosis in our animal model beyond the 
effects of HFD, nevertheless, genes encoding elements of hepatic lipid processing were 
differentially transcribed in the exposure models relative to vehicle-treated controls on the same 
diet.  Key events regulating the development of steatosis include increased fatty acid uptake, 
increased lipid synthesis, decreased fatty acid oxidation, and decreased lipid efflux.56    
Transcription of CD36, a FA uptake receptor, was up-regulated in high-exposure/control diet 
(0.74, p=0.0004) and with HFD alone (CVvsHV: 0.57-fold, p=0.00185), and was down-regulated 
in both moderate exposure models (CVvsC20: -0.75-fold, p=0.00045, and HVvsH20: -0.89-fold, 
p=0.00005).  Transcription of long-chain acyl-CoA synthetase 4 (ACSL4), involved in lipid 
synthesis, was down-regulated in high-exposure/control diet (-0.47-fold, p=0.00315) as in HFD 
alone (-0.91-fold, p=0.00005), but was up-regulated in moderate exposure/HFD (1.05-fold, 
p=0.00005).  These patterns do not suggest a consistent increase in pro-steatotic molecular 
changes, which would be consistent with the observation that Aroclor 1260 exposure (particularly 
at the moderate dose) did not worsen steatosis.  They do, however, suggest that PCB exposure 
at both high and low levels affects cellular events which can alter hepatocellular lipid flux, and, 
moreover, PCB exposure affects the components of those events which are known to be 
influenced by nuclear receptor-driven transcriptional changes.56   
The classically understood function of xenobiotic receptors is to respond to the presence 
of chemical ligands by heterodimerizing with RXR (nuclear receptors) or ARNT (AhR), 
translocating to the nucleus, and binding response elements in the promoters of their respective 
cytochrome p450 oxidase targets.  A more nuanced understanding includes the association of 
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unliganded receptors with specific binding partners in a corepressor complex and liganded 
receptors with coactivators.  In addition to ligand-binding, post-translational modifications such as 
phosphorylation, acetylation, and sumoylation can change the receptor’s protein-protein 
associations, adding tremendous range to both the direct and indirect transcriptional targets 
affected by xenobiotic sensing. This provides a compelling mechanism by which the changing 
chemical environment can shape the pattern of physiological metabolism. 
Just as multiple systems create a dynamic balance by shifting chemical pressures, 
rhythmic metabolic processes affected by the central or peripheral circadian clock alter metabolic 
tides in response to temporal cues. An exploration of PCB effects on the suprachiasmatic nucleus 
(SCN) which regulates the central clock is beyond the scope of this work, however, the behavioral 
changes in our mouse model described in Chapter 2 (anachronistically increased movement 
during typical sleep cycles in transgenic mice chronically exposed to 20mg/kg Aroclor 1260) are 
most likely a manifestation of central clock alterations.  In peripheral tissues including the liver, 
however, oscillations in the transcription of specific gene sets create feedback loops which 
reinforce the periodic cycling within those tissues. Importantly, the challenge of nutritional stress – 
HFD136 or time-restricted135 feeding – can uncouple the peripheral circadian clock from the 
central, leading to differential temporal expression of targets of timekeeping transcription factors 
(CLOCK and BMAL1) as well as new oscillations of previously non-cycling gene targets of 
transcription factors such as PPARγ136.   
It is not now known whether the behavioral changes seen in our transgenic mouse model 
were a direct effect of PCBs on the SCN neurons or a product of peripheral PCB effect feeding 
back by some mechanism to reprogram the central clock.  Studies investigating the effects of 
dietary stresses on circadian cycling have indicated that while peripheral tissues are 
reprogrammed by nutritional challenge, the SCN central pacemaker remains unaffected.  
However, these studies have also reported changes to the clock output genes (Per1/2 and Cry1/2 
isoforms) without changes to expression of the core clock genes (Clock and Bmal1).  In our in 
vivo experiment, we observed changes in both clock output and core clock genes under multiple 
conditions (Table 64).  Differential transcription of Clock, however, was unique to the moderate 
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Table 64  
Differentially transcribed circadian-rhythm related targets from in vivo and in vitro experiments 
In vivo In vitro
HFD vs CD FC vs. CD/V FC vs. HFD/V FC vs. DMSO
C20 C200 H20 H200 PCN BA
Core Clock Genes 
Clock 0.77
Bmal1 2.19 1.04 -0.81 -0.73
Clock output Genes 
Cry1 -0.73 0.65
Cry2 0.48 -0.47 
Per1 -0.97






ROR-g -0.74 0.88 0.53
TrkB 0.66 -1.28 -2.03 0.72
Table 64 shows fold changes for the comparisons listed above.  Targets are grouped by their 
relationship to circadian rhythm control machinery (core clock genes, clock output genes, or 
clock-associated genes).  Numbers are fold change vs. the indicated control, p<.05.  Blank 
fields were not significantly different in the listed comparison. 
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PCB/control diet condition, however, where it was up-regulated compared to vehicle/control diet 
(0.77-fold, p=0.00005).  Our in vitro experiment did not indicate differential regulation of clock-
related genes with Aroclor 1260 exposure, but did indicate down-regulation of one core clock 
gene (Bmal1) with PCN or BA, and down-regulation of one clock output gene (Cry2) with PCN 
exposure.  The direction of fold change was again opposite from any of the in vivo conditions in 
which these genes were differentially transcribed. 
The mechanism by which PCBs affect the transcription of peripheral circadian rhythm 
machinery is unclear from our in vivo or in vitro experiments, although there exists no shortage of 
potential interactions between elements of these processes and xenobiotic receptors. BMALl1, 
also known as the arylhydrocarbon receptor nuclear translocator-like (ARNTL), and CLOCK are 
PAS-domain proteins which readily associate with AhR, and their regulation of Per1 has been 
shown to be disrupted by AhR activity in response to TCDD196. In addition, the hepatocyte-
specific cyclic AMP responsive element-binding protein (CREBH) is a transcription factor with 
transcriptional activity controlling the rhythmic expression of hepatic triglyceride and fatty acid 
metabolic targets via its associations with PPARα and LXRα131, which crosstalk with xenobiotic 
nuclear receptors as previously described.  The processes leading to circadian activation of 
CREBH are controlled by BMAL1 via GSK3β/AKT pathways131.  Other isoforms of CREB 
physically interact with and are inhibited by PXR (Figure 13).197  
A clear limitation of the experiment in this area is the lack of tissue harvest timepoints 
designed to capture oscillations in transcription at multiple timepoints. Harvest was carried out 
only during the light cycle and over a period of approximately 8 hours. Future studies to explore 
PCB effect in this area could be modeled on the methods of Eckel-Mahan et al.136, to capture 
potential PCB exposure-related shifts in the temporal expression of normally cyclic or normally 
acyclic hepatic genes. 
 A final pattern observed in the enrichment analyses of both the in vivo and in vitro study 
was that of cell adhesion and related cell-cell communications apparatus.  Components of ephrin 
signaling were highly differentially expressed between conditions.  Ephrin receptors are part of a 
large class of receptor tyrosine kinases which form bi-directional communication complexes 
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between cells. Ephrins and ephrin receptors are well-studied in the context of cytoskeletal 
remodeling during neuronal path-finding and development, and, importantly, play a role in 
adhesion and communication between cells of the same or different types, including monocytes 
and endothelial cells198.  The ephrin signaling system consists of two classes of receptor (A and 
B, based on sequence homology and corresponding to structural characteristics) which respond 
to ligands produced by neighboring cells199.  Both receptor and ligand are generally membrane-
bound, facilitating communication between cells that are in physical contact, however, there is 
evidence that some ligands, specifically Ephrin A1, can be shed as soluble ligands to affect cells 
over longer distances200.  In the ephrin signaling system, signal transduction in the direction of the 
receptor is described as forward-signaling and signal transduction in the direction of the ligand is 
described as reverse signaling.  Ephrin-A/EphA forward signaling affects many of the pathways 
activated by other RTKs, including IGF-1-activated Ras-Erk, and may inhibit or activate these 
cascades in a cell-type specific manner201.     
In our experimental models, both ephrin receptors and ephrin ligands were differentially 
regulated under some or all conditions (Figures 23-25).  Interestingly, Ephrin A1 (Efna1) was 
significantly up-regulated in every in vivo comparison except moderate PCB/control diet exposure 
as well as in vitro PCB exposure, and was one of the targets which was uniquely regulated in 
PCB exposure (Figure 23).  Ephrin A5 (Efna5), another ligand, was also up-regulated in all HFD-
exposed groups and and upon exposure to 200 mg/kg PCB with CD (Figure 24). Ephrin A3 
(Efna3) was strongly up-regulated only in the moderate PCB/HFD coexposure (3.85-fold, 
p=0.00095), and was otherwise not significantly different from vehicle/CD.  Ephrin receptor B2 
was differentially regulated under all conditions (Figure 25).   
Differential expression of ephrin receptors and ligands is associated with pro-
inflammatory states and changes in inflammatory cytokines in multiple tissue.  Expression of 
EphA2 (receptor) and Ephrin A1 (ligand) have been shown to increase in lung tissue after LPS 
exposure, and posttreatment with mAb against EphA2 receptor reduces lung injury and 
permeability in LPS-exposed animals, as well as the production of pro-inflammatory cytokines 
(IL1β, MIP-2)202.   
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Figure 23. Ephrin ligand A1 (Efna1) was differentially regulated in multiple comparisons.  The 
vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads 
(FPKM) for each condition, with significant differences indicated by bridging lines.  Panel A shows 
the respective aggregate FPKM for six in vivo conditions, while Panel B shows the same for the in 
vitro experiment, with exposure to Aroclor 1260 and PCN shown.  Treatment with prototypical 
ligands for AhR, CAR, and LXR did not induce significant changes in Efna1 expression. 
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Figure 24. Ephrin ligand A5 (Efna5) was differentially regulated in multiple comparisons.  The 
vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads 
(FPKM) for each condition, with significant differences indicated by bridging lines. 
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Figure 25. Ephrin receptor B2 (EphB2) was differentially regulated in multiple comparisons.  The 
vertical axis shows aggregate fragments per kilobase of transcript per million mapped reads 
(FPKM) for each condition, with significant differences indicated by bridging lines.   
174
 
Differential expression of ephrin receptors and ligands is also associated with transitions 
between differentiated (epithelial) and undifferentiated (mesenchymal) cell characteristics.  In the 
context of cancer, it has been observed that overexpression of ephrin receptors tends to favor 
metastatic characteristics (loss of adhesion), while overexpression of ligand tends to favor 
increased cell adhesion203.  To that effect, EphA2 was found to be overexpressed in neoplastic  
cells, and the distribution changed from clustered localization of EphA2 at sites of cell-cell 
contacts to either a diffuse pattern or concentration in the leading edge of migrating cells204.  This 
loss of localization at sites of stable cell-cell contacts led to decreased ligand-dependent 
phosphorylation of EphA2, because the membrane-bound Ephrin-A ligands also localize at these 
sites.  E-cadherin forms homodimers with E-cadherin in adjacent cells to mediate highly stable 
calcium-dependent cell adhesion foci, and E-cadherin function in these cell-cell junctions is 
necessary to prevent decreased phosphorylation of EphA2. Given the role of ephrin receptors 
and ligands in cytoskeletal remodeling during growth and development as well as regeneration, 
development, especially with the sequential events necessary for cells to form properly oriented 
relationships with one another.  In all PCB exposures, both in vivo and in vitro, the expression of 
adhesion proteins such as Claudin-1 and E-Cadherin was up-regulated vs. untreated control.  
Most literature describing changes to these proteins in the context of liver disease deals with their 
importance as biomarkers of cell identity during periods of physiological or pathological change: 
development, regeneration, and neoplasia.  Up-regulation of these proteins is associated with a 
more terminally differentiated, epithelioid cell, but in the larger context, expression of these 
proteins is necessary for proper orientation of cells relative to one another within the larger tissue 
structure. 
Ephrin signaling is important in other tissues which participate in metabolic allostasis.  
For instance, pancreatic beta cells employ ephrin signaling to synchronize release of insulin in 
response to glucose, using engagement of EphA forward signaling to inhibit insulin secretion and 
ephrin-A reverse signaling to stimulate insulin secretion205.  If expression of Ephrin-A1 is similarly 
up-regulated in the pancreas as it is in the liver, this may represent another mechanism by which 
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PCBs and PCB+HFD contribute to the phenotype of reduced serum insulin observed in both 
Anniston and our mouse model. 
Xenobiotic receptors are known to crosstalk with signaling cascades down-stream of 
tyrosine kinase signaling.  Ephrin receptor signaling may crosstalk with regulation of the 
constitutive androstane receptor in a similar way to EGFR.  The receptor for activated c-kinase 1 
(RACK-1) associates with ligand-bound, autophosphorylated and active EphB3, forming a 
complex with PP2A and AKT and promoting the dephosphorylation of AKT at S473203. an event 
which leads to reduced cell migration as well as apoptosis.  Active (dephosphorylated) RACK-1 
also facilitates the interaction of CAR with PP2A, an event which is necessary for the nuclear 
translocation of CAR, the indirect or ligand-independent pathway for CAR activation described by 
Mutoh   et al.21 This pathway is critical to PCB research, because it activates CAR via EGFR 
inhibition, a mechanism which is shared by phenobarbital and PCB congeners20.  Input into CAR 
transcriptional activity via ephrin signaling represents a mechanism by which inflammatory status 
and cell-cell communication status can crosstalk with the output of xenobiotic receptors, providing 
more nuanced control over adaptive metabolic control.  Our in vitro experiment, however, 
indicated that only one target related to ephrin signaling was differentially regulated by Aroclor 
1260 exposure: the Ephrin A ligand Efna1 (Figure 26, Panel B).  Interestingly, Efna1 was also 
differentially regulated in hepatocytes cells exposed to PCN, although in an opposite direction (-
0.66-fold, p=0.00005), which may be another example of the trend of PCB-dependent up-
regulation of targets in vivo which are negatively regulated by PCN exposure, and presumably 
PXR activation, in vitro.   
Our combined approach of epidemiological assessment followed by in vivo and in vitro 
mechanistic exploration has uncovered many interesting relationships between environmental 
PCB exposure and human disease.  While the question of the roles of xenobiotic receptors in 
PCB-associated fatty liver disease is far from resolved, we have at least pushed the 
understanding of those roles beyond direct, ligand-activated transcriptional activity of a few (or 
worse, one), xenobiotic-responsive transcription factor.  It is likely that a great many of the effects 
of PCB-associated TASH are independent of direct effects of CAR, PXR, or AhR.  It is equally 
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likely that input from these receptors is indirectly involved in the pathways and processes 
modulated by PCB effects. We have described three groups of effects which are related to effects 
seen in all three of our models:  systemic inflammatory dysregulation via IL-6 signalling, 
disruption of circadian rhythm processes, and modulation of cell adhesion and cell-cell 
communication via differential expression of E-cadherin/claudin-1 and related ephrin signaling 
pathways.  These effects appear to be directly related to PCB exposure, are strongly involved in 
and modulated by dietary coexposures, and are likely to affect multiple systems involved in 
metabolic disease.  Simultaneous dysregulation of these systems during PCB exposure could 
explain the “2-hit” phenomenon, providing a mechanism by which PCB/HFD coexposures could 
accelerate allostatic overload – crippling the normal adaptive response to metabolic challenge.   
Future studies will likely focus on individual components of these effects, and may involve 
analysis of tissues other than liver. It remains to be determined whether PCB-dependent changes 
to IL-6 signaling lead to failure of feedback inhibition from hepatocytes to Kupffer cells and 
subsequent uncontrolled inflammation, or whether the systemic IL-6 elevations seen in Anniston 
arise from a different tissue – adipose, for instance.  Likewise, an assessment of the PCB-
dependent changes to circadian signaling require evaluation of PCB-dependent changes to clock 
output and, more intriguingly, core clock gene transcription not only in peripheral tissues, but in 
the SCN as well.  Exploring the mechanism  and effects of the PCB-dependent transcriptional 
changes to ephrin signaling components and cell adhesion molecules may allow us to determine 
whether cell-cell communication between hepatocytes, endothelial cells, and/or Kupffer cells are 
dysregulated in PCB exposure, and whether changes to cell adhesion mediators is indicative of 
failed regenerative processes which could explain the apparent “chronic necrosis” observed in the 
Anniston population as well as the increased biomarkers of fibrosis.  
As for the activities of the xenobiotic receptors themselves, our in vitro model was 
interesting from the standpoint that it showed that a substantial portion of the targets differentially 
transcribed with Aroclor 1260 exposure were not attributable to activation of AhR, PXR, CAR, or 
LXR.  Targets within the set differentially transcribed with Aroclor 1260 exposure were associated 
with many liver and metabolic disease states, however, in a direct comparison between targets 
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differentially transcribed with Aroclor 1260 exposure in vitro and in vivo, there were very few 
shared between the in vitro (Figure 27) and moderate exposure, with far more shared between 
the in vitro and high exposure.  Although the in vitro experiment used 5 µg/ml Aroclor 1260, a 
concentration lower than the concentration used to induce activity of human PXR, CAR, and AhR 
transfected into a HepG2 model luciferase reporter system19, there were more DTGs shared 
between the in vitro and the two high-dose in vivo models than the in vitro and two moderate-
dose in vivo models.  It is possible, therefore, that 5 µg/ml is still too high to accurately model a 
relevant environmental exposure in primary hepatocytes.  With that in mind, however, targets 
such as Claudin-1, E-Cadherin, Ephrin-A, and Tribbles-3 pseudokinase were conserved across 
more than one of the comparisons, suggesting that they may be part of common mechanisms for 
PCB effect. Because the raw data from the in vitro work will be available for further interrogation, 
it is likely that alternative bioinformatics tools may bring some clarity to the specific roles of these 
receptors in the observed transcriptional changes.  If, instead of direct transactivation PXR, CAR, 
and/or AhR are involved via protein-protein interactions with other transcription factors, this may 
be due to a PCB-dependent intracellular milieu that favors specific post-translational 
modifications and corresponding specific protein associations.    
This laboratory set out to investigate the relationship between exposure to PCBs a 
widespread class of persistent organic pollutant, and steatohepatitis, a widespread manifestation 
of metabolic disease.  Because xenobiotic receptors drive the metabolic machinery responsible 
for recognizing and detoxifying foreign chemicals, and because of historic attention to the role of 
one part of this machinery, the cytochrome p450s, in generating carcinogenic metabolites from 
polycyclic aromatic hydrocarbons206 including PCBs, we and others expected to find a central role 
for these receptors which placed down-stream transcriptional targets as effectors in disease.  
Although some targets of these receptors are undoubtedly involved in steatohepatitis and other 
disease states, I find that the evidence from this study suggests a more peripheral role for these 
xenobiotic receptors in PCB-associated TASH: modulating metabolic responses with the 
additional information about the presence of toxicants.  This makes sense from a standpoint of 
phenotype: moderate-dose PCBs alone did not induce steatohepatitis in our mouse model, and 
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Figure 26. In vivo comparison diagrams. Venn diagrams show the overlapping region between 
in vitro study (white), 20 mg/kg Aroclor 1260 in vivo (red) and 200 mg/kg in vivo (black) on in  
vivo datasets grouped by diet.  Panel A, control diet, shows a larger proportion of DTGs 
overlapping between the in vivo and high Aroclor.  Shared targets include Gstm3, Cldn1, Pim1, 
Orm3, Trib3, and Akr1b7.  In Panel B, which shows the overlap with the HFD in vivo expsoures, 
a larger proportion of the DTGs identified in the in vitro Aroclor 1260 exposure overlapped with 
the moderate in vivo exposure + high fat diet.  Shared targets include Cdh1, Moxd1, Slc10a2, 




there is not a clear dose-response relationship between total PCB load or the concentration of a 
defined PCB functional grouping and TASH in Anniston.  The requirement for co-occurring 
metabolic stress would also explain the convergence in phenotype seen in both human 
NASH/TASH and in mouse models.  PCB exposure appears to change elements of the response 
to this metabolic pressure – hepatocyte death mechanism, and inflammatory response, for 
instance, or elements of cell-cell signaling and adhesion important in regeneration.  Lastly, the 
extrahepatic effects of PCBs on the liver cannot be overemphasized.  Our human population 
showed inappropriate insulin production in response to hyperglycemia, strongly suggesting direct 
PCB effects in the pancreas, and a transgenic mouse (CAR-/-) in our laboratory demonstrated 
altered circadian patterns in response to PCB.  One or both of these effects may involve the 
activity of xenobiotic receptors – their role in mediation of PCB effect in extrahepatic tissues is 
beyond the scope of this project – however, both effects have the potential to impact the 
development of steatohepatitis through effects on other metabolic allostasis machinery. These 
studies have strengthened the body of evidence connecting environmental PCB exposures to 
toxicant-associated steatohepatitis, have shifted the focus of mechanism from strictly xenobiotic-
receptor-mediated effects, and have pointed to new areas of inquiry we can explore to address 
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